{
  "questions": [
    {
      "id": "67e6cf2618b1e36f2e0000d0",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27052640",
        "http://www.ncbi.nlm.nih.gov/pubmed/17334672",
        "http://www.ncbi.nlm.nih.gov/pubmed/21880994",
        "http://www.ncbi.nlm.nih.gov/pubmed/21983866",
        "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
        "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
        "http://www.ncbi.nlm.nih.gov/pubmed/21330749",
        "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
        "http://www.ncbi.nlm.nih.gov/pubmed/28514722",
        "http://www.ncbi.nlm.nih.gov/pubmed/26786929"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Symptomatic epilepsy is a common complication of glioblastoma and requires pharmacotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 340,
          "text": "Several uncontrolled retrospective case series and a post hoc analysis of the registration trial for temozolomide indicated an association between valproic acid (VPA) use and improved survival outcomes in patients with newly diagnosed glioblastoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 1073,
          "text": "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741).",
          "score": 0.8977354764938354
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1074,
          "offsetInEndSection": 1264,
          "text": "Progression-free survival (PFS) and overall survival (OS) were compared between: (1) any VPA use and no VPA use at baseline or (2) VPA use both at start of and still after chemoradiotherapy.",
          "score": 0.8770427107810974
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1265,
          "offsetInEndSection": 1377,
          "text": "Results of Cox regression models stratified by trial and adjusted for baseline prognostic factors were analyzed.",
          "score": 0.8421160578727722
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1378,
          "offsetInEndSection": 1436,
          "text": "The same analyses were performed with levetiracetam (LEV).",
          "score": 0.8590326309204102
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1437,
          "offsetInEndSection": 1667,
          "text": "VPA use at start of chemoradiotherapy was not associated with improved PFS or OS compared with all other patients pooled (PFS: hazard ratio [HR], 0.91; 95% CI, 0.77 to 1.07; P = .241; OS: HR, 0.96; 95% CI, 0.80 to 1.15; P = .633).",
          "score": 0.8790671825408936
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1668,
          "offsetInEndSection": 1941,
          "text": "Furthermore, PFS and OS of patients taking VPA both at start of and still after chemoradiotherapy were not different from those without antiepileptic drug use at both time points (PFS: HR, 0.92; 95% CI, 0.74 to 1.15; P = .467; OS: HR, 1.10; 95% CI, 0.86 to 1.40; P = .440).",
          "score": 0.8809891939163208
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1942,
          "offsetInEndSection": 2016,
          "text": "Similarly, no association with improved outcomes was observed for LEV use.",
          "score": 0.8539931774139404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2017,
          "offsetInEndSection": 2192,
          "text": "The results of this analysis do not justify the use of VPA or LEV for reasons other than seizure control in patients with newly diagnosed glioblastoma outside clinical trials."
        }
      ]
    },
    {
      "id": "680d5e47353a4a2e6b000005",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8286427",
        "http://www.ncbi.nlm.nih.gov/pubmed/26380465",
        "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
        "http://www.ncbi.nlm.nih.gov/pubmed/27695175",
        "http://www.ncbi.nlm.nih.gov/pubmed/20477251",
        "http://www.ncbi.nlm.nih.gov/pubmed/24977015",
        "http://www.ncbi.nlm.nih.gov/pubmed/26770619",
        "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
        "http://www.ncbi.nlm.nih.gov/pubmed/6984375",
        "http://www.ncbi.nlm.nih.gov/pubmed/19704328"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "we reviewed the imaging findings in 7 patients with idiopathic giant bullous emphysema.",
          "score": 0.8737348318099976
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 260,
          "text": "This is a chronic, progressive condition usually affecting young male smokers and is characterized by giant emphysematous bullae, which commonly develop in the upper lobes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 397,
          "text": "Extensive paraseptal emphysema coalesces to form giant bullae, compressing the normal lung parenchyma and often displacing it centrally.",
          "score": 0.8884834051132202
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 398,
          "offsetInEndSection": 453,
          "text": "These bullae occupy at least one-third of a hemithorax.",
          "score": 0.83660888671875
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 454,
          "offsetInEndSection": 687,
          "text": "Seven patients with chest radiographic evidence of a bulla or bullae occupying at least one-third of a hemithorax, who had also been examined with high-resolution computed tomography (HRCT), were included in this retrospective study.",
          "score": 0.880840539932251
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 688,
          "offsetInEndSection": 818,
          "text": "On HRCT scans, the size, location, and distribution of the bullae were documented and categorized as either subpleural or central.",
          "score": 0.8719281554222107
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 819,
          "offsetInEndSection": 1020,
          "text": "The HRCT scan findings in all 7 study patients included numerous bullae ranging in size from a few centimeters in diameter to giant bullae nearly filling an entire hemithorax, mimicking a pneumothorax.",
          "score": 0.8756044507026672
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1021,
          "offsetInEndSection": 1286,
          "text": "Five of the 7 patients had extensive upper lobe predominant bullae, 4 of the 7 patients showed severe bilateral disease with asymmetric involvement, 2 of the 7 patients demonstrated left lung predominance and whereas 1 patient showed right lung predominant disease.",
          "score": 0.8823481798171997
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1440,
          "text": "All of our patients had subpleural bullae, had parenchymal fibrosis, another had extensive subcutaneous emphysema, and 1 had accompanying bronchiectasis.",
          "score": 0.8874942064285278
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1441,
          "offsetInEndSection": 1544,
          "text": "The predominant findings on HRCT scans are extensive paraseptal emphysema coalescing into giant bullae.",
          "score": 0.8905327320098877
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1545,
          "offsetInEndSection": 1679,
          "text": "HRCT is helpful in confirming the diagnosis of VLS, assessing the degree of the disease, and providing information to guide treatment.",
          "score": 0.8716638088226318
        }
      ]
    },
    {
      "id": "680f4a68353a4a2e6b000007",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24696870",
        "http://www.ncbi.nlm.nih.gov/pubmed/29559781",
        "http://www.ncbi.nlm.nih.gov/pubmed/16634707",
        "http://www.ncbi.nlm.nih.gov/pubmed/34855694",
        "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
        "http://www.ncbi.nlm.nih.gov/pubmed/27274384",
        "http://www.ncbi.nlm.nih.gov/pubmed/22762295",
        "http://www.ncbi.nlm.nih.gov/pubmed/25852975",
        "http://www.ncbi.nlm.nih.gov/pubmed/19033200",
        "http://www.ncbi.nlm.nih.gov/pubmed/36262632"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "The utility of classical drugs used to treat psychiatric disorders (e.g., antidepressants, anxiolytics) is often limited by issues of lack of efficacy, delayed onset of action or side effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 193,
          "offsetInEndSection": 343,
          "text": "Psychoactive substances have a long history of being used as tools to alter consciousness and as a gateway to approach the unknown and the divinities.",
          "score": 0.8884320855140686
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 344,
          "offsetInEndSection": 606,
          "text": "These substances were initially obtained from plants and animals and more recently by chemical synthesis, and its consumption evolved toward a more recreational use, leading to drug abuse-related disorders, trafficking, and subsequent banning by the authorities.",
          "score": 0.8782661557197571
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 758,
          "text": "However, these substances, by modulation of certain neurochemical pathways, have been proven to have a beneficial effect on some psychiatric disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 759,
          "offsetInEndSection": 987,
          "text": "This evidence obtained under medically controlled conditions and often associated with psychotherapy, makes these substances an alternative to conventional medicines, to which in many cases the patient does not respond properly.",
          "score": 0.9211419820785522
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 988,
          "offsetInEndSection": 1228,
          "text": "Such disorders include post-traumatic stress disease and treatment-resistant depression, for which classical drugs such as MDMA, ketamine, psilocybin and LSD, among others, have already been clinically tested, reporting successful outcomes.",
          "score": 0.9100117683410645
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1229,
          "offsetInEndSection": 1445,
          "text": "The irruption of new psychoactive substances (NPS), especially during the last decade and despite their recreational and illicit uses, has enlarged the library of substances with potential utility on these disorders.",
          "score": 0.9039331078529358
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1446,
          "offsetInEndSection": 1609,
          "text": "In fact, many of them were synthetized with therapeutic purposes and were withdrawn for concrete reasons (e.g., adverse effects, improper pharmacological profile).",
          "score": 0.8926120400428772
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1610,
          "offsetInEndSection": 1869,
          "text": "In this review we focus on the basis, existing evidence and possible use of synthetic cathinones and psychedelics (specially tryptamines) for the treatment of mental illnesses and the properties that should be found in NPS to obtain new therapeutic compounds.",
          "score": 0.9165487885475159
        }
      ]
    },
    {
      "id": "680a083218b1e36f2e00014d",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23141534",
        "http://www.ncbi.nlm.nih.gov/pubmed/26156998",
        "http://www.ncbi.nlm.nih.gov/pubmed/23570941",
        "http://www.ncbi.nlm.nih.gov/pubmed/21206757",
        "http://www.ncbi.nlm.nih.gov/pubmed/27273464",
        "http://www.ncbi.nlm.nih.gov/pubmed/27664583",
        "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
        "http://www.ncbi.nlm.nih.gov/pubmed/22138506",
        "http://www.ncbi.nlm.nih.gov/pubmed/23732542",
        "http://www.ncbi.nlm.nih.gov/pubmed/23533697"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by a progressive loss of memory and cognitive skills.",
          "score": 0.8736550807952881
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 383,
          "text": "Although much attention has been devoted concerning the contribution of the microscopic lesions, senile plaques, and neurofibrillary tangles to the disease process, inflammation has long been suspected to play a major role in the etiology of AD.",
          "score": 0.8868430852890015
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 384,
          "offsetInEndSection": 605,
          "text": "Recently, a novel variant in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) has been identified that has refocused the spotlight back onto inflammation as a major contributing factor in AD.",
          "score": 0.888185977935791
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 606,
          "offsetInEndSection": 670,
          "text": "Variants in TREM2 triple one's risk of developing late-onset AD.",
          "score": 0.8509445786476135
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 671,
          "offsetInEndSection": 871,
          "text": "TREM2 is expressed on microglial cells, the resident macrophages in the CNS, and functions to stimulate phagocytosis on one hand and to suppress cytokine production and inflammation on the other hand."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 872,
          "offsetInEndSection": 1114,
          "text": "The purpose of this paper is to discuss these recent developments including the potential role that TREM2 normally plays and how loss of function may contribute to AD pathogenesis by enhancing oxidative stress and inflammation within the CNS.",
          "score": 0.905106782913208
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1115,
          "offsetInEndSection": 1267,
          "text": "In this context, an overview of the pathways linking beta-amyloid, neurofibrillary tangles (NFTs), oxidative stress, and inflammation will be discussed.",
          "score": 0.8737000226974487
        }
      ]
    },
    {
      "id": "67e5557c18b1e36f2e0000ac",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37343519",
        "http://www.ncbi.nlm.nih.gov/pubmed/37462862",
        "http://www.ncbi.nlm.nih.gov/pubmed/27611920",
        "http://www.ncbi.nlm.nih.gov/pubmed/31415087",
        "http://www.ncbi.nlm.nih.gov/pubmed/24535888",
        "http://www.ncbi.nlm.nih.gov/pubmed/32102086",
        "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
        "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
        "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
        "http://www.ncbi.nlm.nih.gov/pubmed/31369274"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Folate receptor \u03b1 (FR\u03b1) is a well-studied tumor biomarker highly expressed in many epithelial tumors such as breast, ovarian, and lung cancers.",
          "score": 0.8848671913146973
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 299,
          "text": "Mirvetuximab soravtansine (IMGN853) is the antibody-drug conjugate of FR\u03b1-binding humanized monoclonal antibody M9346A and cytotoxic maytansinoid drug DM4.",
          "score": 0.8694854378700256
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 300,
          "offsetInEndSection": 480,
          "text": "IMGN853 is currently being evaluated in multiple clinical trials, in which the immunohistochemical evaluation of an archival tumor or biopsy specimen is used for patient screening.",
          "score": 0.837518572807312
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 576,
          "text": "However, limited tissue collection may lead to inaccurate diagnosis due to tumor heterogeneity.",
          "score": 0.8109996318817139
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 614,
          "text": "Herein, we developed a zirconium-89 (",
          "score": 0.8310948610305786
        }
      ]
    },
    {
      "id": "6810fef8353a4a2e6b000016",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2199873",
        "http://www.ncbi.nlm.nih.gov/pubmed/24161312",
        "http://www.ncbi.nlm.nih.gov/pubmed/12114921",
        "http://www.ncbi.nlm.nih.gov/pubmed/15702702",
        "http://www.ncbi.nlm.nih.gov/pubmed/27875769",
        "http://www.ncbi.nlm.nih.gov/pubmed/9279523",
        "http://www.ncbi.nlm.nih.gov/pubmed/20131283",
        "http://www.ncbi.nlm.nih.gov/pubmed/3303067",
        "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
        "http://www.ncbi.nlm.nih.gov/pubmed/23090264"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60,
          "text": "Prolactinoma is the most common secreting pituitary adenoma.",
          "score": 0.8506044745445251
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 61,
          "offsetInEndSection": 151,
          "text": "It is typically diagnosed in women of reproductive age and is common cause of infertility.",
          "score": 0.8910953402519226
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 301,
          "text": "Currently the treatment of choice is pharmacotherapy with dopamine agonists, whereas surgical treatment is reserved for a selected group of patients.",
          "score": 0.8702512383460999
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 302,
          "offsetInEndSection": 417,
          "text": "Pituitary-tumor apoplexy is a rare, life-threatening condition associated with significant morbidity and mortality.",
          "score": 0.8630796670913696
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 418,
          "offsetInEndSection": 518,
          "text": "The authors present the case of a 25-year-old woman with prolactinoma treated with dopamine agonist.",
          "score": 0.8919295072555542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 577,
          "text": "In course of such a treatment the patient became pregnant."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 578,
          "offsetInEndSection": 620,
          "text": "The bromocriptine was gradually withdrawn.",
          "score": 0.8638592958450317
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 717,
          "text": "In the 14th week of pregnancy she was admitted for symptoms suggesting pituitary tumor apoplexy.",
          "score": 0.898379385471344
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 718,
          "offsetInEndSection": 767,
          "text": "The treatment with bromocriptine was reinitiated.",
          "score": 0.8752550482749939
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 768,
          "offsetInEndSection": 905,
          "text": "In the 20th week of pregnancy further deterioration of the patient's neurological condition and visual-field abnormalities were observed.",
          "score": 0.8941779136657715
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 906,
          "offsetInEndSection": 996,
          "text": "The patient was qualified for surgical treatment - selective transsphenoidal adenomectomy.",
          "score": 0.884398341178894
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 997,
          "offsetInEndSection": 1065,
          "text": "The successful surgery led to improvement of neurological condition.",
          "score": 0.8710281848907471
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1066,
          "offsetInEndSection": 1177,
          "text": "The early postoperative PRL level decreased significantly and hormonal function of the pituitary was preserved.",
          "score": 0.8698296546936035
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1178,
          "offsetInEndSection": 1236,
          "text": "The pregnancy ended in 38th week with a caesarean section.",
          "score": 0.8880513906478882
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1237,
          "offsetInEndSection": 1348,
          "text": "Endocrinological evaluation conducted after the uneventful delivery confirmed normal function of the pituitary.",
          "score": 0.8884060978889465
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1349,
          "offsetInEndSection": 1413,
          "text": "Magnetic resonance imaging (MRI) did not reveal tumor re-growth.",
          "score": 0.844725489616394
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1414,
          "offsetInEndSection": 1462,
          "text": "The patient is kept under constant medical care.",
          "score": 0.8475563526153564
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1463,
          "offsetInEndSection": 1645,
          "text": "In this case study the authors discussed therapeutic management and reviewed literature regarding gestational pituitary-tumor apoplexy with particular emphasis on surgical treatment.",
          "score": 0.8966699838638306
        }
      ]
    },
    {
      "id": "6810cb23353a4a2e6b000012",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28813765",
        "http://www.ncbi.nlm.nih.gov/pubmed/24171820",
        "http://www.ncbi.nlm.nih.gov/pubmed/25534557",
        "http://www.ncbi.nlm.nih.gov/pubmed/28084708",
        "http://www.ncbi.nlm.nih.gov/pubmed/21790283",
        "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
        "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
        "http://www.ncbi.nlm.nih.gov/pubmed/28406319",
        "http://www.ncbi.nlm.nih.gov/pubmed/28545978",
        "http://www.ncbi.nlm.nih.gov/pubmed/27119985"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Nonresponders to maximal guideline-based therapies of asthma account for most of the morbidity, mortality, and economic burden of the disease.",
          "score": 0.8866428136825562
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 330,
          "text": "Because eosinophils are key effector cells in asthmatic airway inflammation, blocking IL-5, the main cytokine responsible for its survival and activation, seems to be a rational strategy.",
          "score": 0.8896017074584961
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 331,
          "offsetInEndSection": 481,
          "text": "While previous monoclonal antibodies against the IL-5 ligand resulted in inconsistent improvements in asthma outcomes, benralizumab has shown promise.",
          "score": 0.9100391864776611
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 618,
          "text": "Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function.",
          "score": 0.8961548805236816
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 619,
          "offsetInEndSection": 801,
          "text": "In this article, we review the theoretical advantages of benralizumab compared to previous compounds, as well as current status of the clinical development of benralizumab in asthma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 802,
          "offsetInEndSection": 905,
          "text": "Lastly, we briefly discuss the potential role of benralizumab in chronic obstructive pulmonary disease.",
          "score": 0.9096075892448425
        }
      ]
    },
    {
      "id": "680bc7a718b1e36f2e000156",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
        "http://www.ncbi.nlm.nih.gov/pubmed/24818721",
        "http://www.ncbi.nlm.nih.gov/pubmed/33375686",
        "http://www.ncbi.nlm.nih.gov/pubmed/2046748",
        "http://www.ncbi.nlm.nih.gov/pubmed/32235439",
        "http://www.ncbi.nlm.nih.gov/pubmed/12542976",
        "http://www.ncbi.nlm.nih.gov/pubmed/22235994",
        "http://www.ncbi.nlm.nih.gov/pubmed/26110128",
        "http://www.ncbi.nlm.nih.gov/pubmed/22382701",
        "http://www.ncbi.nlm.nih.gov/pubmed/29358503"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC).",
          "score": 0.8891764879226685
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 441,
          "text": "Although cCRT is potentially curative, 5-year overall survival has hovered around 20%, despite extensive efforts to improve outcomes with increasing doses of conformal radiation and intensification of systemic therapy with either induction or consolidation chemotherapy.",
          "score": 0.8657554984092712
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 442,
          "offsetInEndSection": 555,
          "text": "PD-1/PD-L1 immune checkpoint inhibitors have demonstrated unprecedented efficacy in patients with stage IV NSCLC.",
          "score": 0.8672006130218506
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 839,
          "text": "In addition, preclinical and early clinical evidence suggests that chemotherapy and radiation may work synergistically with anti-PD-1/PD-L1 therapy to promote antitumor immunity, which has led to the initiation of clinical trials testing these drugs in patients with stage III NSCLC.",
          "score": 0.8904531598091125
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 840,
          "offsetInEndSection": 1072,
          "text": "A preliminary report of a randomized phase III trial, the PACIFIC trial, demonstrated an impressive increase in median progression-free survival with consolidative durvalumab, a PD-L1 inhibitor, compared with observation after cCRT.",
          "score": 0.8538475632667542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1235,
          "text": "Here, we discuss the clinical and translational implications of integrating PD-1/PD-L1 inhibitors in the management of patients with unresectable stage III NSCLC.",
          "score": 0.8596882820129395
        }
      ]
    },
    {
      "id": "67e56f2018b1e36f2e0000b0",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12538828",
        "http://www.ncbi.nlm.nih.gov/pubmed/30924130",
        "http://www.ncbi.nlm.nih.gov/pubmed/29931593",
        "http://www.ncbi.nlm.nih.gov/pubmed/37735554",
        "http://www.ncbi.nlm.nih.gov/pubmed/19158349",
        "http://www.ncbi.nlm.nih.gov/pubmed/23683707",
        "http://www.ncbi.nlm.nih.gov/pubmed/11685722",
        "http://www.ncbi.nlm.nih.gov/pubmed/29310513",
        "http://www.ncbi.nlm.nih.gov/pubmed/15998742",
        "http://www.ncbi.nlm.nih.gov/pubmed/18956258"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Telomerase plays a pivotal role in cellular immortality and tumorigenesis.",
          "score": 0.874273955821991
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 198,
          "text": "Its activity is normally not detectable in most somatic cells while it is reactivated in the vast majority of cancer cells.",
          "score": 0.8427122831344604
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 326,
          "text": "Therefore, inhibition of telomerase has been viewed as a promising anticancer approach due to its specificity for cancer cells.",
          "score": 0.8943531513214111
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 489,
          "text": "Studies so far have shown that telomerase inhibition can inhibit the proliferation of cancer cells or cause apoptosis while it has no effect on most normal cells.",
          "score": 0.8822710514068604
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 490,
          "offsetInEndSection": 698,
          "text": "Strategies currently being applied to induce telomerase inhibition target virtually all of the major components of the ribonucleoprotein holoenzyme and related cell signal pathways that regulate its activity.",
          "score": 0.8910369277000427
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 699,
          "offsetInEndSection": 892,
          "text": "These strategies include inhibition of telomerase through targeting at the telomerase reverse transcriptase (TERT) catalytic subunit, the telomerase RNA (TR) component, and associated proteins.",
          "score": 0.8912790417671204
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 893,
          "offsetInEndSection": 1035,
          "text": "Other strategies have been developed to target the proteins associated with telomerase at the telomeric ends of chromosomes such as tankyrase.",
          "score": 0.8648451566696167
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1036,
          "offsetInEndSection": 1152,
          "text": "The specific mechanisms that mediate those inhibition effects include small molecules, antisense RNA, and ribozymes.",
          "score": 0.8924849033355713
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1153,
          "offsetInEndSection": 1323,
          "text": "Although the beneficial evidence of telomerase inhibition is obvious, limitations of strategies remain to be resolved to increase the feasibility of clinical application.",
          "score": 0.8842062950134277
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1324,
          "offsetInEndSection": 1412,
          "text": "This analysis will summarize recent developments of strategies in telomerase inhibition.",
          "score": 0.8821260929107666
        }
      ]
    },
    {
      "id": "67fe5f0918b1e36f2e000144",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26559820",
        "http://www.ncbi.nlm.nih.gov/pubmed/24320032",
        "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
        "http://www.ncbi.nlm.nih.gov/pubmed/24320038",
        "http://www.ncbi.nlm.nih.gov/pubmed/29604126",
        "http://www.ncbi.nlm.nih.gov/pubmed/28918421",
        "http://www.ncbi.nlm.nih.gov/pubmed/22829586",
        "http://www.ncbi.nlm.nih.gov/pubmed/26956847",
        "http://www.ncbi.nlm.nih.gov/pubmed/31931543",
        "http://www.ncbi.nlm.nih.gov/pubmed/29457836"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Alcoholic liver disease (ALD) is characterized by lipid accumulation and liver injury."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 87,
          "offsetInEndSection": 178,
          "text": "However, how chronic alcohol consumption causes hepatic lipid accumulation remains elusive.",
          "score": 0.890895426273346
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 359,
          "text": "The present study demonstrates that activation of the mechanistic target of rapamycin complex 1 (mTORC1) plays a causal role in alcoholic steatosis, inflammation, and liver injury.",
          "score": 0.8962897658348083
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 360,
          "offsetInEndSection": 539,
          "text": "Chronic-plus-binge ethanol feeding led to hyperactivation of mTORC1, as evidenced by increased phosphorylation of mTOR and its downstream kinase S6 kinase 1 (S6K1) in hepatocytes.",
          "score": 0.894925057888031
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 540,
          "offsetInEndSection": 842,
          "text": "Aberrant activation of mTORC1 was likely attributed to the defects of the DEP domain-containing mTOR-interacting protein (DEPTOR) and the nicotinamide adenine dinucleotide-dependent deacetylase sirtuin 1 (SIRT1) in the liver of chronic-plus-binge ethanol-fed mice and in the liver of patients with ALD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 843,
          "offsetInEndSection": 1018,
          "text": "Conversely, adenoviral overexpression of hepatic DEPTOR suppressed mTORC1 signaling and ameliorated alcoholic hepatosteatosis, inflammation, and acute-on-chronic liver injury.",
          "score": 0.9053765535354614
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1019,
          "offsetInEndSection": 1278,
          "text": "Mechanistically, the lipid-lowering effect of hepatic DEPTOR was attributable to decreased proteolytic processing, nuclear translocation, and transcriptional activity of the lipogenic transcription factor sterol regulatory element-binding protein-1 (SREBP-1).",
          "score": 0.893507719039917
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1279,
          "offsetInEndSection": 1475,
          "text": "DEPTOR-dependent inhibition of mTORC1 also attenuated alcohol-induced cytoplasmic accumulation of the lipogenic regulator lipin 1 and prevented alcohol-mediated inhibition of fatty acid oxidation.",
          "score": 0.8997063636779785
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1476,
          "offsetInEndSection": 1658,
          "text": "Pharmacological intervention with rapamycin alleviated the ability of alcohol to up-regulate lipogenesis, to down-regulate fatty acid oxidation, and to induce steatogenic phenotypes.",
          "score": 0.8904263973236084
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1659,
          "offsetInEndSection": 1785,
          "text": "Chronic-plus-binge ethanol feeding led to activation of SREBP-1 and lipin 1 through S6K1-dependent and independent mechanisms.",
          "score": 0.8831996917724609
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1786,
          "offsetInEndSection": 1968,
          "text": "Furthermore, hepatocyte-specific deletion of SIRT1 disrupted DEPTOR function, enhanced mTORC1 activity, and exacerbated alcoholic fatty liver, inflammation, and liver injury in mice.",
          "score": 0.9080984592437744
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1969,
          "offsetInEndSection": 2198,
          "text": "The dysregulation of SIRT1-DEPTOR-mTORC1 signaling is a critical determinant of ALD pathology; targeting SIRT1 and DEPTOR and selectively inhibiting mTORC1-S6K1 signaling may have therapeutic potential for treating ALD in humans."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2199,
          "offsetInEndSection": 2217,
          "text": "(Hepatology 2018).",
          "score": 0.8677853345870972
        }
      ]
    },
    {
      "id": "67fbe4d718b1e36f2e00011d",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
        "http://www.ncbi.nlm.nih.gov/pubmed/12060782",
        "http://www.ncbi.nlm.nih.gov/pubmed/28949931",
        "http://www.ncbi.nlm.nih.gov/pubmed/24923803",
        "http://www.ncbi.nlm.nih.gov/pubmed/21575270",
        "http://www.ncbi.nlm.nih.gov/pubmed/26834590",
        "http://www.ncbi.nlm.nih.gov/pubmed/23510020",
        "http://www.ncbi.nlm.nih.gov/pubmed/20696312",
        "http://www.ncbi.nlm.nih.gov/pubmed/18451130",
        "http://www.ncbi.nlm.nih.gov/pubmed/10943908"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Heritable factors account for approximately 40-60% of the total variance of liability to alcohol dependence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 320,
          "text": "The present study tested whether a novel functional polymorphism in the promotor region of the X-chromosomal monoamine oxidase A gene (MAOA) was related to antisocial and anxious-depressive traits in alcoholics.",
          "score": 0.9015063047409058
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 321,
          "offsetInEndSection": 480,
          "text": "Due to the X-chromosomal localization of the MAOA gene, psychobiological traits were compared separately for both genders of 298 male and 66 female alcoholics.",
          "score": 0.9002926349639893
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 655,
          "text": "In males, 30 of 59 alcoholics with antisocial personality disorder carried the low-activity 3-repeat allele in contrast to only 7 of 31 anxious-depressive alcoholics (51% vs.",
          "score": 0.8763111233711243
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 656,
          "offsetInEndSection": 671,
          "text": "23%; p = 0.02).",
          "score": 0.8391249179840088
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 672,
          "offsetInEndSection": 857,
          "text": "Likewise, female anxious-depressive alcoholics showed a trend towards a low frequency of genotypes with the 3 repeat allele compared to female alcoholics without these symptoms (29% vs.",
          "score": 0.871370792388916
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 858,
          "offsetInEndSection": 873,
          "text": "53%; p = 0.09).",
          "score": 0.8371235132217407
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 874,
          "offsetInEndSection": 1074,
          "text": "Taken together, these findings suggest that the 3-repeat allele of the MAOA polymorphism contributes modestly to the dimension of overand underreactive behaviors as possible antecedents of alcoholism.",
          "score": 0.8945516347885132
        }
      ]
    },
    {
      "id": "680a079718b1e36f2e000147",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34535671",
        "http://www.ncbi.nlm.nih.gov/pubmed/24941379",
        "http://www.ncbi.nlm.nih.gov/pubmed/30009514",
        "http://www.ncbi.nlm.nih.gov/pubmed/1423320",
        "http://www.ncbi.nlm.nih.gov/pubmed/23372568",
        "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
        "http://www.ncbi.nlm.nih.gov/pubmed/7517178",
        "http://www.ncbi.nlm.nih.gov/pubmed/29163501",
        "http://www.ncbi.nlm.nih.gov/pubmed/24348481",
        "http://www.ncbi.nlm.nih.gov/pubmed/29642292"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Curcumin is known to possess various biological functions, including anti-inflammatory, antioxidative, and anti-cancer activities.",
          "score": 0.8652849197387695
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 211,
          "text": "Natural killer (NK) cells are large lymphocytes that directly kill cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 212,
          "offsetInEndSection": 358,
          "text": "However, many aggressive cancers, including breast cancer, were reported to escape the successful killing of NK cells in a tumor microenvironment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 359,
          "offsetInEndSection": 496,
          "text": "In this study, we investigated the anti-cancer effect of curcumin in coculture of human breast carcinoma MDA-MB-231 and NK (NK-92) cells.",
          "score": 0.9068818092346191
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 620,
          "text": "We found that curcumin had an immune-stimulatory effect on NK-92 by increasing the surface expression of the CD16\u207a and CD56",
          "score": 0.898406445980072
        }
      ]
    },
    {
      "id": "67e5749b18b1e36f2e0000b5",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23153524",
        "http://www.ncbi.nlm.nih.gov/pubmed/33168588",
        "http://www.ncbi.nlm.nih.gov/pubmed/24014301",
        "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
        "http://www.ncbi.nlm.nih.gov/pubmed/25685858",
        "http://www.ncbi.nlm.nih.gov/pubmed/21371446",
        "http://www.ncbi.nlm.nih.gov/pubmed/26894970",
        "http://www.ncbi.nlm.nih.gov/pubmed/31547472",
        "http://www.ncbi.nlm.nih.gov/pubmed/24009233",
        "http://www.ncbi.nlm.nih.gov/pubmed/26642065"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 349,
          "text": "In this article, we not only review the preclinical and clinical studies of cyclin-dependent kinase (CDK) 4/6 inhibitors in breast cancer, liposarcoma, mantel cell lymphoma, melanoma and germ cell tumors, but also examine promising preclinical data in glioblastoma, renal and ovarian cancer models that may provide directions for future development.",
          "score": 0.8833122253417969
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 350,
          "offsetInEndSection": 436,
          "text": "Targeting CDKs has been the focus of considerable basic science and clinical research.",
          "score": 0.885269284248352
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 573,
          "text": "The CDK 4/6 inhibitors are a novel class of therapeutics that target the CDK 4/6 kinases that promote transition through the cell cycle.",
          "score": 0.8740459084510803
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 574,
          "offsetInEndSection": 725,
          "text": "Currently, palbociclib (PD0332991, Pfizer), abemaciclib (LY2835219, Lilly) and ribociclib (LEE011, Novartis) are being investigated in clinical trials.",
          "score": 0.8686584830284119
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 726,
          "offsetInEndSection": 848,
          "text": "These oral agents offer the hope of clinical efficacy in many tumor types, and have been associated with minimal toxicity.",
          "score": 0.8482779860496521
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 849,
          "offsetInEndSection": 1019,
          "text": "Amplification/overexpression of cyclin D, loss of CDKN2A (p16) and amplification/overexpression of CDK4 are proposed biomarkers of improved response to CDK4/6 inhibition.",
          "score": 0.870684027671814
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1020,
          "offsetInEndSection": 1176,
          "text": "Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma.",
          "score": 0.8788506984710693
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1177,
          "offsetInEndSection": 1362,
          "text": "Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development.",
          "score": 0.8758033514022827
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1363,
          "offsetInEndSection": 1531,
          "text": "Further preclinical and clinical research is needed to better understand mechanisms of resistance and develop rational combination therapies with other targeted agents.",
          "score": 0.8532071709632874
        }
      ]
    },
    {
      "id": "680d5f2a353a4a2e6b000006",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21881964",
        "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
        "http://www.ncbi.nlm.nih.gov/pubmed/24730627",
        "http://www.ncbi.nlm.nih.gov/pubmed/24019633",
        "http://www.ncbi.nlm.nih.gov/pubmed/9559208",
        "http://www.ncbi.nlm.nih.gov/pubmed/9927835",
        "http://www.ncbi.nlm.nih.gov/pubmed/21172808",
        "http://www.ncbi.nlm.nih.gov/pubmed/27421131",
        "http://www.ncbi.nlm.nih.gov/pubmed/37064719",
        "http://www.ncbi.nlm.nih.gov/pubmed/19529061"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Kartagener Syndrome is a rare autosomal recessive disorder consisting of triad of sinusitis, bronchiectasis and situs inversus with dextrocardia.",
          "score": 0.887844979763031
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 322,
          "text": "It is the subset of disorder called primary ciliary dyskinesia in which the cilia have abnormal structure and/or function resulting in multisystem diseases of various severity.",
          "score": 0.8667125701904297
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 323,
          "offsetInEndSection": 463,
          "text": "Clinical manifestations include lifelong, chronic upper and lower respiratory tract diseases secondary to ineffective mucociliary clearance.",
          "score": 0.8783475160598755
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 464,
          "offsetInEndSection": 601,
          "text": "Early diagnosis and management of chest infections can prevent irreversible damage to lungs and prevent potential lifelong complications.",
          "score": 0.8713406324386597
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 602,
          "offsetInEndSection": 757,
          "text": "This case report is on a patient who presented with long standing history of sinusitis, bronchiectasis and on examination situs inversus with dextrocardia."
        }
      ]
    },
    {
      "id": "6810f6f0353a4a2e6b000015",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22675341",
        "http://www.ncbi.nlm.nih.gov/pubmed/32233338",
        "http://www.ncbi.nlm.nih.gov/pubmed/26587691",
        "http://www.ncbi.nlm.nih.gov/pubmed/27042424",
        "http://www.ncbi.nlm.nih.gov/pubmed/19436648",
        "http://www.ncbi.nlm.nih.gov/pubmed/30678612",
        "http://www.ncbi.nlm.nih.gov/pubmed/25202980",
        "http://www.ncbi.nlm.nih.gov/pubmed/24247648",
        "http://www.ncbi.nlm.nih.gov/pubmed/34431633",
        "http://www.ncbi.nlm.nih.gov/pubmed/25237400"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been shown to possess pleiotropic effects including body weight reduction.",
          "score": 0.9228579998016357
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 280,
          "text": "However, long-term effect of liraglutide on body weight and glycemic control has not been elucidated in Japanese type 2 diabetes (T2D) subjects.",
          "score": 0.9189140796661377
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 281,
          "offsetInEndSection": 441,
          "text": "Present study investigates whether liraglutide treatment maintains the body weight-decreasing and glucose-lowering effects for 2\u00a0years in Japanese T2D subjects.",
          "score": 0.9168131351470947
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 442,
          "offsetInEndSection": 667,
          "text": "The enrolled subjects were 86 T2D patients [age; 59.8\u2009\u00b1\u200912.8\u00a0years, duration of diabetes; 15.8\u2009\u00b1\u20099.5\u00a0years, glycated hemoglobin (HbA1c); 8.5\u2009\u00b1\u20091.5%, body mass index (BMI); 27.3\u2009\u00b1\u20095.4\u00a0kg/m(2) (15.8 - 46.5\u00a0kg/m(2)), mean\u2009\u00b1\u2009SD].",
          "score": 0.9012815952301025
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 668,
          "offsetInEndSection": 793,
          "text": "Among 86 subjects, liraglutide was introduced in 25 inpatients and 61 outpatients, and 46 subjects were followed for 2\u00a0years.",
          "score": 0.9155371189117432
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 794,
          "offsetInEndSection": 902,
          "text": "Clinical parameters were measured at baseline and 3, 6, 9, 12, and 24\u00a0months after liraglutide introduction.",
          "score": 0.905988872051239
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 903,
          "offsetInEndSection": 1027,
          "text": "The increase in liraglutide dosage and the additional usage of glucose-lowering agents depended on each attending physician.",
          "score": 0.9019826054573059
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1028,
          "offsetInEndSection": 1162,
          "text": "At 1\u00a0year after liraglutide introduction, 69 patients (80.2%) decreased body weight and 58 patients (67.4%) improved glycemic control.",
          "score": 0.9226374626159668
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1163,
          "offsetInEndSection": 1356,
          "text": "Body mass index (BMI) was changed 27.3\u2009\u00b1\u20095.4\u00a0kg/m(2) to 25.9\u2009\u00b1\u20094.8\u00a0kg/m(2) and percent reduction of body weight was significant and maintained over 4% at 2\u00a0years after liraglutide introduction.",
          "score": 0.9229544401168823
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1357,
          "offsetInEndSection": 1433,
          "text": "HbA1c was significantly decreased from 8.5\u2009\u00b1\u20091.5% to 7.7\u2009\u00b1\u20091.2% for 2\u00a0years.",
          "score": 0.8804873824119568
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1434,
          "offsetInEndSection": 1511,
          "text": "Liraglutide treatment tended to ameliorate lipid profile and hepatic enzymes.",
          "score": 0.8906134963035583
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1512,
          "offsetInEndSection": 1763,
          "text": "Stepwise regression analysis demonstrated that baseline BMI and previous insulin dose were positively associated with body weight reduction and baseline HbA1c was positively associated with reduction of HbA1c at 2\u00a0years after liraglutide introduction.",
          "score": 0.9175651669502258
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1764,
          "offsetInEndSection": 1954,
          "text": "Long-term liraglutide treatment effectively maintained the reduction of body weight and the fair glycemic control, and also improved lipid profile and liver enzymes in Japanese T2D subjects.",
          "score": 0.9151724576950073
        }
      ]
    },
    {
      "id": "680a237618b1e36f2e000152",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34687436",
        "http://www.ncbi.nlm.nih.gov/pubmed/35587830",
        "http://www.ncbi.nlm.nih.gov/pubmed/22882019",
        "http://www.ncbi.nlm.nih.gov/pubmed/34775780",
        "http://www.ncbi.nlm.nih.gov/pubmed/20428822",
        "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
        "http://www.ncbi.nlm.nih.gov/pubmed/26420896",
        "http://www.ncbi.nlm.nih.gov/pubmed/21035151",
        "http://www.ncbi.nlm.nih.gov/pubmed/31088835",
        "http://www.ncbi.nlm.nih.gov/pubmed/35456984"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Despite the multidisciplinary management in the treatment of glioblastomas, the average survival of GBM patients is still 15 months.",
          "score": 0.902229905128479
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 258,
          "text": "In recent years, molecular biomarkers have gained more and more importance both in the diagnosis and therapy of glial tumors.",
          "score": 0.9085580706596375
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 427,
          "text": "At the same time, it has become clear that non neoplastic cells, which constitute about 30% of glioma mass, dramatically influence tumor growth, spread, and recurrence.",
          "score": 0.8943578600883484
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 428,
          "offsetInEndSection": 632,
          "text": "This is the main reason why, in recent years, scientific research has been focused on understanding the function and the composition of tumor microenvironment and its role in gliomagenesis and recurrence.",
          "score": 0.9199979305267334
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 633,
          "offsetInEndSection": 856,
          "text": "The aim of this review is to summarize the most recent discovery about resident microglia, tumor-associated macrophages, lymphocytes, and the role of extracellular vesicles and their bijective interaction with glioma cells.",
          "score": 0.8829233050346375
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 857,
          "offsetInEndSection": 990,
          "text": "Moreover, we reported the most recent updates about new therapeutic strategies targeting immune system receptors and soluble factors.",
          "score": 0.8520982265472412
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 991,
          "offsetInEndSection": 1220,
          "text": "Understanding how glioma cells interact with non-neoplastic cells in tumor microenvironment is an essential step to comprehend mechanisms at the base of disease progression and to find new therapeutic strategies for GBM patients.",
          "score": 0.910332441329956
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1221,
          "offsetInEndSection": 1499,
          "text": "However, no significant results have yet been obtained in studies targeting single molecules/pathways; considering the complex microenvironment, it is likely that only by using multiple therapeutic agents acting on multiple molecular targets can significant results be achieved.",
          "score": 0.8636308908462524
        }
      ]
    },
    {
      "id": "68110110353a4a2e6b000018",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12856055",
        "http://www.ncbi.nlm.nih.gov/pubmed/2582337",
        "http://www.ncbi.nlm.nih.gov/pubmed/20659474",
        "http://www.ncbi.nlm.nih.gov/pubmed/30261763",
        "http://www.ncbi.nlm.nih.gov/pubmed/11130352",
        "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
        "http://www.ncbi.nlm.nih.gov/pubmed/29540258",
        "http://www.ncbi.nlm.nih.gov/pubmed/9806661",
        "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
        "http://www.ncbi.nlm.nih.gov/pubmed/29454747"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Acetaminophen (APAP)-induced liver injury in mice is associated with activation of the coagulation cascade and deposition of fibrin in liver.",
          "score": 0.9225401878356934
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 309,
          "text": "Plasminogen activator inhibitor-1 (PAI-1) is an important physiological inhibitor of tissue-type plasminogen activator (tPA) and plays a critical role in fibrinolysis.",
          "score": 0.8647059202194214
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 310,
          "offsetInEndSection": 425,
          "text": "PAI-1 expression is increased in both experimental APAP-induced liver injury and patients with acute liver failure.",
          "score": 0.9115930795669556
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 426,
          "offsetInEndSection": 575,
          "text": "Prior studies have shown that PAI-1 prevents intrahepatic hemorrhage and mortality after APAP challenge, but the downstream mechanisms are not clear.",
          "score": 0.9225019216537476
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 703,
          "text": "We tested the hypothesis that PAI-1 limits liver-related morbidity after APAP challenge by reducing tPA-dependent fibrinolysis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 704,
          "offsetInEndSection": 924,
          "text": "Compared with APAP-challenged (300 mg/kg) wild-type mice, hepatic deposition of cross-linked fibrin was reduced, with intrahepatic congestion and hemorrhage increased in PAI-1-deficient mice 24 hours after APAP overdose.",
          "score": 0.9172580242156982
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 925,
          "offsetInEndSection": 1047,
          "text": "Administration of recombinant wild-type human PAI-1 reduced intrahepatic hemorrhage 24 hours after APAP challenge in PAI-1",
          "score": 0.9065083265304565
        }
      ]
    },
    {
      "id": "680f4c63353a4a2e6b00000d",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24469437",
        "http://www.ncbi.nlm.nih.gov/pubmed/17364993",
        "http://www.ncbi.nlm.nih.gov/pubmed/11808344",
        "http://www.ncbi.nlm.nih.gov/pubmed/11831069",
        "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
        "http://www.ncbi.nlm.nih.gov/pubmed/2515622",
        "http://www.ncbi.nlm.nih.gov/pubmed/12082821",
        "http://www.ncbi.nlm.nih.gov/pubmed/8115806",
        "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
        "http://www.ncbi.nlm.nih.gov/pubmed/26940379"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Bladder pain syndrome (BPS)/interstitial cystitis (IC) is associated with sensory lower urinary tract symptoms.",
          "score": 0.8828205466270447
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 284,
          "text": "Unfortunately, many of the existing oral treatments are ineffective in most patients of BPS/IC, which is the motivation for developing new drugs and therapeutic approaches.",
          "score": 0.9024878144264221
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 285,
          "offsetInEndSection": 368,
          "text": "This review covers the latest drugs that have been investigated in BPS/IC patients.",
          "score": 0.8870254755020142
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 486,
          "text": "Intravesical treatments offer the opportunity to directly target the painful bladder with less systemic side effects.",
          "score": 0.9170116186141968
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 487,
          "offsetInEndSection": 692,
          "text": "In this review, the authors analyze the existing literature supporting the treatment of BPS/IC with conventional drugs including heparin, hyaluronic acid, chondroitin sulfate, and dimethylsulfoxide (DMSO).",
          "score": 0.9069463014602661
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 693,
          "offsetInEndSection": 864,
          "text": "Furthermore, investigational drugs such as tanezumab and adalimumab, capable of sequestering nerve growth factor (NGF), and Tumor necrosis factor-\u03b1 (TNF- \u03b1) are discussed.",
          "score": 0.8739814758300781
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 865,
          "offsetInEndSection": 1092,
          "text": "Investigational treatments such as liposomes, botulinum toxin (BTX), liposomal BTX, PD-0299685 (a Ca(2+) channel \u02512\u03b4 ligand), continuous intravesical lidocaine, and AQX-1125 (a novel SHIP1 activating compound) are also covered.",
          "score": 0.8999282121658325
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1093,
          "offsetInEndSection": 1284,
          "text": "New investigational drugs offer promising improvements in clinical outcomes for BPS/IC patients; however, BPS/IC is a chronic pain disorder that is very vulnerable to a strong placebo effect.",
          "score": 0.8901001214981079
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1285,
          "offsetInEndSection": 1380,
          "text": "In addition, BPS/IC is a heterogeneous disorder that can be classified into several phenotypes.",
          "score": 0.8643142580986023
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1381,
          "offsetInEndSection": 1688,
          "text": "Since different phenotypes of BPS/IC respond differently to systemic and intravesical treatments, the authors believe that new drugs developed for BPS/IC are more likely to meet their predetermined clinical endpoints if the inclusion/exclusion criterion is tailored to specific phenotype of BPS/IC patients.",
          "score": 0.8889302015304565
        }
      ]
    },
    {
      "id": "680a087218b1e36f2e00014f",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
        "http://www.ncbi.nlm.nih.gov/pubmed/33817641",
        "http://www.ncbi.nlm.nih.gov/pubmed/26338180",
        "http://www.ncbi.nlm.nih.gov/pubmed/37132268",
        "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
        "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
        "http://www.ncbi.nlm.nih.gov/pubmed/34539983",
        "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
        "http://www.ncbi.nlm.nih.gov/pubmed/27556661",
        "http://www.ncbi.nlm.nih.gov/pubmed/20207611"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 61,
          "text": "Meningiomas are among the most common brain tumors in adults.",
          "score": 0.8822447061538696
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 62,
          "offsetInEndSection": 182,
          "text": "They are most commonly located over the cerebral convexities and are infrequently found in an intraventricular location.",
          "score": 0.8667961359024048
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 289,
          "text": "Ionizing cranial radiation is a risk factor for late occurrence of meningiomas within the radiation field.",
          "score": 0.8875441551208496
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 290,
          "offsetInEndSection": 446,
          "text": "While pathologic grading of meningiomas is straightforward, significant variability often exists between pathologists in applying standard grading criteria.",
          "score": 0.8844828605651855
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 447,
          "offsetInEndSection": 483,
          "text": "This has implications for prognosis.",
          "score": 0.8599409461021423
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 484,
          "offsetInEndSection": 550,
          "text": "Radiation-induced meningiomas may also have predilection to recur.",
          "score": 0.8847398161888123
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 551,
          "offsetInEndSection": 701,
          "text": "The authors describe a case of an intraventricular meningioma occurring 23 years after cranial irradiation for childhood acute lymphoblastic leukemia.",
          "score": 0.8549734950065613
        }
      ]
    },
    {
      "id": "6810daad353a4a2e6b000013",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26204547",
        "http://www.ncbi.nlm.nih.gov/pubmed/23844515",
        "http://www.ncbi.nlm.nih.gov/pubmed/27194400",
        "http://www.ncbi.nlm.nih.gov/pubmed/27648772",
        "http://www.ncbi.nlm.nih.gov/pubmed/24440934",
        "http://www.ncbi.nlm.nih.gov/pubmed/28506071",
        "http://www.ncbi.nlm.nih.gov/pubmed/16215086",
        "http://www.ncbi.nlm.nih.gov/pubmed/29020255",
        "http://www.ncbi.nlm.nih.gov/pubmed/25548572",
        "http://www.ncbi.nlm.nih.gov/pubmed/29450831"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection (CDI)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 360,
          "text": "There have been many well-conducted randomized controlled trials and thousands of patients reported in case series that describe success rates of approximately 90% following one or more FMT.",
          "score": 0.8988414406776428
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 361,
          "offsetInEndSection": 648,
          "text": "Although the exact mechanisms of FMT have yet to be fully elucidated, replacement or restoration of a 'normal' microbiota (or at least a microbiota resembling those who have never had CDI) appears to have a positive effect on the gut dysbiosis that is thought to exist in these patients.",
          "score": 0.9078157544136047
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 649,
          "offsetInEndSection": 834,
          "text": "Furthermore, despite being aesthetically unappealing, this 'ultimate probiotic' is a particularly attractive solution to a difficult problem that avoids repeated courses of antibiotics.",
          "score": 0.8768661618232727
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 835,
          "offsetInEndSection": 1116,
          "text": "The lack of clarity about the exact mechanism of action and the 'active ingredient' of FMT (e.g., individual or communities of bacteria, bacteriophage, or bioactive molecules such as bile acids) has hindered the ability to produce a standardized and well-characterized FMT product.",
          "score": 0.8954950571060181
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1117,
          "offsetInEndSection": 1270,
          "text": "There is no standard method to produce material for FMT, and there are a multitude of factors that can vary between institutions that offer this therapy.",
          "score": 0.8939803838729858
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1271,
          "offsetInEndSection": 1421,
          "text": "Only a few studies have directly compared clinical efficacy in groups of patients who have been treated with FMT prepared differently (e.g., fresh vs.",
          "score": 0.9049869775772095
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1422,
          "offsetInEndSection": 1556,
          "text": "frozen) or administered by different route (e.g., by nasojejunal tube, colonoscopy or by oral administration of encapsulated product).",
          "score": 0.8696881532669067
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1557,
          "offsetInEndSection": 1659,
          "text": "More of these studies should be undertaken to clarify the superiority or otherwise of these variables.",
          "score": 0.8218501210212708
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1660,
          "offsetInEndSection": 1834,
          "text": "This review describes the methods and protocols that two English NHS hospitals independently adopted over the same time period to provide FMT for patients with recurrent CDI.",
          "score": 0.8888951539993286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1835,
          "offsetInEndSection": 2021,
          "text": "There are several fundamental differences in the methods used, including selection and testing of donors, procedures for preparation and storage of material, and route of administration.",
          "score": 0.8455137610435486
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2022,
          "offsetInEndSection": 2107,
          "text": "These methods are described in detail in this review highlighting differing practice.",
          "score": 0.8240725994110107
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2108,
          "offsetInEndSection": 2256,
          "text": "Despite these significant methodological variations, clinical outcomes in terms of cure rate appear to be remarkably similar for both FMT providers.",
          "score": 0.8856555223464966
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2257,
          "offsetInEndSection": 2461,
          "text": "Although both hospitals have treated only modest numbers of patients, these findings suggest that many of the described differences may not be critical factors in influencing the success of the procedure.",
          "score": 0.8517664074897766
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2462,
          "offsetInEndSection": 2709,
          "text": "As FMT is increasingly being proposed for a number of conditions other than CDI, harmonization of methods and techniques may be more critical to the success of FMT, and thus it will be important to standardize these as far as practically possible.",
          "score": 0.897711992263794
        }
      ]
    },
    {
      "id": "6810c27b353a4a2e6b000010",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22934167",
        "http://www.ncbi.nlm.nih.gov/pubmed/25345238",
        "http://www.ncbi.nlm.nih.gov/pubmed/17074941",
        "http://www.ncbi.nlm.nih.gov/pubmed/12672169",
        "http://www.ncbi.nlm.nih.gov/pubmed/22090498",
        "http://www.ncbi.nlm.nih.gov/pubmed/23042258",
        "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
        "http://www.ncbi.nlm.nih.gov/pubmed/23681158",
        "http://www.ncbi.nlm.nih.gov/pubmed/17440145",
        "http://www.ncbi.nlm.nih.gov/pubmed/23425613"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "The present analysis evaluates the prevalence and medication use in inpatients with depression during childhood and adolescence at the KinderAGATE hospitals in 2010.",
          "score": 0.8987232446670532
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 210,
          "text": "Also discussed are age and sex distribution.",
          "score": 0.8595725297927856
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 418,
          "text": "Since 2009 the following information has been recorded anonymously twice a year from each patient at the participating hospitals of KinderAGATE: age, sex, leading diagnosis, prescribed medication and dosage.",
          "score": 0.8684254884719849
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 419,
          "offsetInEndSection": 564,
          "text": "The data obtained provide an excellent epidemiological basis for the observation of the prescription practice in child and adolescent psychiatry.",
          "score": 0.8713647723197937
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 565,
          "offsetInEndSection": 673,
          "text": "In 2010, 8.4 % of the patients included were treated for a depressive disorder at the KinderAGATE hospitals.",
          "score": 0.8802658319473267
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 674,
          "offsetInEndSection": 772,
          "text": "This is only a small portion compared to the rates found in adult psychiatry (25.8 % of patients).",
          "score": 0.8638603687286377
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 773,
          "offsetInEndSection": 950,
          "text": "In our sample male patients diagnosed with depression (58 % DPat, mean age 13.8 years) were treated more often and earlier than female patients (42 % DPat, mean age 15.3 years).",
          "score": 0.8913359642028809
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 951,
          "offsetInEndSection": 1025,
          "text": "Fluoxetine and mirtazapine were the most frequently prescribed substances.",
          "score": 0.8879485130310059
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1026,
          "offsetInEndSection": 1088,
          "text": "Sertraline, escitalopram, and citalopram were also prescribed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1089,
          "offsetInEndSection": 1170,
          "text": "A reserved medical treatment can be observed in child and adolescence psychiatry.",
          "score": 0.8854755163192749
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1171,
          "offsetInEndSection": 1261,
          "text": "Off-label use seems to be nearly unavoidable due to the lack of newly authorized medicine.",
          "score": 0.842113196849823
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1262,
          "offsetInEndSection": 1438,
          "text": "Moreover, the numerous prescriptions for fluoxetine, the only SSRI currently approved for this age group in Germany, lead to the question of possible unauthorized alternatives."
        }
      ]
    },
    {
      "id": "680a07a418b1e36f2e000148",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11994452",
        "http://www.ncbi.nlm.nih.gov/pubmed/21439318",
        "http://www.ncbi.nlm.nih.gov/pubmed/31856298",
        "http://www.ncbi.nlm.nih.gov/pubmed/32687059",
        "http://www.ncbi.nlm.nih.gov/pubmed/28382035",
        "http://www.ncbi.nlm.nih.gov/pubmed/14727085",
        "http://www.ncbi.nlm.nih.gov/pubmed/29395860",
        "http://www.ncbi.nlm.nih.gov/pubmed/11188932",
        "http://www.ncbi.nlm.nih.gov/pubmed/24325394",
        "http://www.ncbi.nlm.nih.gov/pubmed/11570584"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Due to their central role in controlling immunity, dendritic cells are logical targets for priming naive cytotoxic T lymphocytes against tumour cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 306,
          "text": "In a strictly autologous system, we fused dendritic cells with melanoma cells, both of which were derived from patients with metastatic malignant melanoma.",
          "score": 0.8919882774353027
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 307,
          "offsetInEndSection": 458,
          "text": "Hybridomas were positive for major histocompatibility complex (MHC) class II, CD40, CD54, CD83, CD86, and the pro-inflammatory cytokine interleukin-12.",
          "score": 0.904024600982666
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 459,
          "offsetInEndSection": 518,
          "text": "Autologous T lymphocytes were co-incubated with hybridomas.",
          "score": 0.8904680013656616
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 669,
          "text": "After 6 days, in-vitro-primed T lymphocytes revealed a strong proliferation activity and released Th-1-associated, but not Th-2-associated, cytokines.",
          "score": 0.9028486013412476
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 670,
          "offsetInEndSection": 789,
          "text": "Furthermore they showed effective anti-melanoma activity, resulting in death of 70 +/- 9% of autologous melanoma cells.",
          "score": 0.8684507608413696
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 790,
          "offsetInEndSection": 951,
          "text": "After depletion of CD4+ cells from the mixed population of primed T lymphocytes, the remaining CD8+ cells were able to kill 63+/-8% of autologous melanoma cells.",
          "score": 0.897200345993042
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 952,
          "offsetInEndSection": 1108,
          "text": "Following depletion of CD8+ cells, however, the cytotoxic capacity of the remaining T lymphocytes caused death in only 32+/-6% of autologous melanoma cells.",
          "score": 0.8853713274002075
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1109,
          "offsetInEndSection": 1299,
          "text": "Blocking of MHC class I, but not class II, molecules on hybridomas impaired T cell proliferation, secretion of Th-1-associated cytokines, as well as the cytotoxic activity of primed T cells.",
          "score": 0.9092658162117004
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1300,
          "offsetInEndSection": 1536,
          "text": "These findings strongly suggest that hybridomas deliver melanoma-associated antigens via MHC class I molecules to T lymphocytes, resulting in the generation of CD8+ cytotoxic T lymphocytes with effective anti-melanoma activity in vitro.",
          "score": 0.9039414525032043
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1537,
          "offsetInEndSection": 1644,
          "text": "The data may serve as a basis for the use of hybridomas in the immunotherapy of malignant melanoma in vivo.",
          "score": 0.8699615001678467
        }
      ]
    },
    {
      "id": "67fbd58c18b1e36f2e00010e",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23225525",
        "http://www.ncbi.nlm.nih.gov/pubmed/28751258",
        "http://www.ncbi.nlm.nih.gov/pubmed/22405725",
        "http://www.ncbi.nlm.nih.gov/pubmed/37905874",
        "http://www.ncbi.nlm.nih.gov/pubmed/19378813",
        "http://www.ncbi.nlm.nih.gov/pubmed/23965852",
        "http://www.ncbi.nlm.nih.gov/pubmed/29441009",
        "http://www.ncbi.nlm.nih.gov/pubmed/23629963",
        "http://www.ncbi.nlm.nih.gov/pubmed/20356930",
        "http://www.ncbi.nlm.nih.gov/pubmed/25645281"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Several neurodegenerative diseases such as transmissible spongiform encephalopathies, Alzheimer's and Parkinson's diseases are caused by the conversion of cellular proteins to a pathogenic conformer.",
          "score": 0.9420049786567688
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 200,
          "offsetInEndSection": 508,
          "text": "Despite differences in the primary structure and subcellular localization of these proteins, which include the prion protein, \u03b1-synuclein and amyloid precursor protein (APP), striking similarity has been observed in their ability to seed and convert na\u00efve protein molecules as well as transfer between cells.",
          "score": 0.9258695840835571
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 509,
          "offsetInEndSection": 843,
          "text": "This review aims to cover what is known about the intracellular trafficking of these proteins as well as their degradation mechanisms and highlight similarities in their movement through the endocytic pathway that could contribute to the pathogenic conversion and seeding of these proteins which underlies the basis of these diseases.",
          "score": 0.9282490015029907
        }
      ]
    },
    {
      "id": "67fbe10618b1e36f2e000111",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30127341",
        "http://www.ncbi.nlm.nih.gov/pubmed/24065914",
        "http://www.ncbi.nlm.nih.gov/pubmed/23602925",
        "http://www.ncbi.nlm.nih.gov/pubmed/22958973",
        "http://www.ncbi.nlm.nih.gov/pubmed/17347940",
        "http://www.ncbi.nlm.nih.gov/pubmed/1623312",
        "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
        "http://www.ncbi.nlm.nih.gov/pubmed/27974283",
        "http://www.ncbi.nlm.nih.gov/pubmed/21571763",
        "http://www.ncbi.nlm.nih.gov/pubmed/23666287"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "The Autistic Spectrum Disorders (ASD) are characterized by an atypical sociability, alterations in communication, restricted interests and stereotypies, with adding affective and adaptative disabilities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 204,
          "offsetInEndSection": 325,
          "text": "The suicidal behaviors are frequently observed in the adolescents and adults with an ASD without intellectual deficience.",
          "score": 0.9137104749679565
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 435,
          "text": "However, the clinical research on the topic is limited and the diagnosis not assessed in the emergency units.",
          "score": 0.8642103672027588
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 436,
          "offsetInEndSection": 598,
          "text": "Among the individual risk factors of the suicidal behavior in ASD patients, mood and anxiety disorders are found as well as a familial affective disorder history.",
          "score": 0.9145143032073975
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 599,
          "offsetInEndSection": 714,
          "text": "The intimidation and the lack of socio-professional integration were also reported as environnemental risk factors.",
          "score": 0.848859429359436
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 715,
          "offsetInEndSection": 850,
          "text": "Laters tudies taking into account the cognitive characteristics would permit to investigate the suicidal phenomenology in ASD patients.",
          "score": 0.8843029737472534
        }
      ]
    },
    {
      "id": "680fcb72353a4a2e6b00000e",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8918594",
        "http://www.ncbi.nlm.nih.gov/pubmed/32370812",
        "http://www.ncbi.nlm.nih.gov/pubmed/23105285",
        "http://www.ncbi.nlm.nih.gov/pubmed/9150551",
        "http://www.ncbi.nlm.nih.gov/pubmed/23105292",
        "http://www.ncbi.nlm.nih.gov/pubmed/16157351",
        "http://www.ncbi.nlm.nih.gov/pubmed/2687698",
        "http://www.ncbi.nlm.nih.gov/pubmed/22067045",
        "http://www.ncbi.nlm.nih.gov/pubmed/22560084",
        "http://www.ncbi.nlm.nih.gov/pubmed/22390546"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Human polyclonal IgG antibodies directly against the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc) are potential biomarkers and mechanistic contributors to cancer and other diseases associated with chronic inflammation.",
          "score": 0.8879387378692627
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 230,
          "offsetInEndSection": 390,
          "text": "Using a sialoglycan microarray, we screened the binding pattern of such antibodies (anti-Neu5Gc IgG) in several samples of clinically approved human IVIG (IgG).",
          "score": 0.8931282758712769
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 519,
          "text": "These results were used to select an appropriate sample for a multistep affinity purification of the xeno-autoantibody fraction.",
          "score": 0.8777855038642883
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 520,
          "offsetInEndSection": 711,
          "text": "The sample was then analyzed via our multienzyme digestion procedure followed by nano liquid chromatography (nanoLC) coupled to linear ion trap-Fourier transform mass spectrometry (LTQ-FTMS).",
          "score": 0.8413970470428467
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 962,
          "text": "We used characteristic and unique peptide sequences to determine the IgG subclass distribution and thus provided direct evidence that all four IgG subclasses can be generated during a xeno-autoantibody immune response to carbohydrate Neu5Gc-antigens.",
          "score": 0.9118553400039673
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 963,
          "offsetInEndSection": 1072,
          "text": "Furthermore, we obtained a significant amount of sequence coverage of both the constant and variable regions.",
          "score": 0.853691816329956
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1238,
          "text": "The approach described here, therefore, provides a way to characterize these clinically significant antibodies, helping to understand their origins and significance.",
          "score": 0.9022745490074158
        }
      ]
    },
    {
      "id": "6805568118b1e36f2e000145",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26478806",
        "http://www.ncbi.nlm.nih.gov/pubmed/23964859",
        "http://www.ncbi.nlm.nih.gov/pubmed/23282091",
        "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
        "http://www.ncbi.nlm.nih.gov/pubmed/26416477",
        "http://www.ncbi.nlm.nih.gov/pubmed/29105160",
        "http://www.ncbi.nlm.nih.gov/pubmed/24488306",
        "http://www.ncbi.nlm.nih.gov/pubmed/33179277",
        "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
        "http://www.ncbi.nlm.nih.gov/pubmed/21067460"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "genetic and pharmacologically-driven variations in common mechanisms involved in the disposition of antidepressant medications may contribute to variable interpatient response.",
          "score": 0.8657318353652954
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 355,
          "text": "This review describes the pharmacological properties underlying the safety and efficacy of desvenlafaxine, a second-generation serotonin-norepinephrine reuptake inhibitor (SNRI).",
          "score": 0.9053385853767395
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 356,
          "offsetInEndSection": 456,
          "text": "literature published between January 2006 and September 2010 evaluating desvenlafaxine was reviewed.",
          "score": 0.8638365268707275
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 457,
          "offsetInEndSection": 563,
          "text": "Desvenlafaxine therapy is initiated at the therapeutic dose (50 mg/day) without a need for dose titration.",
          "score": 0.8927726745605469
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 564,
          "offsetInEndSection": 725,
          "text": "Desvenlafaxine metabolism and distribution are not appreciably affected by altered function of cytochrome P450 (CYP) enzymes or permeability glycoprotein (P-gp).",
          "score": 0.8772532939910889
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 726,
          "offsetInEndSection": 810,
          "text": "Desvenlafaxine has clinically insignificant effects on the activity of CYP and P-gp.",
          "score": 0.8837558031082153
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 811,
          "offsetInEndSection": 901,
          "text": "The efficacy of desvenlafaxine in treating major depressive disorder has been established.",
          "score": 0.8895628452301025
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 902,
          "offsetInEndSection": 954,
          "text": "Adverse events are characteristic of the SNRI class.",
          "score": 0.8628922700881958
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 955,
          "offsetInEndSection": 1102,
          "text": "Notably, the rate of discontinuation due to adverse events with the 50 mg/day recommended therapeutic dose is comparable to that seen with placebo.",
          "score": 0.8802109956741333
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1416,
          "text": "incremental benefits with desvenlafaxine, derived from straight-forward dosing, a simple metabolic profile and lack of interaction with active transporter P-gp and CYP enzymes may contribute to more consistent response, good tolerability and lower incidence of drug-drug interactions with concomitant medications.",
          "score": 0.8940450549125671
        }
      ]
    },
    {
      "id": "67e26b0b18b1e36f2e000073",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18688681",
        "http://www.ncbi.nlm.nih.gov/pubmed/35198223",
        "http://www.ncbi.nlm.nih.gov/pubmed/23765730",
        "http://www.ncbi.nlm.nih.gov/pubmed/31752657",
        "http://www.ncbi.nlm.nih.gov/pubmed/16387374",
        "http://www.ncbi.nlm.nih.gov/pubmed/38090463",
        "http://www.ncbi.nlm.nih.gov/pubmed/32693809",
        "http://www.ncbi.nlm.nih.gov/pubmed/22427775",
        "http://www.ncbi.nlm.nih.gov/pubmed/21503250",
        "http://www.ncbi.nlm.nih.gov/pubmed/19185360"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19185360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Tako-Tsubo cardiomyopathy is characterized by a transient and reversible left ventricular dysfunction possibly due to a catecholamine-mediated myocardial stunning.",
          "score": 0.9267423152923584
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19185360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 236,
          "text": "This form of cardiomyopathy is rarely associated with cardiogenic shock.",
          "score": 0.8911932706832886
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19185360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 421,
          "text": "Here we report on a patient with Tako-Tsubo cardiomyopathy induced low output failure in which blood flow disturbances in the thoracic aorta mimicked an acute type A aortic dissection.",
          "score": 0.9070626497268677
        }
      ]
    },
    {
      "id": "680a080b18b1e36f2e00014b",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34780382",
        "http://www.ncbi.nlm.nih.gov/pubmed/28865512",
        "http://www.ncbi.nlm.nih.gov/pubmed/22939693",
        "http://www.ncbi.nlm.nih.gov/pubmed/21416408",
        "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
        "http://www.ncbi.nlm.nih.gov/pubmed/36286062",
        "http://www.ncbi.nlm.nih.gov/pubmed/18988199",
        "http://www.ncbi.nlm.nih.gov/pubmed/30598662",
        "http://www.ncbi.nlm.nih.gov/pubmed/33256196",
        "http://www.ncbi.nlm.nih.gov/pubmed/32863742"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32863742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 3,
          "text": "The"
        }
      ]
    },
    {
      "id": "6810db0a353a4a2e6b000014",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19412502",
        "http://www.ncbi.nlm.nih.gov/pubmed/21176430",
        "http://www.ncbi.nlm.nih.gov/pubmed/17653994",
        "http://www.ncbi.nlm.nih.gov/pubmed/28624931",
        "http://www.ncbi.nlm.nih.gov/pubmed/16283319",
        "http://www.ncbi.nlm.nih.gov/pubmed/28690860",
        "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
        "http://www.ncbi.nlm.nih.gov/pubmed/37609293",
        "http://www.ncbi.nlm.nih.gov/pubmed/33388011",
        "http://www.ncbi.nlm.nih.gov/pubmed/14636645"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Familial Mediterranean fever (FMF) is an autosomal recessive disorder characterized by recurrent attacks of fever, serositis, and a risk for AA amyloidosis.",
          "score": 0.9150549173355103
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 304,
          "text": "FMF is caused by mutations in the Mediterranean fever gene (MEFV), which is expressed in blood cells of the myelomonocytic differentiation pathway."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 305,
          "offsetInEndSection": 405,
          "text": "We identified a novel mutation S1791 in exon 2 of MEFV in two members of a family of Turkish origin.",
          "score": 0.8602355718612671
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 406,
          "offsetInEndSection": 564,
          "text": "In both cases, S1791 was in compound heterozygosity with MEFV mutation M694V, and the characteristic clinical syndrome of FMF including amyloidosis was found.",
          "score": 0.8611241579055786
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 565,
          "offsetInEndSection": 866,
          "text": "The location of S1791 in exon 2 is of interest because (1) amyloidosis in FMF has previously been found to be strongly associated with compound exon 10 mutations and (2) it supports the notion that the mechanism causing FMF is connected to the cytoplasmic rather than nuclear function of the molecule.",
          "score": 0.8825743198394775
        }
      ]
    },
    {
      "id": "67e2cfcf18b1e36f2e00009a",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
        "http://www.ncbi.nlm.nih.gov/pubmed/22338309",
        "http://www.ncbi.nlm.nih.gov/pubmed/22716221",
        "http://www.ncbi.nlm.nih.gov/pubmed/19382614",
        "http://www.ncbi.nlm.nih.gov/pubmed/16463613",
        "http://www.ncbi.nlm.nih.gov/pubmed/23757624",
        "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
        "http://www.ncbi.nlm.nih.gov/pubmed/28131133",
        "http://www.ncbi.nlm.nih.gov/pubmed/21170699",
        "http://www.ncbi.nlm.nih.gov/pubmed/21113693"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Osteoporosis in men is finally receiving some attention; it has been realized that men are more likely to die after hip fracture.",
          "score": 0.9138846397399902
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 316,
          "text": "Methods for screening men for osteoporosis include dual energy x-ray absorptiometry and use of fracture risk calculators such as FRAX (World Health Organization) and the Garvan nomogram.",
          "score": 0.9182946681976318
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 317,
          "offsetInEndSection": 421,
          "text": "Evaluation of men will often identify secondary causes of osteoporosis as well as multiple risk factors.",
          "score": 0.9196932315826416
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 422,
          "offsetInEndSection": 550,
          "text": "Alendronate, risedronate, zoledronic acid, and teriparatide are US Food and Drug Administration (FDA)--approved therapy for men.",
          "score": 0.9123983383178711
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 551,
          "offsetInEndSection": 707,
          "text": "Men on androgen deprivation therapy (ADT) are at high risk for bone loss and fracture, and all the bisphosphonates have been shown to increase bone density.",
          "score": 0.9240270256996155
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 708,
          "offsetInEndSection": 935,
          "text": "The new antiresorptive drug, denosumab, although FDA-approved only for postmenopausal women, has been shown in a study of men on ADT to increase bone density in spine, hip, and forearm and decrease vertebral fractures on x-ray.",
          "score": 0.9344779253005981
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1038,
          "text": "Thus, there is great progress in osteoporosis in men, and recognition of its importance is increasing.",
          "score": 0.9055620431900024
        }
      ]
    },
    {
      "id": "680a081d18b1e36f2e00014c",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
        "http://www.ncbi.nlm.nih.gov/pubmed/25518365",
        "http://www.ncbi.nlm.nih.gov/pubmed/32962914",
        "http://www.ncbi.nlm.nih.gov/pubmed/21041318",
        "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
        "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
        "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
        "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
        "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
        "http://www.ncbi.nlm.nih.gov/pubmed/17676593"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Astrocytes express voltage-gated calcium channels (VGCCs) that are upregulated in the context of the reactive astrogliosis occurring in several CNS pathologies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 308,
          "text": "Moreover, the ability of selective calcium channel blockers to inhibit reactive astrogliosis has been revealed in a variety of experimental models.",
          "score": 0.9134448766708374
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 309,
          "offsetInEndSection": 397,
          "text": "However, the functions and regulation of VGCC in astrocytes are still poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 398,
          "offsetInEndSection": 594,
          "text": "Interestingly, protein kinase C epsilon (PKCepsilon), one of the known regulators of VGCC in several cell types, induces in astrocytes a stellated morphology similar to that associated to gliosis.",
          "score": 0.9185462594032288
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 595,
          "offsetInEndSection": 704,
          "text": "Thereby, here we explored the possible regulation of VGCC by adenovirally expressed PKCepsilon in astrocytes.",
          "score": 0.9090698957443237
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 705,
          "offsetInEndSection": 875,
          "text": "We found that PKCepsilon potently increases the mRNA levels of two different calcium channel alpha(1) subunits, Ca(V)1.2 (L-type channel) and Ca(V)2.1 (P/Q-type channel).",
          "score": 0.8711429238319397
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 876,
          "offsetInEndSection": 962,
          "text": "The mRNA upregulation was followed by a robust increase in the corresponding peptides.",
          "score": 0.8598887920379639
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 963,
          "offsetInEndSection": 1186,
          "text": "Moreover, the new calcium channels formed as a consequence of PKCepsilon activation are functional, since overexpression of constitutively-active PKCepsilon increased significantly the calcium current density in astrocytes.",
          "score": 0.9067997336387634
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1187,
          "offsetInEndSection": 1255,
          "text": "PKCepsilon raised currents carried by both L- and P/Q-type channels.",
          "score": 0.8524832129478455
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1256,
          "offsetInEndSection": 1429,
          "text": "However, the effect on the P/Q-type channel was more prominent since an increase of the relative contribution of this channel to the whole cell calcium current was observed.",
          "score": 0.8682119250297546
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1430,
          "offsetInEndSection": 1670,
          "text": "Finally, we found that PKCepsilon-induced stellation was significantly reduced by the specific L-type channel blocker nifedipine, indicating that calcium influx through VGCC mediates the change in astrocyte morphology induced by PKCepsilon.",
          "score": 0.9128358364105225
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1671,
          "offsetInEndSection": 1804,
          "text": "Therefore, here we describe a novel regulatory pathway involving VGCC that participates in PKCepsilon-dependent astrocyte activation.",
          "score": 0.916244387626648
        }
      ]
    },
    {
      "id": "6810ff8f353a4a2e6b000017",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21561807",
        "http://www.ncbi.nlm.nih.gov/pubmed/2943896",
        "http://www.ncbi.nlm.nih.gov/pubmed/22695290",
        "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
        "http://www.ncbi.nlm.nih.gov/pubmed/16804313",
        "http://www.ncbi.nlm.nih.gov/pubmed/18425908",
        "http://www.ncbi.nlm.nih.gov/pubmed/21764126",
        "http://www.ncbi.nlm.nih.gov/pubmed/23277022",
        "http://www.ncbi.nlm.nih.gov/pubmed/16034960",
        "http://www.ncbi.nlm.nih.gov/pubmed/22845405"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "The outcome of ovarian cancer remains poor with conventional therapy.",
          "score": 0.9039199352264404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 213,
          "text": "Intraperitoneal chemotherapy has some advantages over systemic chemotherapy, including favorable pharmacokinetics and optimal treatment timing.",
          "score": 0.8881193399429321
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 430,
          "text": "Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) provides improved exposure of the entire seroperitoneal surface to the agent and utilizes the direct cytoxic and drug-enhancing effect of hyperthermia.",
          "score": 0.896963357925415
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 648,
          "text": "While standard normothermic, nonintraoperative, intraperitoneal chemotherapy has been demonstrated to be beneficial in randomized trials and meta-analyses, there are no data from randomized HIPEC trials available yet.",
          "score": 0.8982545137405396
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 649,
          "offsetInEndSection": 911,
          "text": "Cautious extrapolation of data from standard normothermic, nonintraoperative, intraperitoneal chemotherapy and data from Phase II and nonrandomized comparative studies suggest that HIPEC delivered at the time of surgery for ovarian cancer has definite potential.",
          "score": 0.9134789705276489
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 912,
          "offsetInEndSection": 1161,
          "text": "Data from ongoing randomized HIPEC trials to adequately answer the question of whether the addition of HIPEC actually prolongs survival in patients with peritoneal dissemination of primary and recurrent ovarian cancer are awaited in the near future.",
          "score": 0.8959447145462036
        }
      ]
    },
    {
      "id": "67fbe21818b1e36f2e000113",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15132715",
        "http://www.ncbi.nlm.nih.gov/pubmed/8608779",
        "http://www.ncbi.nlm.nih.gov/pubmed/19138419",
        "http://www.ncbi.nlm.nih.gov/pubmed/18055323",
        "http://www.ncbi.nlm.nih.gov/pubmed/22019751",
        "http://www.ncbi.nlm.nih.gov/pubmed/21789282",
        "http://www.ncbi.nlm.nih.gov/pubmed/22649416",
        "http://www.ncbi.nlm.nih.gov/pubmed/22560341",
        "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
        "http://www.ncbi.nlm.nih.gov/pubmed/22891351"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Although tyrosine-phosphorylated or activated STAT3 (pY-STAT3) is a well-described mediator of tumorigenesis, its role in thyroid cancer has not been investigated.",
          "score": 0.9140414595603943
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 346,
          "text": "We observed that 63 of 110 (57%) human primary papillary thyroid carcinoma (PTC) cases expressed nuclear pY-STAT3 in tumor cells, preferentially in association with the tumor stroma.",
          "score": 0.9034192562103271
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 467,
          "text": "An inverse relationship between pY-STAT3 expression with tumor size and the presence of distant metastases was observed.",
          "score": 0.8793469071388245
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 468,
          "offsetInEndSection": 751,
          "text": "Using human thyroid cancer-derived cell lines [harboring rearranged during transfection (RET)/PTC, v-RAF murine sarcoma viral oncogene homolog B (BRAF), or rat sarcoma virus oncogene (RAS) alterations], we determined that IL-6/gp130/JAK signaling is responsible for STAT3 activation.",
          "score": 0.9003925919532776
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 752,
          "offsetInEndSection": 891,
          "text": "STAT3 knockdown by shRNA in representative thyroid cancer cell lines that express high levels of pY-STAT3 had no effect on in vitro growth.",
          "score": 0.8941644430160522
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 892,
          "offsetInEndSection": 982,
          "text": "However, xenografted short hairpin STAT3 cells generated larger tumors than control cells.",
          "score": 0.8342328667640686
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 983,
          "offsetInEndSection": 1153,
          "text": "Similarly, STAT3 deficiency in a murine model of BRAFV600E-induced PTC led to thyroid tumors that were more proliferative and larger than those tumors expressing STAT3wt.",
          "score": 0.8993992805480957
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1154,
          "offsetInEndSection": 1344,
          "text": "Genome expression analysis revealed that STAT3 knockdown resulted in the down-regulation of multiple transcripts, including the tumor suppressor insulin-like growth factor binding protein 7.",
          "score": 0.8789158463478088
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1345,
          "offsetInEndSection": 1572,
          "text": "Furthermore, STAT3 knockdown led to an increase in glucose consumption, lactate production, and expression of Hypoxia-inducible factor 1 (HIF1\u03b1) target genes, suggesting that STAT3 is a negative regulator of aerobic glycolysis.",
          "score": 0.859076738357544
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1573,
          "offsetInEndSection": 1690,
          "text": "Our studies show that, in the context of thyroid cancer, STAT3 is paradoxically a negative regulator of tumor growth.",
          "score": 0.9123899936676025
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1691,
          "offsetInEndSection": 1846,
          "text": "These findings suggest that targeting STAT3 in these cancers could enhance tumor size and highlight the complexities of the role of STAT3 in tumorigenesis.",
          "score": 0.8856923580169678
        }
      ]
    },
    {
      "id": "67fc20ee18b1e36f2e00012a",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35311140",
        "http://www.ncbi.nlm.nih.gov/pubmed/35920986",
        "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
        "http://www.ncbi.nlm.nih.gov/pubmed/35269652",
        "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
        "http://www.ncbi.nlm.nih.gov/pubmed/28767130",
        "http://www.ncbi.nlm.nih.gov/pubmed/27959923",
        "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
        "http://www.ncbi.nlm.nih.gov/pubmed/32998960",
        "http://www.ncbi.nlm.nih.gov/pubmed/19107440"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Gliomas account for more than 70% of all brain tumors, and of these, glioblastoma is the most frequent and malignant histologic type (World Health Organization [WHO] grade IV)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 280,
          "text": "There is a tendency toward a higher incidence of gliomas in highly developed, industrialized countries.",
          "score": 0.8932200074195862
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 281,
          "offsetInEndSection": 377,
          "text": "Some reports indicate that Caucasians have a higher incidence than African or Asian populations.",
          "score": 0.8598268628120422
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 378,
          "offsetInEndSection": 485,
          "text": "With the exception of pilocytic astrocytomas (WHO grade I), the prognosis of glioma patients is still poor.",
          "score": 0.8971065282821655
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 657,
          "text": "Fewer than 3% of glioblastoma patients are still alive at 5 years after diagnosis, older age being the most significant and consistent prognostic factor of poorer outcome.",
          "score": 0.888107180595398
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 658,
          "offsetInEndSection": 769,
          "text": "Gliomas are components of several inherited tumor syndromes, but the prevalence of these syndromes is very low.",
          "score": 0.8878074884414673
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 770,
          "offsetInEndSection": 1041,
          "text": "Many environmental and lifestyle factors including several occupations, environmental carcinogens, and diet have been reported to be associated with an elevated glioma risk, but the only factor unequivocally associated with an increased risk is therapeutic X-irradiation.",
          "score": 0.8853908777236938
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1042,
          "offsetInEndSection": 1257,
          "text": "In particular, children treated with X-irradiation for acute lymphoblastic leukemia show a significantly elevated risk of developing gliomas and primitive neuroectodermal tumors, often within 10 years after therapy.",
          "score": 0.869303822517395
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1258,
          "offsetInEndSection": 1632,
          "text": "Significant correlation between G:C --> A:T transitions in the TP53 gene and promoter methylation of the O6 -methylguanine-DNA methyltransferase (MGMT) gene in glio-mas have been reported in several studies, suggesting the possible involvement of O6-methylguanine DNA adducts, which may be produced by exogenous or endogenous alkylating agents in the development of gliomas.",
          "score": 0.8698525428771973
        }
      ]
    },
    {
      "id": "67f8527318b1e36f2e000104",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36389300",
        "http://www.ncbi.nlm.nih.gov/pubmed/23984569",
        "http://www.ncbi.nlm.nih.gov/pubmed/19762171",
        "http://www.ncbi.nlm.nih.gov/pubmed/9181534",
        "http://www.ncbi.nlm.nih.gov/pubmed/24163979",
        "http://www.ncbi.nlm.nih.gov/pubmed/20642659",
        "http://www.ncbi.nlm.nih.gov/pubmed/20018387",
        "http://www.ncbi.nlm.nih.gov/pubmed/23903677",
        "http://www.ncbi.nlm.nih.gov/pubmed/25000345",
        "http://www.ncbi.nlm.nih.gov/pubmed/25010615"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "A close relationship between obstructive sleep apnea (OSA) and difficult intubation has been suggested.",
          "score": 0.9006615877151489
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 104,
          "offsetInEndSection": 239,
          "text": "We hypothesized that the STOP-Bang questionnaire, a screening tool for obstructive sleep apnea (OSA), can predict difficult intubation.",
          "score": 0.8949352502822876
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 240,
          "offsetInEndSection": 453,
          "text": "In this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the STOP-Bang questionnaire for predicting difficult intubation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 454,
          "offsetInEndSection": 579,
          "text": "STOP-Bang questionnaire results, Mallampati score and tonsil size, as well as demographic data, were recorded preoperatively.",
          "score": 0.8677433729171753
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 580,
          "offsetInEndSection": 762,
          "text": "Cormack & Lehane grading and difficulty of intubation (Cormack & Lehane grade III or IV, need of an intubation aid, or need of three or more intubation attempts) were also evaluated.",
          "score": 0.9066576957702637
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 763,
          "offsetInEndSection": 856,
          "text": "Eighty-three out of 200 patients had a high risk of OSA based on the STOP-Bang questionnaire.",
          "score": 0.8507181406021118
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 857,
          "offsetInEndSection": 1023,
          "text": "The occurrence of difficult intubation was higher in the patients at a high risk of OSA (i.e., a STOP-Bang score of \u2265 3) than in the patients at a low risk (13.3% vs.",
          "score": 0.8989412188529968
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1024,
          "offsetInEndSection": 1042,
          "text": "2.6%) (p = 0.004).",
          "score": 0.8340354561805725
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1043,
          "offsetInEndSection": 1374,
          "text": "Higher age, greater weight, higher body mass index, greater neck circumference, male gender, presence of comorbidities, lower preoperative SpO2, longer extubation times, higher Mallampati score, higher Cormack & Lehane grading, tonsil size and difficult intubation were significantly correlated with a high risk of OSA (p < 0.001).",
          "score": 0.8973738551139832
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1375,
          "offsetInEndSection": 1433,
          "text": "Fourteen out of 200 patients had difficulty in intubation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1434,
          "offsetInEndSection": 1531,
          "text": "A STOP-Bang score of \u2265 3 was seen more frequently in the difficult intubation patients (78.6% vs.",
          "score": 0.8906254768371582
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1532,
          "offsetInEndSection": 1551,
          "text": "38.7%) (p = 0.009).",
          "score": 0.8406285047531128
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1552,
          "offsetInEndSection": 1727,
          "text": "Greater weight, greater neck circumference, greater Mallampati score, a STOP-Bang score \u2265 3 and male gender were significantly correlated with difficult intubation (p < 0.05).",
          "score": 0.8962802290916443
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1728,
          "offsetInEndSection": 1794,
          "text": "A STOP-Bang score of \u2265 3 was a predictor for difficult intubation.",
          "score": 0.8859273791313171
        }
      ]
    },
    {
      "id": "680f4ae9353a4a2e6b000009",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2124757",
        "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
        "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
        "http://www.ncbi.nlm.nih.gov/pubmed/35713776",
        "http://www.ncbi.nlm.nih.gov/pubmed/23340416",
        "http://www.ncbi.nlm.nih.gov/pubmed/22322415",
        "http://www.ncbi.nlm.nih.gov/pubmed/25710834",
        "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
        "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
        "http://www.ncbi.nlm.nih.gov/pubmed/15638775"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Epilepsy is one of the most prevalent neurological syndromes in the world today.",
          "score": 0.9091951847076416
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 244,
          "text": "Epilepsy describes a group of brain disorders whose symptoms and causes are diverse and complicated, but all share a common behavioural manifestation: the seizure.",
          "score": 0.911727249622345
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 245,
          "offsetInEndSection": 443,
          "text": "Seizures result from the abnormal discharge of groups of neurons within the brain, usually within a focal point, that can result in the recruitment of large brain regions into epileptiform activity.",
          "score": 0.8883872628211975
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 605,
          "text": "Although the range of explanations for the development of seizures can be as varied as genetic composition to acute head trauma, the net result is often similar.",
          "score": 0.8999360799789429
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 606,
          "offsetInEndSection": 739,
          "text": "The excitability of neurons is governed by the input they receive from their neighbours and the intrinsic excitability of the neuron.",
          "score": 0.8641785383224487
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 740,
          "offsetInEndSection": 897,
          "text": "In this review we focus on elements that are crucial to determining the intrinsic excitability of neurons in the CNS, the voltage gated ion channels (VGICs).",
          "score": 0.8778756856918335
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 898,
          "offsetInEndSection": 1050,
          "text": "VGICs as well as being important for physiological function are critical in producing hyperexcitability such as that associated with seizure discharges.",
          "score": 0.9013335704803467
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1051,
          "offsetInEndSection": 1243,
          "text": "Many drugs routinely used in the clinical setting, as well as several novel experimental drugs, have shown interactions with VGICs that underpin, at least in part, their anticonvulsant action.",
          "score": 0.9113699197769165
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1244,
          "offsetInEndSection": 1438,
          "text": "We review the physiological roles of voltage gated ion channels that are selective for sodium, potassium and calcium conductance and attempt to highlight their role in the pathology of epilepsy.",
          "score": 0.9056720733642578
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1439,
          "offsetInEndSection": 1588,
          "text": "This is supplemented by the mechanisms of drug action at these important anticonvulsant targets for classical and clinically relevant compounds (e.g.",
          "score": 0.9215708374977112
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1589,
          "offsetInEndSection": 1669,
          "text": "phenytoin, ethosuximide) as well as some important second generation drugs (e.g.",
          "score": 0.9096659421920776
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1670,
          "offsetInEndSection": 1732,
          "text": "gabapentin, levetiracetam) and novel experimental agents (e.g.",
          "score": 0.8899825215339661
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1733,
          "offsetInEndSection": 1769,
          "text": "retigabine, losigamone, safinamide).",
          "score": 0.8588268756866455
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1770,
          "offsetInEndSection": 1925,
          "text": "We also briefly discuss the urgent need for new drugs in this arena and the potential of combinatorial methods and recombinant screening to identify leads.",
          "score": 0.8554636836051941
        }
      ]
    },
    {
      "id": "67fd922518b1e36f2e000143",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29594035",
        "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
        "http://www.ncbi.nlm.nih.gov/pubmed/28341752",
        "http://www.ncbi.nlm.nih.gov/pubmed/32708142",
        "http://www.ncbi.nlm.nih.gov/pubmed/33050070",
        "http://www.ncbi.nlm.nih.gov/pubmed/33881837",
        "http://www.ncbi.nlm.nih.gov/pubmed/25620672",
        "http://www.ncbi.nlm.nih.gov/pubmed/29436395",
        "http://www.ncbi.nlm.nih.gov/pubmed/25110953",
        "http://www.ncbi.nlm.nih.gov/pubmed/37218976"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Glioblastoma (GBM) is a common and highly malignant primary tumor of the central nervous system in adults.",
          "score": 0.8960863351821899
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 107,
          "offsetInEndSection": 262,
          "text": "Ever more recent papers are focusing on understanding the role of the tumor microenvironment (TME) in affecting tumorigenesis and the subsequent prognosis.",
          "score": 0.9241498112678528
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 360,
          "text": "We assessed the impact of macrophages in the TME on the prognosis in patients with recurrent GBM.",
          "score": 0.9036123752593994
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 361,
          "offsetInEndSection": 523,
          "text": "A PubMed, MEDLINE and Scopus review was conducted to identify all studies dealing with macrophages in the GBM microenvironment from January 2016 to December 2022.",
          "score": 0.9020717144012451
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 725,
          "text": "Glioma-associated macrophages (GAMs) act critically in enhancing tumor progression and can alter drug resistance, promoting resistance to radiotherapy and establishing an immunosuppressive environment.",
          "score": 0.9116634130477905
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 726,
          "offsetInEndSection": 1002,
          "text": "M1 macrophages are characterized by increased secretion of proinflammatory cytokines, such as IL-1\u00df, tumor necrosis factor (TNF), IL-27, matrix metalloproteinase (MMPs), CCL2, and VEGF (vascular endothelial growth factor), IGF1, that can lead to the destruction of the tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1003,
          "offsetInEndSection": 1209,
          "text": "In contrast, M2 is supposed to participate in immunosuppression and tumor progression, which is formed after being exposed to the macrophage M-CSF, IL-10, IL-35 and the transforming growth factor-\u00df (TGF-\u03b2)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1210,
          "offsetInEndSection": 1562,
          "text": "Because there is currently no standard of care in recurrent GBM, novel identified targeted therapies based on the complex signaling and interactions between the glioma stem cells (GSCs) and the TME, especially resident microglia and bone-marrow-derived macrophages, may be helpful in improving the overall survival of these patients in the near future.",
          "score": 0.900390625
        }
      ]
    },
    {
      "id": "67fc1a3818b1e36f2e000129",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
        "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
        "http://www.ncbi.nlm.nih.gov/pubmed/24117632",
        "http://www.ncbi.nlm.nih.gov/pubmed/23155537",
        "http://www.ncbi.nlm.nih.gov/pubmed/27901639",
        "http://www.ncbi.nlm.nih.gov/pubmed/19951799",
        "http://www.ncbi.nlm.nih.gov/pubmed/31644405",
        "http://www.ncbi.nlm.nih.gov/pubmed/21037442",
        "http://www.ncbi.nlm.nih.gov/pubmed/25012804",
        "http://www.ncbi.nlm.nih.gov/pubmed/28717439"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Achalasia is a chronic incurable esophageal motility disorder characterized by impaired lower esophageal sphincter (LES) relaxation and loss of esophageal peristalsis.",
          "score": 0.8838704228401184
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 358,
          "text": "Although rare, it is currently the most common primary esophageal motility disorder, with an annual incidence of around 1.6 per 100,000 persons and prevalence of around 10.8/100,000 persons.",
          "score": 0.8619571328163147
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 359,
          "offsetInEndSection": 481,
          "text": "Symptoms of achalasia include dysphagia to both solids and liquids, regurgitation, aspiration, chest pain and weight loss.",
          "score": 0.8558910489082336
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 594,
          "text": "As the underlying etiology of achalasia remains unclear, there is currently no curative treatment for achalasia.",
          "score": 0.8669646978378296
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 595,
          "offsetInEndSection": 719,
          "text": "Management of achalasia mainly involves improving the esophageal outflow in order to provide symptomatic relief to patients.",
          "score": 0.8719526529312134
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 720,
          "offsetInEndSection": 936,
          "text": "The most effective treatment options for achalasia include pneumatic dilation, Heller myotomy and peroral endoscopic myotomy (POEM), with the latter increasingly emerging as the treatment of choice for many patients.",
          "score": 0.8722689151763916
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 937,
          "offsetInEndSection": 1062,
          "text": "This review focusses on evidence for current and emerging treatment options for achalasia with a particular emphasis on POEM.",
          "score": 0.8666115999221802
        }
      ]
    },
    {
      "id": "67e285b018b1e36f2e00007b",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16821224",
        "http://www.ncbi.nlm.nih.gov/pubmed/20197675",
        "http://www.ncbi.nlm.nih.gov/pubmed/697225",
        "http://www.ncbi.nlm.nih.gov/pubmed/11807897",
        "http://www.ncbi.nlm.nih.gov/pubmed/25800473",
        "http://www.ncbi.nlm.nih.gov/pubmed/15797949",
        "http://www.ncbi.nlm.nih.gov/pubmed/8151646",
        "http://www.ncbi.nlm.nih.gov/pubmed/8517687",
        "http://www.ncbi.nlm.nih.gov/pubmed/12966522",
        "http://www.ncbi.nlm.nih.gov/pubmed/26755454"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Rett syndrome is a severe X-linked dominant neurodevelopmental disorder.",
          "score": 0.9118697047233582
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 73,
          "offsetInEndSection": 169,
          "text": "Mutations in the MECP2 gene on chromosome Xq28 have been shown to be the cause of Rett syndrome.",
          "score": 0.9218848943710327
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 321,
          "text": "Sequencing of the MECP2 gene in a patient with clinical suspicion of Rett syndrome revealed c.1160C>T (P387L) in exon 4 of the MECP2 gene homozygously.",
          "score": 0.9073284864425659
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 322,
          "offsetInEndSection": 398,
          "text": "Females with Rett syndrome are usually heterozygous for a mutation in MECP2.",
          "score": 0.9132596254348755
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 399,
          "offsetInEndSection": 552,
          "text": "Uniparental disomy as a probable cause for the homozygous presence of this mutation was ruled out by quantitative fluorescence-polymerase chain reaction.",
          "score": 0.8920758962631226
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 553,
          "offsetInEndSection": 664,
          "text": "Moreover to our knowledge this mutation has only been reported in males with X-linked mental retardation (MRX).",
          "score": 0.8920290470123291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 665,
          "offsetInEndSection": 829,
          "text": "We hypothesize that the presence of this mutation c.1160C>T (P387L) in the homozygous form is responsible for the Rett syndrome-like phenotype seen in this patient.",
          "score": 0.9012097120285034
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 830,
          "offsetInEndSection": 969,
          "text": "This novel report reveals for the first time the homozygous presence of a mutation which has hitherto only been reported in males with MRX.",
          "score": 0.8877516388893127
        }
      ]
    },
    {
      "id": "680a07f918b1e36f2e00014a",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33922020",
        "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
        "http://www.ncbi.nlm.nih.gov/pubmed/19698742",
        "http://www.ncbi.nlm.nih.gov/pubmed/23845246",
        "http://www.ncbi.nlm.nih.gov/pubmed/34849584",
        "http://www.ncbi.nlm.nih.gov/pubmed/34539752",
        "http://www.ncbi.nlm.nih.gov/pubmed/24769127",
        "http://www.ncbi.nlm.nih.gov/pubmed/23721879",
        "http://www.ncbi.nlm.nih.gov/pubmed/25766410",
        "http://www.ncbi.nlm.nih.gov/pubmed/24642372"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 309,
          "text": "Extracellular ATP is an important signaling molecule throughout the inflammatory cascade, serving as a danger signal that causes activation of the inflammasome, enhancement of immune cell infiltration, and fine-tuning of several signaling cascades including those important for the resolution of inflammation.",
          "score": 0.9098225235939026
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 310,
          "offsetInEndSection": 430,
          "text": "Recent studies demonstrated that ATP can be released from cells in a controlled manner through pannexin (Panx) channels."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 722,
          "text": "Panx1-mediated ATP release is involved in inflammasome activation and neutrophil/macrophage chemotaxis, activation of T cells, and a role for Panx1 in inducing and propagating inflammation has been demonstrated in various organs, including lung and the central and peripheral nervous system.",
          "score": 0.9073343276977539
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 723,
          "offsetInEndSection": 945,
          "text": "The recognition and clearance of dying cells and debris from focal points of inflammation is critical in the resolution of inflammation, and Panx1-mediated ATP release from dying cells has been shown to recruit phagocytes.",
          "score": 0.9010603427886963
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 946,
          "offsetInEndSection": 1096,
          "text": "Moreover, extracellular ATP can be broken down by ectonucleotidases into ADP, AMP, and adenosine, which is critical in the resolution of inflammation.",
          "score": 0.9080225825309753
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1097,
          "offsetInEndSection": 1294,
          "text": "Together, Panx1, ATP, purinergic receptors, and ectonucleotidases contribute to important feedback loops during the inflammatory response, and thus represent promising candidates for new therapies.",
          "score": 0.8855127692222595
        }
      ]
    },
    {
      "id": "67cdc78381b102733300001a",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21786507",
        "http://www.ncbi.nlm.nih.gov/pubmed/23626552",
        "http://www.ncbi.nlm.nih.gov/pubmed/10385057",
        "http://www.ncbi.nlm.nih.gov/pubmed/8987005",
        "http://www.ncbi.nlm.nih.gov/pubmed/12390436",
        "http://www.ncbi.nlm.nih.gov/pubmed/2798270",
        "http://www.ncbi.nlm.nih.gov/pubmed/23880115",
        "http://www.ncbi.nlm.nih.gov/pubmed/27468093",
        "http://www.ncbi.nlm.nih.gov/pubmed/31951513",
        "http://www.ncbi.nlm.nih.gov/pubmed/6308196"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Vitamin E malabsorption and deficiency during chronic childhood cholestasis has been associated with a progressive ataxic neurologic syndrome.",
          "score": 0.8886239528656006
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 290,
          "text": "Hyporeflexia, the first sign of neurologic dysfunction, may begin prior to age 2 years, but severe symptoms do not develop until age 5 to 10 years.",
          "score": 0.8847485780715942
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 291,
          "offsetInEndSection": 420,
          "text": "To establish the age of onset of neuropathologic lesions, we prospectively evaluated four young children with severe cholestasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 421,
          "offsetInEndSection": 674,
          "text": "Malabsorption and deficiency of vitamin E were documented by low serum vitamin E concentrations, low serum vitamin E to total serum lipids ratios, elevated hydrogen peroxide hemolysis, and impaired absorption of a pharmacologic dose of alpha-tocopherol.",
          "score": 0.8644698858261108
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 675,
          "offsetInEndSection": 848,
          "text": "Abnormal neurologic findings in two patients were limited to areflexia, ptosis, mild truncal ataxia, and hypotonia; two patients had minimal signs of neurologic dysfunction.",
          "score": 0.8677510023117065
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 849,
          "offsetInEndSection": 1008,
          "text": "Sural nerve histology at age 6 to 25 months revealed a degenerative axonopathy involving large-caliber myelinated fibers, but without quantitative axonal loss.",
          "score": 0.8822242021560669
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1074,
          "text": "Muscle histology and histochemistry tests yielded normal results.",
          "score": 0.8244030475616455
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1075,
          "offsetInEndSection": 1321,
          "text": "Our study suggests that neurologic injury may occur during the first two years of life in vitamin E-deficient children with cholestatic hepatobiliary disease, obligating aggressive attempts at correcting this deficiency state at a very young age."
        }
      ]
    },
    {
      "id": "67d7ff2c18b1e36f2e000049",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23767452",
        "http://www.ncbi.nlm.nih.gov/pubmed/15981987",
        "http://www.ncbi.nlm.nih.gov/pubmed/23567359",
        "http://www.ncbi.nlm.nih.gov/pubmed/16313685",
        "http://www.ncbi.nlm.nih.gov/pubmed/20036949",
        "http://www.ncbi.nlm.nih.gov/pubmed/23496382",
        "http://www.ncbi.nlm.nih.gov/pubmed/21159258",
        "http://www.ncbi.nlm.nih.gov/pubmed/21438963",
        "http://www.ncbi.nlm.nih.gov/pubmed/37546121",
        "http://www.ncbi.nlm.nih.gov/pubmed/12485471"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Gluten sensitive enteropathy has various manifestations, of which the two major forms are classical coeliac disease (cCD) and dermatitis herpetiformis (DH)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 289,
          "text": "In cCD predominantly the small intestine is affected, whereas in DH also the skin is affected showing typical rash and IgA deposits.",
          "score": 0.9048981666564941
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 290,
          "offsetInEndSection": 348,
          "text": "The symptoms in both forms are dependent on gluten intake."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 349,
          "offsetInEndSection": 414,
          "text": "The factors diversifying these two clinical outcomes are unknown.",
          "score": 0.8431253433227539
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 415,
          "offsetInEndSection": 595,
          "text": "In the present report we evaluated the role of the major genetic susceptibility locus, HLA DQ, in 25 families, in which both forms of the disease, cCD and DH, occurred in siblings.",
          "score": 0.8901216983795166
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 596,
          "offsetInEndSection": 848,
          "text": "By using the family-based approach it can be assumed that within each family variation in environmental factors is substantially lower than in the standard case-control setting, and also the problems related to population stratification can be avoided.",
          "score": 0.8605730533599854
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 849,
          "offsetInEndSection": 1157,
          "text": "Results from the Finnish family material with 25 discordant and 85 concordant sib pairs, and from additional case-control material comprising 71 unrelated Hungarian DH and 68 cCD patients, together indicated that the HLA DQ locus did not differ between the two major outcomes of gluten sensitive enteropathy.",
          "score": 0.89284747838974
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1158,
          "offsetInEndSection": 1261,
          "text": "The non-HLA DR;DQ factors are critical for the different clinical manifestations of gluten sensitivity."
        }
      ]
    },
    {
      "id": "680a084018b1e36f2e00014e",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
        "http://www.ncbi.nlm.nih.gov/pubmed/26857494",
        "http://www.ncbi.nlm.nih.gov/pubmed/27377536",
        "http://www.ncbi.nlm.nih.gov/pubmed/15800022",
        "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
        "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
        "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
        "http://www.ncbi.nlm.nih.gov/pubmed/25267439",
        "http://www.ncbi.nlm.nih.gov/pubmed/37983289",
        "http://www.ncbi.nlm.nih.gov/pubmed/12529926"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Lymphocyte recruitment to the central nervous system (CNS) is a critical step in the pathogenesis of diseases such as multiple sclerosis (MS), meningitis and posterior uveitis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 424,
          "text": "The principle sequential stages that control lymphocyte emigration from the blood have been widely reported, but only recently has attention been directed towards the role of the vascular endothelium in actively supporting transvascular migration.",
          "score": 0.8790266513824463
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 531,
          "text": "It has now been shown that adhesion molecules, particularly those of the immunoglobulin super family (e.g.",
          "score": 0.8354052305221558
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 532,
          "offsetInEndSection": 650,
          "text": "ICAM-1, VCAM-1 and PECAM-1), not only act as ligands for leucocyte receptors but can also serve as signal transducers.",
          "score": 0.8568162322044373
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 830,
          "text": "Engagement of these receptors initiates endothelial signalling cascades that result in downstream effector mechanisms which in turn influence the progression of neuroinflammation.",
          "score": 0.8788820505142212
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 831,
          "offsetInEndSection": 1117,
          "text": "In particular, it has been shown that ICAM-1-mediated signalling in brain endothelial cells is a crucial regulatory step in the process of lymphocyte migration through the blood-brain barrier and as such represents an additional phase in the multistep paradigm of leucocyte recruitment.",
          "score": 0.8942835330963135
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1118,
          "offsetInEndSection": 1297,
          "text": "In this article we review current understanding of endothelial cell ICAM-1 signalling and discuss the importance of these findings in relation to leucocyte trafficking to the CNS.",
          "score": 0.9009696245193481
        }
      ]
    },
    {
      "id": "67cde41a81b102733300001d",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26543426",
        "http://www.ncbi.nlm.nih.gov/pubmed/22857835",
        "http://www.ncbi.nlm.nih.gov/pubmed/23438422",
        "http://www.ncbi.nlm.nih.gov/pubmed/21369385",
        "http://www.ncbi.nlm.nih.gov/pubmed/23732207",
        "http://www.ncbi.nlm.nih.gov/pubmed/10720930",
        "http://www.ncbi.nlm.nih.gov/pubmed/22736301",
        "http://www.ncbi.nlm.nih.gov/pubmed/24026180",
        "http://www.ncbi.nlm.nih.gov/pubmed/2669121",
        "http://www.ncbi.nlm.nih.gov/pubmed/20566568"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Medical treatment of obesity and lifestyle modification have limited effectiveness in treating it in morbidly obese individuals.",
          "score": 0.8506890535354614
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 279,
          "text": "Importantly, bariatric surgery is regarded as the only therapy that is effective in maintaining significant weight loss in morbidly obese individuals.",
          "score": 0.8588361740112305
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 280,
          "offsetInEndSection": 546,
          "text": "Despite the fact that bariatric surgery-induced weight loss is associated with a significant decrease in morbidity and mortality and improvement in renal function, bariatric surgery has recently been shown to be associated with a significant risk of nephrolithiasis.",
          "score": 0.8969557881355286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 547,
          "offsetInEndSection": 630,
          "text": "The main risk factor for nephrolithiasis is increased excretion of urinary oxalate.",
          "score": 0.9056574702262878
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 631,
          "offsetInEndSection": 768,
          "text": "In this review, we discuss the association between bariatric surgery, an increased risk of renal stone formation and oxalate nephropathy."
        }
      ]
    },
    {
      "id": "67e2b80618b1e36f2e00008f",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24126522",
        "http://www.ncbi.nlm.nih.gov/pubmed/21687806",
        "http://www.ncbi.nlm.nih.gov/pubmed/18447956",
        "http://www.ncbi.nlm.nih.gov/pubmed/20204066",
        "http://www.ncbi.nlm.nih.gov/pubmed/19863554",
        "http://www.ncbi.nlm.nih.gov/pubmed/12474416",
        "http://www.ncbi.nlm.nih.gov/pubmed/21607086",
        "http://www.ncbi.nlm.nih.gov/pubmed/26463167",
        "http://www.ncbi.nlm.nih.gov/pubmed/18304778",
        "http://www.ncbi.nlm.nih.gov/pubmed/21441598"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "The CRISPR/Cas system in prokaryotes provides resistance against invading viruses and plasmids.",
          "score": 0.8716773986816406
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 153,
          "text": "Three distinct stages in the mechanism can be recognized.",
          "score": 0.8046799898147583
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 253,
          "text": "Initially, fragments of invader DNA are integrated as new spacers into the repetitive CRISPR locus.",
          "score": 0.8529344201087952
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 425,
          "text": "Subsequently, the CRISPR is transcribed and the transcript is cleaved by a Cas protein within the repeats, generating short RNAs (crRNAs) that contain the spacer sequence.",
          "score": 0.8531484603881836
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 426,
          "offsetInEndSection": 586,
          "text": "Finally, crRNAs guide the Cas protein machinery to a complementary invader target, either DNA or RNA, resulting in inhibition of virus or plasmid proliferation.",
          "score": 0.851396918296814
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 587,
          "offsetInEndSection": 777,
          "text": "In this article, we discuss our current understanding of this fascinating adaptive and heritable defense system, and describe functional similarities and differences with RNAi in eukaryotes.",
          "score": 0.8519314527511597
        }
      ]
    },
    {
      "id": "680a21ff18b1e36f2e000151",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
        "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
        "http://www.ncbi.nlm.nih.gov/pubmed/25904790",
        "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
        "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
        "http://www.ncbi.nlm.nih.gov/pubmed/28936965",
        "http://www.ncbi.nlm.nih.gov/pubmed/31420495",
        "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
        "http://www.ncbi.nlm.nih.gov/pubmed/34182142",
        "http://www.ncbi.nlm.nih.gov/pubmed/31186721"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Interleukin (IL)-35 is a novel member of the IL-12 cytokine family, which exhibits a unique immune regulatory function.",
          "score": 0.9040135145187378
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 304,
          "text": "Previously, it was demonstrated that IL-35 expression is significantly increased in a wide range of tumor tissues, promoting angiogenesis and inhibiting the anti-tumor immune response.",
          "score": 0.8982765078544617
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 305,
          "offsetInEndSection": 517,
          "text": "In the present study, the IL-35 protein expression levels were measured in the plasma and tumor tissue of patients with prostate cancer (PCA), and its role was determined in the occurrence and progression of PCA.",
          "score": 0.9050359725952148
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 518,
          "offsetInEndSection": 662,
          "text": "Plasma IL-35 expression levels were measured using ELISA, and the associations of plasma IL-35 and clinicopathological parameters were analyzed.",
          "score": 0.8871380090713501
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 663,
          "offsetInEndSection": 795,
          "text": "Receiver operating characteristic curves were plotted to analyze the role of IL-35 as a clinical biomarker for the diagnosis of PCA.",
          "score": 0.9029072523117065
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 796,
          "offsetInEndSection": 1034,
          "text": "Survival curve analysis demonstrated a significant decrease in the survival time in months in patients with PCA and increased expression levels of IL-35 compared with the participants with relatively lower IL-35 protein expression levels.",
          "score": 0.874580979347229
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1035,
          "offsetInEndSection": 1133,
          "text": "IL-35 expression was detected using immunohistochemical staining of a human PCA tissue microarray.",
          "score": 0.8935126066207886
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1134,
          "offsetInEndSection": 1305,
          "text": "Plasma IL-35 expression levels in the patients with PCA were significantly increased compared with the patients with benign prostatic hyperplasia and the healthy controls.",
          "score": 0.8811017870903015
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1306,
          "offsetInEndSection": 1437,
          "text": "An increase in the plasma concentration of IL-35 was associated with progression of PCA stage and an increase in the Gleason score.",
          "score": 0.8797695636749268
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1438,
          "offsetInEndSection": 1610,
          "text": "Significant differences in AUCs for IL-35 and prostate-specific antigen were observed with regard to the presence of lymph node and distant metastases in patients with PCA.",
          "score": 0.8831955194473267
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1611,
          "offsetInEndSection": 1824,
          "text": "The expression levels of Epstein-barr virus-induced gene 3 (EBI3) and IL-12A (p35; the subunits which together form IL-35) were significantly increased in the tumor tissue compared with the adjacent normal tissue.",
          "score": 0.8858059048652649
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1825,
          "offsetInEndSection": 1916,
          "text": "An association was identified between the Gleason score and the expression of EBI3 and p35.",
          "score": 0.8584802150726318
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1917,
          "offsetInEndSection": 2146,
          "text": "Therefore, increased expression of IL-35 in the plasma and tumor tissues may contribute to the progression and metastasis of PCA, and IL-35 may serve as a novel prognostic biomarker or therapeutic target for the treatment of PCA.",
          "score": 0.9012793302536011
        }
      ]
    },
    {
      "id": "67fc546c18b1e36f2e000130",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24392752",
        "http://www.ncbi.nlm.nih.gov/pubmed/27757389",
        "http://www.ncbi.nlm.nih.gov/pubmed/22108462",
        "http://www.ncbi.nlm.nih.gov/pubmed/34517744",
        "http://www.ncbi.nlm.nih.gov/pubmed/27358410",
        "http://www.ncbi.nlm.nih.gov/pubmed/27468879",
        "http://www.ncbi.nlm.nih.gov/pubmed/24403054",
        "http://www.ncbi.nlm.nih.gov/pubmed/23089199",
        "http://www.ncbi.nlm.nih.gov/pubmed/22403045",
        "http://www.ncbi.nlm.nih.gov/pubmed/17350985"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Retapamulin is the first agent of the pleuromutilin class formulated as a topical antibacterial for treating skin infections.",
          "score": 0.8647778034210205
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 364,
          "text": "The aim of this study was to determine the antimicrobial activity of retapamulin by determining the minimal inhibitory concentration (MIC) values of this new drug and comparators against a wide range of anaerobic bacteria of human origin.",
          "score": 0.8945503234863281
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 365,
          "offsetInEndSection": 573,
          "text": "The in vitro activity of retapamulin and six comparators (amoxicillin, amoxicillin/clavulanic acid, ceftriaxone, imipenem, clindamycin and metronidazole) was evaluated against 232 anaerobic clinical isolates.",
          "score": 0.8950792551040649
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 574,
          "offsetInEndSection": 647,
          "text": "MICs were determined by the CLSI reference agar dilution method (M11-A6).",
          "score": 0.8626694083213806
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 648,
          "offsetInEndSection": 798,
          "text": "Ceftriaxone, clindamycin and amoxicillin/clavulanic acid resistance rates were 54%, 42% and 9.6%, respectively, within the Bacteroides fragilis group.",
          "score": 0.8816167712211609
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 799,
          "offsetInEndSection": 904,
          "text": "Despite high resistance rates to various antibiotics, retapamulin inhibited 37/52 (71%) strains of the B.",
          "score": 0.8910226821899414
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 905,
          "offsetInEndSection": 1008,
          "text": "fragilis group and 85/87 (98%) of the other Gram-negative bacilli at a concentration of 2 mg/L or less.",
          "score": 0.871749997138977
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1102,
          "text": "All the investigated strains of Clostridium perfringens were inhibited by 1 mg/L retapamulin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1122,
          "text": "Three strains of C.",
          "score": 0.8465347290039062
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1123,
          "offsetInEndSection": 1153,
          "text": "difficile and one strain of C.",
          "score": 0.8581000566482544
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1154,
          "offsetInEndSection": 1223,
          "text": "clostridioforme demonstrated decreased susceptibility to retapamulin.",
          "score": 0.8869549632072449
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1224,
          "offsetInEndSection": 1448,
          "text": "Based on inhibitory concentrations, retapamulin was more active than clindamycin, metronidazole and ceftriaxone against Propionibacterium acnes and anaerobic Gram-positive cocci, as all isolates were inhibited by <or=2 mg/L.",
          "score": 0.8943879008293152
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1449,
          "offsetInEndSection": 1665,
          "text": "At <or=2 mg/L, retapamulin inhibited 90% of all 232 anaerobes tested, whereas overall resistance rates for the comparators were as follows: co-amoxiclav, 2%; metronidazole, 12%; clindamycin, 15% and ceftriaxone, 20%.",
          "score": 0.8911543488502502
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1666,
          "offsetInEndSection": 1746,
          "text": "The broad anaerobic spectrum demonstrated by retapamulin in vitro is attractive.",
          "score": 0.8790485858917236
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1747,
          "offsetInEndSection": 1901,
          "text": "Pending further clinical investigation, retapamulin may offer an alternative treatment for anaerobic skin infections in this era of increasing resistance.",
          "score": 0.8839148283004761
        }
      ]
    },
    {
      "id": "680f4aa6353a4a2e6b000008",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1067597",
        "http://www.ncbi.nlm.nih.gov/pubmed/5964959",
        "http://www.ncbi.nlm.nih.gov/pubmed/21422738",
        "http://www.ncbi.nlm.nih.gov/pubmed/4664580",
        "http://www.ncbi.nlm.nih.gov/pubmed/23239357",
        "http://www.ncbi.nlm.nih.gov/pubmed/23925142",
        "http://www.ncbi.nlm.nih.gov/pubmed/17710455",
        "http://www.ncbi.nlm.nih.gov/pubmed/19674480",
        "http://www.ncbi.nlm.nih.gov/pubmed/2514275",
        "http://www.ncbi.nlm.nih.gov/pubmed/19488551"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Botulinum toxin (BTX) is one of the most potent bacterial toxins known and its effectiveness in the treatment of some pain syndromes is well known.",
          "score": 0.8959562182426453
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 240,
          "text": "However, the efficacy of some of its indications is still in the process of being confirmed.",
          "score": 0.8326146602630615
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 403,
          "text": "The objective of this study was to review the history, pharmacological properties, and clinical applications of BTX in the treatment of pain of different origins.",
          "score": 0.8741911053657532
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 404,
          "offsetInEndSection": 511,
          "text": "Botulinum toxin is produced by fermentation of Clostridium botulinum, a Gram-positive, anaerobic bacterium.",
          "score": 0.8860785961151123
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 512,
          "offsetInEndSection": 572,
          "text": "Commercially, BTX comes in two presentations, types A and B.",
          "score": 0.8524538278579712
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 573,
          "offsetInEndSection": 810,
          "text": "Botulinum toxin, a neurotoxin with high affinity for cholinergic synapses, blocks the release of acetylcholine by nerve endings without interfering with neuronal conduction of electrical signals or synthesis and storage of acetylcholine.",
          "score": 0.8900736570358276
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 811,
          "offsetInEndSection": 913,
          "text": "It has been proven that BTX can selectively weaken painful muscles, interrupting the spasm-pain cycle.",
          "score": 0.8498135209083557
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 914,
          "offsetInEndSection": 1072,
          "text": "Several studies have demonstrated the efficacy and safety of BTX-A in the treatment of tension headaches, migraines, chronic lumbar pain, and myofascial pain.",
          "score": 0.8719310760498047
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1214,
          "text": "Botulinum toxin type A is well tolerated in the treatment of chronic pain disorders in which pharmacotherapy regimens can cause side effects.",
          "score": 0.8809405565261841
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1347,
          "text": "The reduction in the consumption of analgesics and length of action of 3 to 4 months per dose represent other advantages of its use.",
          "score": 0.8597650527954102
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1348,
          "offsetInEndSection": 1537,
          "text": "However, further studies are necessary to establish the efficacy of BTX-A in chronic pain disorders and its exact mechanism of action, as well as its potential in multifactorial treatments.",
          "score": 0.8752338290214539
        }
      ]
    },
    {
      "id": "680a078618b1e36f2e000146",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24269728",
        "http://www.ncbi.nlm.nih.gov/pubmed/20454996",
        "http://www.ncbi.nlm.nih.gov/pubmed/28111277",
        "http://www.ncbi.nlm.nih.gov/pubmed/21969581",
        "http://www.ncbi.nlm.nih.gov/pubmed/21501576",
        "http://www.ncbi.nlm.nih.gov/pubmed/25042473",
        "http://www.ncbi.nlm.nih.gov/pubmed/2209722",
        "http://www.ncbi.nlm.nih.gov/pubmed/24925909",
        "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
        "http://www.ncbi.nlm.nih.gov/pubmed/21216828"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 305,
          "text": "In the central nervous system of patients with multiple sclerosis, B cell aggregates populate the meninges, raising the central question as to whether these structures relate to the B cell infiltrates found in parenchymal lesions or instead, represent a separate central nervous system immune compartment.",
          "score": 0.9012545347213745
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 306,
          "offsetInEndSection": 512,
          "text": "We characterized the repertoires derived from meningeal B cell aggregates and the corresponding parenchymal infiltrates from brain tissue derived primarily from patients with progressive multiple sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 642,
          "text": "The majority of expanded antigen-experienced B cell clones derived from meningeal aggregates were also present in the parenchyma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 643,
          "offsetInEndSection": 824,
          "text": "We extended this investigation to include 20 grey matter specimens containing meninges, 26 inflammatory plaques, 19 areas of normal appearing white matter and cerebral spinal fluid.",
          "score": 0.8815436363220215
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 825,
          "offsetInEndSection": 1000,
          "text": "Analysis of 1833 B cell receptor heavy chain variable region sequences demonstrated that antigen-experienced clones were consistently shared among these distinct compartments.",
          "score": 0.8582362532615662
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1001,
          "offsetInEndSection": 1230,
          "text": "This study establishes a relationship between extraparenchymal lymphoid tissue and parenchymal infiltrates and defines the arrangement of B cell clones that populate the central nervous system of patients with multiple sclerosis.",
          "score": 0.8868915438652039
        }
      ]
    },
    {
      "id": "67e098cb18b1e36f2e00006d",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17584678",
        "http://www.ncbi.nlm.nih.gov/pubmed/7991969",
        "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
        "http://www.ncbi.nlm.nih.gov/pubmed/18045856",
        "http://www.ncbi.nlm.nih.gov/pubmed/6065875",
        "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
        "http://www.ncbi.nlm.nih.gov/pubmed/17286271",
        "http://www.ncbi.nlm.nih.gov/pubmed/23710633",
        "http://www.ncbi.nlm.nih.gov/pubmed/2052626",
        "http://www.ncbi.nlm.nih.gov/pubmed/21549607"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Deep brain stimulation (DBS) is the technique of neurostimulation of deep brain structures for the treatment of conditions such as essential tremor, dystonia, Parkinson's disease and chronic pain syndromes.",
          "score": 0.8718692064285278
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 207,
          "offsetInEndSection": 340,
          "text": "The procedure uses implanted deep brain stimulation electrodes connected to extension leads and an implantable pulse generator (IPG).",
          "score": 0.8612308502197266
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 457,
          "text": "Hardware failure related to the DBS procedure is not infrequent, and includes electrode migration and disconnection.",
          "score": 0.8426978588104248
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 617,
          "text": "We describe a patient who received bilateral globus pallidus internus DBS for dystonia with initially good clinical response, but the device eventually failed.",
          "score": 0.8591018915176392
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 618,
          "offsetInEndSection": 771,
          "text": "Radiographs showed multiple twisting of the extension leads with disconnection from the brain electrodes and a diagnosis of Twiddler's syndrome was made.",
          "score": 0.8414314985275269
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 772,
          "offsetInEndSection": 848,
          "text": "Twiddler's syndrome was first described in patients with cardiac pacemakers.",
          "score": 0.8558202385902405
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 849,
          "offsetInEndSection": 931,
          "text": "Patients with mental disability, elderly and obese patients are at increased risk.",
          "score": 0.8275388479232788
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 932,
          "offsetInEndSection": 1075,
          "text": "Twiddler's syndrome should be suspected whenever there is a failure of the DBS device to relieve symptoms previously responsive to stimulation.",
          "score": 0.8461295962333679
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1076,
          "offsetInEndSection": 1116,
          "text": "Surgical correction is usually required.",
          "score": 0.8249858021736145
        }
      ]
    },
    {
      "id": "67d6be8a18b1e36f2e000022",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33433580",
        "http://www.ncbi.nlm.nih.gov/pubmed/30028313",
        "http://www.ncbi.nlm.nih.gov/pubmed/17508036",
        "http://www.ncbi.nlm.nih.gov/pubmed/28590501",
        "http://www.ncbi.nlm.nih.gov/pubmed/24837143",
        "http://www.ncbi.nlm.nih.gov/pubmed/30515001",
        "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
        "http://www.ncbi.nlm.nih.gov/pubmed/30262714",
        "http://www.ncbi.nlm.nih.gov/pubmed/14684236",
        "http://www.ncbi.nlm.nih.gov/pubmed/29018725"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Glaucoma is the most common optic neuropathy characterized by normal to raised intraocular pressure (IOP), visual field defects, loss of retinal nerve fiber layer, thinning of the neuroretinal rim, and cupping of the optic disc.",
          "score": 0.8743487596511841
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 229,
          "offsetInEndSection": 341,
          "text": "IOP reduction by medical, laser, or surgical therapies remains the only clinically proven treatment of glaucoma.",
          "score": 0.877742350101471
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 342,
          "offsetInEndSection": 392,
          "text": "The challenges in glaucoma management are diverse.",
          "score": 0.8553677201271057
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 393,
          "offsetInEndSection": 568,
          "text": "They include early detection and diagnosis, setting of appropriate target IOP, choice of treatment, monitoring of quality of life and sight, and compliance with the treatment.",
          "score": 0.8471710681915283
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 569,
          "offsetInEndSection": 697,
          "text": "Early diagnosis can be made by assessing optic nerve structure using imaging devices and optic nerve function through perimetry.",
          "score": 0.8500690460205078
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 698,
          "offsetInEndSection": 828,
          "text": "Reducing IOP and controlling its fluctuations are considered to be the most important factors in limiting progression of glaucoma.",
          "score": 0.8581650257110596
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 829,
          "offsetInEndSection": 957,
          "text": "Selection of the best suitable therapy out of medical, surgical, or laser treatment options is yet another management challenge.",
          "score": 0.8204500675201416
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 958,
          "offsetInEndSection": 1145,
          "text": "Patients suffering from glaucoma experience poor quality of life owing to the diagnosis itself, functional visual loss, inconvenience and cost of treatment, and side effects of treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1146,
          "offsetInEndSection": 1269,
          "text": "All these factors lead to poor compliance, adherence, and persistence to treatment, and further progression of the disease.",
          "score": 0.8245460987091064
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1270,
          "offsetInEndSection": 1401,
          "text": "It is, therefore, important that ophthalmologists keep all the aforementioned factors in mind when managing patients with glaucoma."
        }
      ]
    },
    {
      "id": "680bc74618b1e36f2e000155",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
        "http://www.ncbi.nlm.nih.gov/pubmed/27430520",
        "http://www.ncbi.nlm.nih.gov/pubmed/37989956",
        "http://www.ncbi.nlm.nih.gov/pubmed/23907003",
        "http://www.ncbi.nlm.nih.gov/pubmed/27846884",
        "http://www.ncbi.nlm.nih.gov/pubmed/25746916",
        "http://www.ncbi.nlm.nih.gov/pubmed/27795534",
        "http://www.ncbi.nlm.nih.gov/pubmed/37637243",
        "http://www.ncbi.nlm.nih.gov/pubmed/33686894",
        "http://www.ncbi.nlm.nih.gov/pubmed/25496336"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Non-small-cell lung cancer (NSCLC) is a highly prevalent and aggressive disease.",
          "score": 0.8824657201766968
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 236,
          "text": "In the metastatic setting, major advances include the incorporation of immunotherapy and targeted therapies into the clinician's therapeutic armamentarium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 421,
          "text": "Standard chemotherapeutic regimens have long been reported to interfere with the immune response to the tumor; conversely, antitumor immunity may add to the effects of those therapies.",
          "score": 0.9231364727020264
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 422,
          "offsetInEndSection": 516,
          "text": "The aim of immunotherapy is to specifically enhance the immune response directed to the tumor.",
          "score": 0.9303475022315979
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 517,
          "offsetInEndSection": 722,
          "text": "Recently, many trials addressed the role of such therapies for metastatic NSCLC treatment: ipilimumab, tremelimumab, nivolumab and lambrolizumab are immunotherapeutic agents of main interest in this field.",
          "score": 0.9223440289497375
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 723,
          "offsetInEndSection": 938,
          "text": "In addition, anti-tumor vaccines, such as MAGE-A3, Tecetomide, TG4010, CIMAvax, ganglioside vaccines, tumor cell vaccines and dendritic cell vaccines, emerged as potent inducers of immune response against the tumor.",
          "score": 0.912582278251648
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 939,
          "offsetInEndSection": 1106,
          "text": "The current work aims to address the most recent developments regarding these innovative immunotherapies and their implementation in the treatment of metastatic NSCLC."
        }
      ]
    },
    {
      "id": "67f857eb18b1e36f2e000105",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10535368",
        "http://www.ncbi.nlm.nih.gov/pubmed/25337310",
        "http://www.ncbi.nlm.nih.gov/pubmed/16732742",
        "http://www.ncbi.nlm.nih.gov/pubmed/19711147",
        "http://www.ncbi.nlm.nih.gov/pubmed/21733178",
        "http://www.ncbi.nlm.nih.gov/pubmed/34194605",
        "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
        "http://www.ncbi.nlm.nih.gov/pubmed/27576903",
        "http://www.ncbi.nlm.nih.gov/pubmed/10979347",
        "http://www.ncbi.nlm.nih.gov/pubmed/21491341"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294,
          "text": "The aim of this study was to examine depression and anxiety disorders and their characteristic symptoms (anhedonia/low positive affect and anxious arousal, respectively), along with measures of state negative affect (NA) and Type D personality, in relation to cardiac surgery related morbidity.",
          "score": 0.9188191294670105
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 547,
          "text": "Patients awaiting elective coronary artery bypass graft surgery (n=158; 20.9% female; 11.4% concomitant valve surgery; age M=64.7, SD=10.6) underwent the structured MINI International Neuropsychiatric Interview to determine current affective disorders.",
          "score": 0.8699003458023071
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 548,
          "offsetInEndSection": 658,
          "text": "Patients also completed the Mood and Anxiety Symptom Questionnaire and a measure of Type D personality traits.",
          "score": 0.8433653712272644
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 659,
          "offsetInEndSection": 919,
          "text": "Postoperative cardiac morbidity was confirmed after surgery during the index hospitalization and included stroke,renal failure, ventilation>24 h, deep sternal wound infection, reoperation, arrhythmia and 30-day mortality at any location (n=59, 37.3% of total)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1203,
          "text": "After adjustment for age, recent myocardial infarction, heart failure, hypertension, urgency of surgery and time spent on cardiopulmonary bypass generalized anxiety disorder was associated with cardiac morbidity (odds ratio [OR]=3.26, 95% confidence interval [CI] 1.10-9.67, p=0.03).",
          "score": 0.9056576490402222
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1204,
          "offsetInEndSection": 1366,
          "text": "Adjusted analysis of personality traits revealed the NA component of Type D personality was associated with cardiac morbidity (OR=1.07, 95% CI 1.01-1.14, p=0.03).",
          "score": 0.8770502209663391
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1367,
          "offsetInEndSection": 1470,
          "text": "The Mood and Anxiety Symptom Questionnaire subscales were not associated with increased morbidity risk.",
          "score": 0.8767107725143433
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1471,
          "offsetInEndSection": 1667,
          "text": "Affective disorders, affective phenotypes, and personality traits were differentially associated with post-cardiac surgery morbidity outcomes independent of cardiac surgery morbidity risk factors.",
          "score": 0.9052647352218628
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1668,
          "offsetInEndSection": 1778,
          "text": "Concurrent investigation of depression and anxiety with respect to cardiac outcomes warrants further research.",
          "score": 0.8878927230834961
        }
      ]
    },
    {
      "id": "67e291a718b1e36f2e000081",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9133488",
        "http://www.ncbi.nlm.nih.gov/pubmed/1474300",
        "http://www.ncbi.nlm.nih.gov/pubmed/12947243",
        "http://www.ncbi.nlm.nih.gov/pubmed/26372543",
        "http://www.ncbi.nlm.nih.gov/pubmed/35747039",
        "http://www.ncbi.nlm.nih.gov/pubmed/12063146",
        "http://www.ncbi.nlm.nih.gov/pubmed/23670060",
        "http://www.ncbi.nlm.nih.gov/pubmed/28280401",
        "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
        "http://www.ncbi.nlm.nih.gov/pubmed/26433894"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Ehlers-Danlos syndromes (EDS) are a heterogeneous group of hereditary connective tissue disorders characterized by joint hypermobility, widespread musculoskeletal pain and tissue fragility.",
          "score": 0.8814444541931152
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 303,
          "text": "Psychiatric disorders and psychosocial impairment are common, yet poorly characterized, findings in EDS patients.",
          "score": 0.8831285238265991
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 304,
          "offsetInEndSection": 482,
          "text": "We investigated the frequency and types of psychiatric disorders and their relationship to systemic manifestations in a cohort of 106 classic and hypermobility type EDS patients.",
          "score": 0.8850678205490112
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 483,
          "offsetInEndSection": 631,
          "text": "In this retrospective study, extensive medical chart review was performed for patients referred at two genetics clinics who were diagnosed with EDS.",
          "score": 0.8599997162818909
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 632,
          "offsetInEndSection": 759,
          "text": "Statistical analysis was undertaken to determine the frequency of psychiatric disorders and association with systemic findings.",
          "score": 0.8734613060951233
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 890,
          "text": "Psychiatric disorders were found in 42.5% of the EDS cohort, with 22.7% of patients affected with 2 or more psychiatric diagnoses.",
          "score": 0.8746082782745361
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 891,
          "offsetInEndSection": 992,
          "text": "Anxiety and depression were most commonly reported, with frequencies of 23.6 and 25.5%, respectively.",
          "score": 0.8810076117515564
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1055,
          "text": "A variety of other psychiatric diagnoses were also identified.",
          "score": 0.8699471950531006
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1056,
          "offsetInEndSection": 1261,
          "text": "Abdominal pain [odds ratio (OR) 7.38], neuropathic pain (OR 4.07), migraines (OR 5.21), joint pain (OR 2.85) and fatigue (OR 5.55) were significantly associated with the presence of a psychiatric disorder.",
          "score": 0.882858395576477
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1262,
          "offsetInEndSection": 1369,
          "text": "The presence of any pain symptom was significantly associated with having a psychiatric disorder (OR 9.68).",
          "score": 0.8855814337730408
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1370,
          "offsetInEndSection": 1559,
          "text": "Muscle pain (OR 2.79), abdominal pain (OR 5.78), neuropathic pain (OR 3.91), migraines (OR 2.63) and fatigue (OR 3.78) were significantly associated with having an anxiety or mood disorder.",
          "score": 0.8814628720283508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1560,
          "offsetInEndSection": 1696,
          "text": "Joint hypermobility and the classic dermatological features of EDS showed no significant association with having a psychiatric disorder.",
          "score": 0.8820756077766418
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1697,
          "offsetInEndSection": 1809,
          "text": "Our findings demonstrate a high frequency of psychiatric disorders and an association with pain symptoms in EDS.",
          "score": 0.8843326568603516
        }
      ]
    },
    {
      "id": "680b7f4818b1e36f2e000154",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28026754",
        "http://www.ncbi.nlm.nih.gov/pubmed/29047032",
        "http://www.ncbi.nlm.nih.gov/pubmed/29846502",
        "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
        "http://www.ncbi.nlm.nih.gov/pubmed/30632193",
        "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
        "http://www.ncbi.nlm.nih.gov/pubmed/20383195",
        "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
        "http://www.ncbi.nlm.nih.gov/pubmed/23648276",
        "http://www.ncbi.nlm.nih.gov/pubmed/31090660"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "This review critically analyzes how machine learning is being used to support clinical decision-making in the management of potentially resectable pancreatic cancer.",
          "score": 0.8958178758621216
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 350,
          "text": "Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines, electronic searches of MEDLINE, Embase, PubMed, and Cochrane Database were undertaken.",
          "score": 0.8555976748466492
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 351,
          "offsetInEndSection": 509,
          "text": "Studies were assessed using the checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist.",
          "score": 0.8647595643997192
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 510,
          "offsetInEndSection": 551,
          "text": "In total 89,959 citations were retrieved.",
          "score": 0.8363335132598877
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 552,
          "offsetInEndSection": 591,
          "text": "Six studies met the inclusion criteria.",
          "score": 0.8388074040412903
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 592,
          "offsetInEndSection": 696,
          "text": "Three studies were Markov decision-analysis models comparing neoadjuvant therapy versus upfront surgery.",
          "score": 0.8761594295501709
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 697,
          "offsetInEndSection": 952,
          "text": "Three studies predicted survival time using Bayesian modeling (n = 1) and artificial neural network (n = 1), and one study explored machine learning algorithms including Bayesian network, decision trees, k-nearest neighbor, and artificial neural networks.",
          "score": 0.8841550350189209
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 953,
          "offsetInEndSection": 1228,
          "text": "The main methodological issues identified were limited data sources, which limits generalizability and potentiates bias; lack of external validation; and the need for transparency in methods of internal validation, consecutive sampling, and selection of candidate predictors.",
          "score": 0.8494474291801453
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1229,
          "offsetInEndSection": 1512,
          "text": "The future direction of research relies on expanding our view of the multidisciplinary team to include professionals from computing and data science with algorithms developed in conjunction with clinicians and viewed as aids, not replacement, to traditional clinical decision-making.",
          "score": 0.8780546188354492
        }
      ]
    },
    {
      "id": "67cde43c81b102733300001e",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32059832",
        "http://www.ncbi.nlm.nih.gov/pubmed/27346786",
        "http://www.ncbi.nlm.nih.gov/pubmed/21209713",
        "http://www.ncbi.nlm.nih.gov/pubmed/30385883",
        "http://www.ncbi.nlm.nih.gov/pubmed/26361263",
        "http://www.ncbi.nlm.nih.gov/pubmed/31356255",
        "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
        "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
        "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
        "http://www.ncbi.nlm.nih.gov/pubmed/21956421"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Graves' disease (GD) is a systemic autoimmune syndrome comprising manifestations in thyroid and orbital connective tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 189,
          "text": "The link between these two tissues in GD eludes our understanding.",
          "score": 0.8860740661621094
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 290,
          "text": "Patients with GD have increased frequency of circulating monocyte lineage cells known as fibrocytes.",
          "score": 0.8721157312393188
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 291,
          "offsetInEndSection": 426,
          "text": "These fibrocytes infiltrate orbital connective tissues in thyroid-associated ophthalmopathy and express functional TSH receptor (TSHR).",
          "score": 0.8881159424781799
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 427,
          "offsetInEndSection": 518,
          "text": "The aim of the study was to identify and characterize CD34(+) fibrocytes in thyroid tissue.",
          "score": 0.8678471446037292
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 622,
          "text": "Patients undergoing surgical thyroidectomy at two academic medical centers were recruited to the study.",
          "score": 0.8691461086273193
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 623,
          "offsetInEndSection": 739,
          "text": "We performed immunohistochemistry, flow cytometry, real-time PCR, cytokine-specific ELISA, and cell differentiation.",
          "score": 0.8307662010192871
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 740,
          "offsetInEndSection": 896,
          "text": "CD34(+)ColI(+)CXCR4(+)TSHR(+) cells can be identified in situ in thyroid tissue from donors with GD, Hashimoto's thyroiditis, or in normal-appearing tissue.",
          "score": 0.8779875040054321
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 897,
          "offsetInEndSection": 996,
          "text": "Thyroid fibroblasts cultivated from these glands express a CD34(-)ColI(+)CXCR4(+)TSHR(+) phenotype.",
          "score": 0.8710924386978149
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 997,
          "offsetInEndSection": 1054,
          "text": "TSHR levels are higher than those in orbital fibroblasts.",
          "score": 0.8493740558624268
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1055,
          "offsetInEndSection": 1121,
          "text": "When treated with TSH, thyroid fibroblasts generate IL-6 and IL-8.",
          "score": 0.8668212294578552
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1122,
          "offsetInEndSection": 1273,
          "text": "The induction of IL-6 can be blocked by dexamethasone, a chemical inhibitor of Akt/Pkb, and by knocking down Akt with a specific small interfering RNA.",
          "score": 0.8406865000724792
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1274,
          "offsetInEndSection": 1397,
          "text": "When treated with TGF-\u03b2 or rosiglitazone, thyroid fibroblasts differentiate into myofibrocytes or adipocytes, respectively.",
          "score": 0.8728137016296387
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1398,
          "offsetInEndSection": 1497,
          "text": "ColI(+)CXCR4(+)TSHR(+) thyroid fibroblasts resemble orbital fibroblasts and circulating fibrocytes.",
          "score": 0.8669676780700684
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1498,
          "offsetInEndSection": 1557,
          "text": "CD34(+) fibrocytes appear to infiltrate both tissues in GD.",
          "score": 0.8668099641799927
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1558,
          "offsetInEndSection": 1662,
          "text": "Thyroid fibroblasts lose CD34 display in culture, unlike orbital fibroblasts and circulating fibrocytes.",
          "score": 0.863430380821228
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1663,
          "offsetInEndSection": 1789,
          "text": "Fibrocytes and their fibroblast derivatives may participate in the pathogenesis of thyroid autoimmunity after TSHR activation.",
          "score": 0.8842114210128784
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1790,
          "offsetInEndSection": 1851,
          "text": "They could represent a therapeutic target for these diseases.",
          "score": 0.8691016435623169
        }
      ]
    },
    {
      "id": "67e2958018b1e36f2e000084",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27528462",
        "http://www.ncbi.nlm.nih.gov/pubmed/24461634",
        "http://www.ncbi.nlm.nih.gov/pubmed/19724244",
        "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
        "http://www.ncbi.nlm.nih.gov/pubmed/24201088",
        "http://www.ncbi.nlm.nih.gov/pubmed/29536439",
        "http://www.ncbi.nlm.nih.gov/pubmed/20435227",
        "http://www.ncbi.nlm.nih.gov/pubmed/19863545",
        "http://www.ncbi.nlm.nih.gov/pubmed/24870131",
        "http://www.ncbi.nlm.nih.gov/pubmed/23683917"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Each year infants, children and young adults die suddenly and unexpectedly.",
          "score": 0.84779292345047
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 310,
          "text": "In many cases the cause of death can be elucidated by medico-legal autopsy, however, a significant number of these cases remain unexplained despite a detailed postmortem investigation and are labeled as sudden unexplained death (SUD).",
          "score": 0.8825392723083496
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 311,
          "offsetInEndSection": 556,
          "text": "Post-mortem genetic testing, so called molecular autopsy, revealed that primary arrhythmogenic disorders including long QT syndrome and catecholaminergic polymorphic ventricular tachycardia (CPVT) may account for a certain number of these cases.",
          "score": 0.8909667134284973
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 698,
          "text": "Because of the inheritance of these diseases, close relatives of the deceased may also at potential risk of carrying fatal cardiac disorders.",
          "score": 0.8698832392692566
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 699,
          "offsetInEndSection": 854,
          "text": "Therefore, advanced diagnostic analyses, genetic counseling and interdisciplinary collaboration should be integral parts of clinical and forensic practice.",
          "score": 0.8571456670761108
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 855,
          "offsetInEndSection": 975,
          "text": "In the present study, we performed mutation analyses of the major genes causing cardiac channelopathies in 15 SUD cases.",
          "score": 0.8902643918991089
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 976,
          "offsetInEndSection": 1058,
          "text": "In four cases we found putative pathogenic mutations in cardiac ion channel genes.",
          "score": 0.8619305491447449
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1059,
          "offsetInEndSection": 1188,
          "text": "Clinical and genetic examination of family members of SUD victims was also performed and affected family members were identified.",
          "score": 0.8960273265838623
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1189,
          "offsetInEndSection": 1309,
          "text": "This study demonstrates that molecular genetic screening needs to become an inherent part of the postmortem examination.",
          "score": 0.8802469968795776
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1310,
          "offsetInEndSection": 1402,
          "text": "This will enhance the ability of screening family members of SUD victims who may be at risk.",
          "score": 0.8661283254623413
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1403,
          "offsetInEndSection": 1661,
          "text": "The present data also illustrate that detection and follow up of familial cases of sudden death is challenging and requires a close multidisciplinary collaboration between different medical disciplines, with great responsibility for the forensic pathologist.",
          "score": 0.8774341344833374
        }
      ]
    },
    {
      "id": "680c174d353a4a2e6b000001",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26598646",
        "http://www.ncbi.nlm.nih.gov/pubmed/15744326",
        "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
        "http://www.ncbi.nlm.nih.gov/pubmed/34495528",
        "http://www.ncbi.nlm.nih.gov/pubmed/29172462",
        "http://www.ncbi.nlm.nih.gov/pubmed/29413177",
        "http://www.ncbi.nlm.nih.gov/pubmed/28414281",
        "http://www.ncbi.nlm.nih.gov/pubmed/16730216",
        "http://www.ncbi.nlm.nih.gov/pubmed/23576281",
        "http://www.ncbi.nlm.nih.gov/pubmed/18228479"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "A concept that has arisen over the last decade is that proteins can, in general, be covalently modified by polypeptides, resulting in alterations in their fate and function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 174,
          "offsetInEndSection": 262,
          "text": "The first-identified and most well studied of these modifying polypeptides is ubiquitin.",
          "score": 0.9061532020568848
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 532,
          "text": "Although targeting for proteasomal degradation is the best studied outcome of ubiquitylation, we now understand that modification of proteins with ubiquitin has numerous other cellular roles that alter protein function and that are unrelated to proteasomal degradation.",
          "score": 0.9185579419136047
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 533,
          "offsetInEndSection": 663,
          "text": "Ubiquitylation is a complex process that is regulated at the level of both addition and removal of ubiquitin from target proteins.",
          "score": 0.9110991358757019
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 664,
          "offsetInEndSection": 846,
          "text": "This unit includes a number of different basic protocols that will facilitate the study of components of the ubiquitin system and substrate ubiquitylation both in vitro and in cells.",
          "score": 0.8960962295532227
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 847,
          "offsetInEndSection": 1000,
          "text": "Because another protein modifier, NEDD8, itself regulates aspects of the ubiquitin system, basic protocols on neddylation are also included in this unit.",
          "score": 0.9091336131095886
        }
      ]
    },
    {
      "id": "67e0053118b1e36f2e000067",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21769097",
        "http://www.ncbi.nlm.nih.gov/pubmed/22989627",
        "http://www.ncbi.nlm.nih.gov/pubmed/36206626",
        "http://www.ncbi.nlm.nih.gov/pubmed/14662797",
        "http://www.ncbi.nlm.nih.gov/pubmed/19129865",
        "http://www.ncbi.nlm.nih.gov/pubmed/24795696",
        "http://www.ncbi.nlm.nih.gov/pubmed/27340836",
        "http://www.ncbi.nlm.nih.gov/pubmed/25470007",
        "http://www.ncbi.nlm.nih.gov/pubmed/32574926",
        "http://www.ncbi.nlm.nih.gov/pubmed/8143741"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "The distribution of cardiolipin across the inner mitochondrial membrane was directly determined by using the ability of the fluorescent dye 10-N-nonyl-3,6-bis(dimethylamino)acridine (10-N-nonyl acridine orange) to form dimers when it interacts with the diacidic phospholipid.",
          "score": 0.892696738243103
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 276,
          "offsetInEndSection": 817,
          "text": "Two independent methods were employed: (a) a spectrophotometric measurement of 10-N-nonyl acridine orange binding to isolated rat liver mitochondria, mitoplasts and inside-out submitochondrial particles, and (b) a flow-cytometric analysis of specific red fluorescence, emitted when two dye molecules are bound to one membrane cardiolipin; the stoichiometry of 10-N-nonyl acridine orange binding to phosphatidylserine and phosphatidylinositol, 1 mol dye/mol phospholipid, prevented dye dimerisation and subsequent red-fluorescence appearance.",
          "score": 0.8930835723876953
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 818,
          "offsetInEndSection": 1026,
          "text": "57% total cardiolipin was present in the outer leaflets of inner membranes of isolated organelles, a distribution confirmed by saturation measurements for mitoplasts and inside-out submitochondrial particles.",
          "score": 0.8846092224121094
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1027,
          "offsetInEndSection": 1184,
          "text": "The same asymmetry was directly observed in situ with mitochondrial membranes of quiescent L1210 cells, and with mitochondrial membranes of respiring yeasts.",
          "score": 0.8778733015060425
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1185,
          "offsetInEndSection": 1401,
          "text": "Nevertheless, alterations in ATP synthesis and inhibition of mitochondrial protein synthesis revealed that cardiolipin distribution was apparently tightly correlated with mitochondrial membrane assembly and activity.",
          "score": 0.8812904357910156
        }
      ]
    },
    {
      "id": "67e2a8d618b1e36f2e000088",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26832999",
        "http://www.ncbi.nlm.nih.gov/pubmed/22929299",
        "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
        "http://www.ncbi.nlm.nih.gov/pubmed/31614529",
        "http://www.ncbi.nlm.nih.gov/pubmed/24946952",
        "http://www.ncbi.nlm.nih.gov/pubmed/36126008",
        "http://www.ncbi.nlm.nih.gov/pubmed/7240694",
        "http://www.ncbi.nlm.nih.gov/pubmed/22453057",
        "http://www.ncbi.nlm.nih.gov/pubmed/23405174",
        "http://www.ncbi.nlm.nih.gov/pubmed/1530123"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Fanconi's anemia is an autosomal recessive disorder with a high incidence (greater than 90%) of aplastic anemia and a premalignant component with a greater than 10% risk of leukemia or solid tumors.",
          "score": 0.9041837453842163
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 436,
          "text": "The diagnosis of Fanconi's anemia depends on increased chromosomal breakage in lymphocytes following treatment with a DNA cross-linking agent; patients have been identified who are clinically well and whose physical appearance is normal.",
          "score": 0.9009418487548828
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 564,
          "text": "Although bone marrow or cord blood transplants can be curative, treatment for the aplastic anemia usually depends on androgens.",
          "score": 0.8983044624328613
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 565,
          "offsetInEndSection": 732,
          "text": "Close to 20 patients with Fanconi's anemia have delivered normal babies, and the mothers' hematologic status was not significantly adversely affected by the pregnancy.",
          "score": 0.8924428820610046
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 733,
          "offsetInEndSection": 900,
          "text": "A few patients have clonal cytogenetic abnormalities in their bone marrow that do not necessarily indicate leukemic transformation, but further follow-up is important.",
          "score": 0.8811991214752197
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 901,
          "offsetInEndSection": 1069,
          "text": "Studies of in vitro erythropoiesis indicate a correlation between the clinical hematologic status and the presence of erythroid progenitors in the blood or bone marrow.",
          "score": 0.8879311084747314
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1070,
          "offsetInEndSection": 1194,
          "text": "Certain hematopoietic growth factors do increase growth in vitro, suggesting that new types of therapy may become available.",
          "score": 0.8605489730834961
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1195,
          "offsetInEndSection": 1234,
          "text": "Not every patient has a poor prognosis.",
          "score": 0.8275930881500244
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1235,
          "offsetInEndSection": 1316,
          "text": "There are now many adults with Fanconi's anemia, some with families of their own.",
          "score": 0.8895230889320374
        }
      ]
    },
    {
      "id": "680a07ed18b1e36f2e000149",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11849819",
        "http://www.ncbi.nlm.nih.gov/pubmed/26866491",
        "http://www.ncbi.nlm.nih.gov/pubmed/24782784",
        "http://www.ncbi.nlm.nih.gov/pubmed/6283380",
        "http://www.ncbi.nlm.nih.gov/pubmed/11104511",
        "http://www.ncbi.nlm.nih.gov/pubmed/6308151",
        "http://www.ncbi.nlm.nih.gov/pubmed/11867382",
        "http://www.ncbi.nlm.nih.gov/pubmed/9339823",
        "http://www.ncbi.nlm.nih.gov/pubmed/34603008",
        "http://www.ncbi.nlm.nih.gov/pubmed/27902931"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Presynaptic receptors are sites at which transmitters, locally formed mediators or hormones inhibit or facilitate the release of a given transmitter from its axon terminals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 174,
          "offsetInEndSection": 444,
          "text": "The interest in the identification of presynaptic receptors has faded in recent years and it may therefore be justified to give an overview of their occurrence in the autonomic and central nervous system; this review will focus on presynaptic receptors in human tissues.",
          "score": 0.9087182879447937
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 445,
          "offsetInEndSection": 600,
          "text": "Autoreceptors are presynaptic receptors at which a given transmitter restrains its further release, though in some instances may also increase its release.",
          "score": 0.9138294458389282
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 601,
          "offsetInEndSection": 781,
          "text": "Inhibitory autoreceptors represent a typical example of a negative feedback; they are tonically activated by the respective endogenous transmitter and/or are constitutively active.",
          "score": 0.8917192816734314
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 854,
          "text": "Autoreceptors also play a role under pathophysiological conditions, e.g.",
          "score": 0.8781846761703491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 855,
          "offsetInEndSection": 943,
          "text": "by limiting the massive noradrenaline release occurring during congestive heart failure.",
          "score": 0.8670028448104858
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 944,
          "offsetInEndSection": 998,
          "text": "They can be used for therapeutic purposes; e.g., the \u03b1",
          "score": 0.8648356199264526
        }
      ]
    },
    {
      "id": "67e93f2d18b1e36f2e0000db",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
        "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
        "http://www.ncbi.nlm.nih.gov/pubmed/30244358",
        "http://www.ncbi.nlm.nih.gov/pubmed/33987427",
        "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
        "http://www.ncbi.nlm.nih.gov/pubmed/32238797",
        "http://www.ncbi.nlm.nih.gov/pubmed/7494397",
        "http://www.ncbi.nlm.nih.gov/pubmed/33243181",
        "http://www.ncbi.nlm.nih.gov/pubmed/10210897",
        "http://www.ncbi.nlm.nih.gov/pubmed/32775816"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman's disease, characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 396,
          "text": "Renal complication of this disease can be life-threatening and sometimes requires hemodialysis, but it has not been elucidated in detail.",
          "score": 0.8954002261161804
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 397,
          "offsetInEndSection": 510,
          "text": "Case-series was designed to evaluate the renal histology of patients with TAFRO syndrome treated at our hospital.",
          "score": 0.8951197862625122
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 511,
          "offsetInEndSection": 556,
          "text": "Seven patients were eligible to the criteria.",
          "score": 0.8429833054542542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 653,
          "text": "All of them had severe diuretic-resistant anasarca and 6 of 7 had mild proteinuria (<1 g daily).",
          "score": 0.8685847520828247
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 654,
          "offsetInEndSection": 864,
          "text": "On light microscopy, all patients showed glomerular endotheliopathy characterized by endothelial cell swelling and a double contour of the glomerular basement membrane with mesangiolysis or mesangial loosening.",
          "score": 0.8681029081344604
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 865,
          "offsetInEndSection": 962,
          "text": "Immunofluorescent staining and electron microscopy did not detect immune deposits in any patient.",
          "score": 0.8531516790390015
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 963,
          "offsetInEndSection": 1145,
          "text": "Electron microscopy revealed endothelial cell swelling with diffuse expansion of the subendothelial space, loss of mesangial architecture, and loss of endothelial cell fenestrations.",
          "score": 0.8604156970977783
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1146,
          "offsetInEndSection": 1286,
          "text": "Treatment with glucocorticoids and molecular-targeting agents, including tocilizumab and rituximab, improved renal dysfunction and anasarca.",
          "score": 0.8901413083076477
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1443,
          "text": "In 4 of 7 patients with persistent thrombocytopenia, hemorrhagic events occurred despite platelet transfusion or thrombopoietin receptor antagonist therapy.",
          "score": 0.8651760816574097
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1444,
          "offsetInEndSection": 1610,
          "text": "Severe diuretic-resistant anasarca with mild proteinuria and severe glomerular endotheliopathy were common characteristics of renal dysfunction due to TAFRO syndrome.",
          "score": 0.901980459690094
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1611,
          "offsetInEndSection": 1933,
          "text": "In addition, endothelial changes mediated via interleukin (IL)-6 and vascular endothelial growth factor (VEGF) that lead to vascular hyperpermeability and water leakage might contribute to anasarca, because molecular-targeting therapy directed against IL-6 or VEGF improved renal dysfunction and severe endothelial damage.",
          "score": 0.8825302124023438
        }
      ]
    },
    {
      "id": "67e2bde318b1e36f2e000093",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17324369",
        "http://www.ncbi.nlm.nih.gov/pubmed/28209226",
        "http://www.ncbi.nlm.nih.gov/pubmed/3542725",
        "http://www.ncbi.nlm.nih.gov/pubmed/23666861",
        "http://www.ncbi.nlm.nih.gov/pubmed/19275628",
        "http://www.ncbi.nlm.nih.gov/pubmed/30680373",
        "http://www.ncbi.nlm.nih.gov/pubmed/16293956",
        "http://www.ncbi.nlm.nih.gov/pubmed/16149210",
        "http://www.ncbi.nlm.nih.gov/pubmed/23914326",
        "http://www.ncbi.nlm.nih.gov/pubmed/27914359"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "text": "There is a growing consensus in the scientific community that suggests a strong association between obstructive sleep apnea (OSA) and cardiovascular (CVD) conditions and events, including coronary artery disease, hypertension, arrhythmia, heart failure, and sudden cardiac death.",
          "score": 0.9330839514732361
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 280,
          "offsetInEndSection": 348,
          "text": "We reviewed evidence on the relationship between OSA and arrhythmia.",
          "score": 0.9076204299926758
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 349,
          "offsetInEndSection": 518,
          "text": "Our conclusion, based on our review of the literature, is that the evidence supports a strong link between OSA and cardiovascular mortality, which warrants treating OSA.",
          "score": 0.9158388376235962
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 608,
          "text": "Continuous positive airway pressure (CPAP) appears to reduce the CVD consequences of OSA.",
          "score": 0.9031676054000854
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 609,
          "offsetInEndSection": 715,
          "text": "Future research is expected to clarify the benefits and optimal application of these treatment approaches.",
          "score": 0.8490128517150879
        }
      ]
    },
    {
      "id": "680c137818b1e36f2e000158",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31119147",
        "http://www.ncbi.nlm.nih.gov/pubmed/29995496",
        "http://www.ncbi.nlm.nih.gov/pubmed/32942567",
        "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
        "http://www.ncbi.nlm.nih.gov/pubmed/28560055",
        "http://www.ncbi.nlm.nih.gov/pubmed/31873723",
        "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
        "http://www.ncbi.nlm.nih.gov/pubmed/27742530",
        "http://www.ncbi.nlm.nih.gov/pubmed/33839323",
        "http://www.ncbi.nlm.nih.gov/pubmed/12888360"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 46,
          "text": "What separates a malignant from a normal cell?",
          "score": 0.8742063045501709
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 47,
          "offsetInEndSection": 97,
          "text": "This question has occupied scientists for decades.",
          "score": 0.8257816433906555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 193,
          "text": "Although a simple answer remains elusive, several hallmarks of malignancy have been identified.",
          "score": 0.9264512658119202
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 402,
          "text": "These critical features include uncontrolled proliferation, insensitivity to negative growth regulation, evasion of apoptosis, lack of senescence, invasion and metastasis, angiogenesis and genomic elasticity.",
          "score": 0.9154534339904785
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 568,
          "text": "Existing therapies predominantly target proliferation either with cytotoxic agents, ionising radiation or more targeted attacks on growth factor signalling pathways.",
          "score": 0.8839566707611084
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 569,
          "offsetInEndSection": 679,
          "text": "Our most successful therapies to date inhibit proliferation via the oestrogen receptor (ER) and HER2 pathways.",
          "score": 0.8727246522903442
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 680,
          "offsetInEndSection": 863,
          "text": "Further improvements in therapy must attack the other hallmarks of malignancy and will undoubtedly be accompanied by a better means of individual patient selection for such therapies.",
          "score": 0.8999394774436951
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 864,
          "offsetInEndSection": 931,
          "text": "Indeed, each of these hallmarks presents a therapeutic opportunity.",
          "score": 0.8999240398406982
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 932,
          "offsetInEndSection": 1070,
          "text": "To believe otherwise would be to assume that a feature is both biologically crucial, yet therapeutically unimportant, an unlikely paradox.",
          "score": 0.876960039138794
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1071,
          "offsetInEndSection": 1190,
          "text": "Here, we suggest the hallmarks of malignancy as a conceptual framework for understanding novel breast cancer therapies.",
          "score": 0.9071918725967407
        }
      ]
    },
    {
      "id": "67ca061181b102733300000a",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26282267",
        "http://www.ncbi.nlm.nih.gov/pubmed/27492478",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171939",
        "http://www.ncbi.nlm.nih.gov/pubmed/25747039",
        "http://www.ncbi.nlm.nih.gov/pubmed/30539545",
        "http://www.ncbi.nlm.nih.gov/pubmed/28947655",
        "http://www.ncbi.nlm.nih.gov/pubmed/29302591",
        "http://www.ncbi.nlm.nih.gov/pubmed/8353487",
        "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
        "http://www.ncbi.nlm.nih.gov/pubmed/23093590"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "The transcriptional silencing of one of the female X-chromosomes is a finely regulated process that requires accumulation in cis of the long non-coding RNA X-inactive-specific transcript (Xist) followed by a series of epigenetic modifications.",
          "score": 0.9257564544677734
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 244,
          "offsetInEndSection": 353,
          "text": "Little is known about the molecular machinery regulating initiation and maintenance of chromosomal silencing.",
          "score": 0.8975717425346375
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 354,
          "offsetInEndSection": 565,
          "text": "Here, we introduce a new version of our algorithm catRAPID to investigate Xist associations with a number of proteins involved in epigenetic regulation, nuclear scaffolding, transcription and splicing processes.",
          "score": 0.9354358315467834
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 566,
          "offsetInEndSection": 800,
          "text": "Our method correctly identifies binding regions and affinities of protein interactions, providing a powerful theoretical framework for the study of X-chromosome inactivation and other events mediated by ribonucleoprotein associations.",
          "score": 0.9210145473480225
        }
      ]
    },
    {
      "id": "67e26d6218b1e36f2e000074",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25516474",
        "http://www.ncbi.nlm.nih.gov/pubmed/891079",
        "http://www.ncbi.nlm.nih.gov/pubmed/1437923",
        "http://www.ncbi.nlm.nih.gov/pubmed/23019977",
        "http://www.ncbi.nlm.nih.gov/pubmed/7979581",
        "http://www.ncbi.nlm.nih.gov/pubmed/20120828",
        "http://www.ncbi.nlm.nih.gov/pubmed/25186992",
        "http://www.ncbi.nlm.nih.gov/pubmed/22724593",
        "http://www.ncbi.nlm.nih.gov/pubmed/27498665",
        "http://www.ncbi.nlm.nih.gov/pubmed/29038968"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Systemic sclerosis is a connective tissue disease characterized by progressive skin thickening and a wide spectrum of internal organ involvement."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 209,
          "text": "Pathogenesis includes vasculopathy, inflammation, and fibrosis.",
          "score": 0.8790146112442017
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 210,
          "offsetInEndSection": 417,
          "text": "Although immunosuppressants such as cyclophosphamide and mycophenolate mofetil have shown some benefit in interstitial lung disease management, it is still a major cause of morbi-mortality in these patients.",
          "score": 0.881483256816864
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 418,
          "offsetInEndSection": 471,
          "text": "Therefore, there is a current need for new therapies.",
          "score": 0.8227405548095703
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 472,
          "offsetInEndSection": 615,
          "text": "Here, we report a 65-year-old female patient with limited cutaneous systemic sclerosis, anti-topoisomerase-positive and extensive lung disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 616,
          "offsetInEndSection": 771,
          "text": "The patient developed progressive lung fibrosis under several immunosuppressants and was started on nintedanib, with clinical and functional stabilization.",
          "score": 0.8829879760742188
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 772,
          "offsetInEndSection": 972,
          "text": "Nintedanib is a tyrosine-kinase inhibitor that blocks several profibrotic pathways, inhibiting proliferation and migration of fibroblasts and decreasing the synthesis of extracellular matrix proteins.",
          "score": 0.8505322933197021
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 973,
          "offsetInEndSection": 1214,
          "text": "It is approved for idiopathic lung fibrosis and has demonstrated good results in inhibiting migration and proliferation of systemic sclerosis dermal fibroblasts, constituting a promising agent for systemic sclerosis-associated lung fibrosis.",
          "score": 0.8996790647506714
        }
      ]
    },
    {
      "id": "680a21eb18b1e36f2e000150",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21720767",
        "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
        "http://www.ncbi.nlm.nih.gov/pubmed/23780694",
        "http://www.ncbi.nlm.nih.gov/pubmed/28925106",
        "http://www.ncbi.nlm.nih.gov/pubmed/24760871",
        "http://www.ncbi.nlm.nih.gov/pubmed/21343408",
        "http://www.ncbi.nlm.nih.gov/pubmed/27829268",
        "http://www.ncbi.nlm.nih.gov/pubmed/21818782",
        "http://www.ncbi.nlm.nih.gov/pubmed/27638763",
        "http://www.ncbi.nlm.nih.gov/pubmed/27821050"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "The transcription factor SOX10 is essential for all stages of Schwann cell development including myelination."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 299,
          "text": "SOX10 cooperates with other transcription factors to activate the expression of key myelin genes in Schwann cells and is therefore a context-dependent, pro-myelination transcription factor.",
          "score": 0.9329837560653687
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 300,
          "offsetInEndSection": 424,
          "text": "As such, the identification of genes regulated by SOX10 will provide insight into Schwann cell biology and related diseases.",
          "score": 0.9086172580718994
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 577,
          "text": "While genome-wide studies have successfully revealed SOX10 target genes, these efforts mainly focused on myelinating stages of Schwann cell development.",
          "score": 0.9220670461654663
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 578,
          "offsetInEndSection": 677,
          "text": "We propose that less-biased approaches will reveal novel functions of SOX10 outside of myelination.",
          "score": 0.9062632918357849
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 678,
          "offsetInEndSection": 789,
          "text": "We developed a stringent, computational-based screen for genome-wide identification of SOX10 response elements.",
          "score": 0.855664074420929
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 790,
          "offsetInEndSection": 1047,
          "text": "Experimental validation of a pilot set of predicted binding sites in multiple systems revealed that SOX10 directly regulates a previously unreported alternative promoter at SOX6, which encodes a transcription factor that inhibits glial cell differentiation.",
          "score": 0.9070841073989868
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1244,
          "text": "We further explored the utility of our computational approach by combining it with DNase-seq analysis in cultured Schwann cells and previously published SOX10 ChIP-seq data from rat sciatic nerve.",
          "score": 0.8975616693496704
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1245,
          "offsetInEndSection": 1431,
          "text": "Remarkably, this analysis enriched for genomic segments that map to loci involved in the negative regulation of gliogenesis including SOX5, SOX6, NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2.",
          "score": 0.895902693271637
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1432,
          "offsetInEndSection": 1731,
          "text": "Functional studies in Schwann cells revealed that: (1) all eight loci are expressed prior to myelination and down-regulated subsequent to myelination; (2) seven of the eight loci harbor validated SOX10 binding sites; and (3) seven of the eight loci are down-regulated upon repressing SOX10 function.",
          "score": 0.9170381426811218
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1732,
          "offsetInEndSection": 1974,
          "text": "Our computational strategy revealed a putative novel function for SOX10 in Schwann cells, which suggests a model where SOX10 activates the expression of genes that inhibit myelination during non-myelinating stages of Schwann cell development.",
          "score": 0.9315898418426514
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1975,
          "offsetInEndSection": 2153,
          "text": "Importantly, the computational and functional datasets we present here will be valuable for the study of transcriptional regulation, SOX protein function, and glial cell biology.",
          "score": 0.8969931602478027
        }
      ]
    },
    {
      "id": "67fa3c5818b1e36f2e000109",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20122157",
        "http://www.ncbi.nlm.nih.gov/pubmed/33835457",
        "http://www.ncbi.nlm.nih.gov/pubmed/34864895",
        "http://www.ncbi.nlm.nih.gov/pubmed/21937656",
        "http://www.ncbi.nlm.nih.gov/pubmed/24044569",
        "http://www.ncbi.nlm.nih.gov/pubmed/28718905",
        "http://www.ncbi.nlm.nih.gov/pubmed/27980099",
        "http://www.ncbi.nlm.nih.gov/pubmed/28707064",
        "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
        "http://www.ncbi.nlm.nih.gov/pubmed/22442327"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Melioidosis is an emerging infectious disease caused by the soil bacterium Burkholderia pseudomallei.",
          "score": 0.869572103023529
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "text": "In diagnostic and forensic settings, molecular detection assays need not only high sensitivity with low limits of detection but also high specificity.",
          "score": 0.8537755012512207
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 387,
          "text": "In a direct comparison of published and newly developed TaqMan PCR assays, we found the TTS1-orf2 assay to be superior in detecting B.",
          "score": 0.8591665625572205
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 434,
          "text": "pseudomallei directly from clinical specimens.",
          "score": 0.8424502015113831
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 435,
          "offsetInEndSection": 673,
          "text": "The YLF/BTFC multiplex assay (targeting the Yersinia-like fimbrial/Burkholderia thailandensis-like flagellum and chemotaxis region) also showed high diagnostic sensitivity and provides additional information on possible geographic origin.",
          "score": 0.8643617033958435
        }
      ]
    },
    {
      "id": "6810c54b353a4a2e6b000011",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
        "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
        "http://www.ncbi.nlm.nih.gov/pubmed/21301338",
        "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
        "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
        "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
        "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
        "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
        "http://www.ncbi.nlm.nih.gov/pubmed/27905012",
        "http://www.ncbi.nlm.nih.gov/pubmed/22696384"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people are not well controlled by a single antiepileptic drug and usually require treatment with a combination of two or more antiepileptic drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 453,
          "text": "In recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.",
          "score": 0.9120017886161804
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 454,
          "offsetInEndSection": 559,
          "text": "To investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.",
          "score": 0.9046332240104675
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 560,
          "offsetInEndSection": 763,
          "text": "We searched the Cochrane Epilepsy Group Specialized Register (1 May 2012), the Cochrane Central Register of Controlled Trials (CENTRAL Issue 4 of 12, The Cochrane Library, 2012) and MEDLINE (1 May 2012).",
          "score": 0.8834089636802673
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 764,
          "offsetInEndSection": 897,
          "text": "We searched trials registers and contacted the\u00a0manufacturer of losigamone and authors of included studies for additional information.",
          "score": 0.864881157875061
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 898,
          "offsetInEndSection": 934,
          "text": "There were no language restrictions.",
          "score": 0.8357266187667847
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 935,
          "offsetInEndSection": 1026,
          "text": "Randomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.",
          "score": 0.8986793160438538
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1027,
          "offsetInEndSection": 1102,
          "text": "Two review authors independently assessed trial quality and extracted data.",
          "score": 0.8502697348594666
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1264,
          "text": "The primary outcomes were 50% or greater reduction in seizure frequency and seizure freedom; the secondary outcomes were treatment withdrawal and adverse events.",
          "score": 0.9051536321640015
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1265,
          "offsetInEndSection": 1439,
          "text": "Results are presented as risk ratios (RR) with 95% confidence intervals (CIs) or 99% CIs (for the individual listed adverse events to make an allowance for multiple testing).",
          "score": 0.8728784322738647
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1440,
          "offsetInEndSection": 1513,
          "text": "Two trials involving a total of 467 patients were eligible for inclusion.",
          "score": 0.8762524127960205
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1514,
          "offsetInEndSection": 1606,
          "text": "Both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.",
          "score": 0.9002010226249695
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1607,
          "offsetInEndSection": 1709,
          "text": "One trial was assessed as being of good methodologic quality while the other was of uncertain quality.",
          "score": 0.8409456610679626
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1710,
          "offsetInEndSection": 2041,
          "text": "For the efficacy outcomes, results did show patients taking losigamone were significantly more likely to achieve a 50% or greater reduction in seizure frequency (RR 1.75; 95% CI 1.14 to 2.72), but associated with a significant increase of treatment withdrawal when compared with those taking placebo (RR 2.16; 95% CI 1.28 to 3.67).",
          "score": 0.8999249935150146
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2042,
          "offsetInEndSection": 2341,
          "text": "For the safety outcomes, results indicated the proportion of patients who experienced adverse events in the losigamone group was higher than the placebo group (RR 1.34; 95% CI 1.00 to 1.80), dizziness was the only adverse event significantly in relation to losigamone (RR 3.82; 99% CI 1.69 to 8.64).",
          "score": 0.8763732314109802
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2342,
          "offsetInEndSection": 2435,
          "text": "The proportion of patients achieving seizure freedom was not reported in either trial report.",
          "score": 0.8794944286346436
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2436,
          "offsetInEndSection": 2693,
          "text": "A subgroup analysis according to different doses of losigamone showed that a higher dose of losigamone (1500 mg/d) is associated with a greater reduction in seizure frequency than lower doses, but is also associated with more dropouts due to adverse events.",
          "score": 0.8962757587432861
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2694,
          "offsetInEndSection": 2883,
          "text": "The results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.",
          "score": 0.9106042385101318
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2884,
          "offsetInEndSection": 2959,
          "text": "However, trials included were of short-term duration and uncertain quality.",
          "score": 0.86949223279953
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2960,
          "offsetInEndSection": 3072,
          "text": "Future well-designed randomized, double-blind, placebo-controlled trials with a longer-term duration are needed.",
          "score": 0.87348872423172
        }
      ]
    },
    {
      "id": "67fd5d6518b1e36f2e000138",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30542515",
        "http://www.ncbi.nlm.nih.gov/pubmed/1320666",
        "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
        "http://www.ncbi.nlm.nih.gov/pubmed/8370584",
        "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
        "http://www.ncbi.nlm.nih.gov/pubmed/17456751",
        "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
        "http://www.ncbi.nlm.nih.gov/pubmed/15924253",
        "http://www.ncbi.nlm.nih.gov/pubmed/10850866",
        "http://www.ncbi.nlm.nih.gov/pubmed/26257825"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "With recent advancements in molecular techniques, the opportunities to gather whole genome information have increased, even in degraded samples such as FFPE tissues.",
          "score": 0.8754990100860596
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 251,
          "text": "As a result, a broader view of the genomic landscape of solid tumors may be explored.",
          "score": 0.8861722946166992
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 252,
          "offsetInEndSection": 390,
          "text": "Whole genome copy number and loss of heterozygosity patterns can advance our understanding of mechanisms and complexity of various tumors.",
          "score": 0.9132819175720215
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 597,
          "text": "Genome-wide alterations involving copy number changes and loss of heterozygosity were identified in 17 glioma samples with positive FISH results for 1p19q co-deletions (n\u2009=\u20099) or EGFR amplification (n\u2009=\u20098)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 698,
          "text": "Gliomas positive for 1p19q co-deletions did not have other frequently recurrent genomic alterations.",
          "score": 0.916365385055542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 699,
          "offsetInEndSection": 865,
          "text": "Additional copy-number alterations were observed in individual cases, and consisted primarily of large-scale changes, including gains or losses of entire chromosomes.",
          "score": 0.9121913909912109
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 866,
          "offsetInEndSection": 997,
          "text": "The genomic architecture of EGFR amplified gliomas was much more complex, with a high number of gains and losses across the genome.",
          "score": 0.9307425022125244
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 998,
          "offsetInEndSection": 1138,
          "text": "Recurrent alterations in EGFR amplified gliomas were both focal, such as CDKN2A homozygous deletions, and large, such as chromosome 10 loss.",
          "score": 0.9292001724243164
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1139,
          "offsetInEndSection": 1229,
          "text": "Microarray enabled a broader picture of the genomic alterations occurring in glioma cases.",
          "score": 0.9245853424072266
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1230,
          "offsetInEndSection": 1328,
          "text": "Gliomas with 1p19q co-deletion had a relatively quiet genome, apart from the selected co-deletion.",
          "score": 0.9051271677017212
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1329,
          "offsetInEndSection": 1409,
          "text": "Additional alterations in isolated cases, involved primarily larger aberrations.",
          "score": 0.8817852735519409
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1410,
          "offsetInEndSection": 1547,
          "text": "On the other hand, EGFR amplified cases tended to be more complex and have specific abnormalities associated with the EGFR amplification.",
          "score": 0.898106038570404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1548,
          "offsetInEndSection": 1674,
          "text": "Furthermore, 1p19q co-deletions and EGFR amplification associated copy number changes appeared to often be mutually exclusive.",
          "score": 0.8971917629241943
        }
      ]
    },
    {
      "id": "67fb046e18b1e36f2e00010c",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
        "http://www.ncbi.nlm.nih.gov/pubmed/36102999",
        "http://www.ncbi.nlm.nih.gov/pubmed/28028563",
        "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
        "http://www.ncbi.nlm.nih.gov/pubmed/32620751",
        "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
        "http://www.ncbi.nlm.nih.gov/pubmed/25145264",
        "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
        "http://www.ncbi.nlm.nih.gov/pubmed/32291635",
        "http://www.ncbi.nlm.nih.gov/pubmed/12721663"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Cardiac-restricted genes play important roles in cardiovascular system.",
          "score": 0.8731828927993774
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 225,
          "text": "In an effort to identify such novel genes we identified a novel cardiac-specific kinase gene TNNI3K localized on 1p31.1 based on bioinformatics analyses.",
          "score": 0.8872506618499756
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 319,
          "text": "Sequence analysis suggested that TNNI3K is a distant family member of integrin-linked kinase.",
          "score": 0.8699012398719788
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 320,
          "offsetInEndSection": 449,
          "text": "Northern blot and 76-tissue array analyses showed that TNNI3K is highly expressed in heart, but is undetectable in other tissues.",
          "score": 0.8918360471725464
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 450,
          "offsetInEndSection": 545,
          "text": "Immunohistochemical analysis predominantly localized TNNI3K in the nucleus of cardiac myocytes.",
          "score": 0.8663200736045837
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 546,
          "offsetInEndSection": 610,
          "text": "In vitro kinase assay showed that TNNI3K is a functional kinase.",
          "score": 0.8577326536178589
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 611,
          "offsetInEndSection": 776,
          "text": "The yeast two-hybrid system showed that TNNI3K could directly interact with cardiac troponin I, results that were further confirmed by coimmunoprecipitation in vivo.",
          "score": 0.8635740280151367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 777,
          "offsetInEndSection": 878,
          "text": "Our data suggest that TNNI3K is a cardiac-specific kinase and play important roles in cardiac system.",
          "score": 0.8764806389808655
        }
      ]
    },
    {
      "id": "67d6bbfa18b1e36f2e000020",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22908365",
        "http://www.ncbi.nlm.nih.gov/pubmed/24856744",
        "http://www.ncbi.nlm.nih.gov/pubmed/18685551",
        "http://www.ncbi.nlm.nih.gov/pubmed/28273857",
        "http://www.ncbi.nlm.nih.gov/pubmed/1441463",
        "http://www.ncbi.nlm.nih.gov/pubmed/27272704",
        "http://www.ncbi.nlm.nih.gov/pubmed/26936099",
        "http://www.ncbi.nlm.nih.gov/pubmed/28872274",
        "http://www.ncbi.nlm.nih.gov/pubmed/27187878",
        "http://www.ncbi.nlm.nih.gov/pubmed/24849622"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Adolescents and young adults are the fastest growing age group of human immunodeficiency virus (HIV) positive individuals in the US, and many who are infected do not know their HIV status.",
          "score": 0.9091819524765015
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 395,
          "text": "The HIV home test has the potential to help curb the HIV epidemic by improving detection of persons living with HIV and enabling them to seek follow-up care but it has not yet been evaluated in adolescents.",
          "score": 0.920864999294281
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 602,
          "text": "Analogous to the home pregnancy test, which was met with much resistance and only successfully marketed during a time of social change, the HIV home test has been met with resistance since its FDA approval.",
          "score": 0.8973625898361206
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 603,
          "offsetInEndSection": 760,
          "text": "This commentary summarizes the need to systematically evaluate positive and untoward/unanticipated effects of HIV home testing, particularly in young adults.",
          "score": 0.9127287864685059
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 761,
          "offsetInEndSection": 900,
          "text": "The overall incidence of HIV has been declining in the US, yet it continues to grow at alarming rates for adolescents and young adults [1].",
          "score": 0.8989551663398743
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 901,
          "offsetInEndSection": 971,
          "text": "Almost 40 % of new HIV infections in the US are in this age group [2].",
          "score": 0.9089397192001343
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 972,
          "offsetInEndSection": 1059,
          "text": "Further, many HIV infected adolescents and young adults are unaware of their infection.",
          "score": 0.9045107960700989
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1060,
          "offsetInEndSection": 1158,
          "text": "Nationwide, only 22.6 % of sexually active high school students have ever been tested for HIV [3].",
          "score": 0.8955689668655396
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1316,
          "text": "While advances in drug regimens have transformed HIV into a chronic disease, infected individuals need to be identified and subsequently engaged in care [4].",
          "score": 0.9201205968856812
        }
      ]
    },
    {
      "id": "680fe1e3353a4a2e6b00000f",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20569258",
        "http://www.ncbi.nlm.nih.gov/pubmed/30380071",
        "http://www.ncbi.nlm.nih.gov/pubmed/24661571",
        "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
        "http://www.ncbi.nlm.nih.gov/pubmed/28551783",
        "http://www.ncbi.nlm.nih.gov/pubmed/15587301",
        "http://www.ncbi.nlm.nih.gov/pubmed/27245382",
        "http://www.ncbi.nlm.nih.gov/pubmed/15347815",
        "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
        "http://www.ncbi.nlm.nih.gov/pubmed/30183645"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30183645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Genome-Wide Association Studies (GWAS) are used to identify statistically significant genetic variants in case-control studies.",
          "score": 0.9164688587188721
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30183645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 257,
          "text": "The main objective is to find single nucleotide polymorphisms (SNPs) that influence a particular phenotype (i.e., disease trait)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30183645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 304,
          "text": "GWAS typically use a p-value threshold of 5*10",
          "score": 0.8887900114059448
        }
      ]
    },
    {
      "id": "680d5dd8353a4a2e6b000004",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29495398",
        "http://www.ncbi.nlm.nih.gov/pubmed/7776900",
        "http://www.ncbi.nlm.nih.gov/pubmed/21041995",
        "http://www.ncbi.nlm.nih.gov/pubmed/12957828",
        "http://www.ncbi.nlm.nih.gov/pubmed/30915128",
        "http://www.ncbi.nlm.nih.gov/pubmed/24228714",
        "http://www.ncbi.nlm.nih.gov/pubmed/28566124",
        "http://www.ncbi.nlm.nih.gov/pubmed/23477202",
        "http://www.ncbi.nlm.nih.gov/pubmed/24610704",
        "http://www.ncbi.nlm.nih.gov/pubmed/16488965"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Human tears contain hundreds of proteins that may exert a significant influence on tear film stability, ocular surface integrity, and visual function.",
          "score": 0.8791710138320923
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 238,
          "text": "The authors hypothesise that many of these proteins originate from the meibomian gland.",
          "score": 0.8864343762397766
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 239,
          "offsetInEndSection": 348,
          "text": "This study's aim was to begin to develop the proteomic methodology to permit the testing of their hypothesis.",
          "score": 0.834663987159729
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 349,
          "offsetInEndSection": 478,
          "text": "Meibomian gland secretions were collected from the lower eyelids of adult volunteers and placed in a chloroform-methanol mixture.",
          "score": 0.8898953795433044
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 479,
          "offsetInEndSection": 647,
          "text": "Samples were partitioned in a biphasic system and non-lipid phase materials were reduced, alkylated, and trypsin digested to obtain peptides for protein identification.",
          "score": 0.8335253596305847
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 648,
          "offsetInEndSection": 806,
          "text": "This peptide mixture was separated by micro-capillary reverse phase chromatography and the effluent examined by nano-electrospray MS and data dependent MS/MS.",
          "score": 0.8362668752670288
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 807,
          "offsetInEndSection": 877,
          "text": "SEQUEST software was used to identify proteins from the MS/MS spectra.",
          "score": 0.8263453245162964
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 878,
          "offsetInEndSection": 1008,
          "text": "The methodological approach to date has permitted the identification of more than 90 proteins in human meibomian gland secretions.",
          "score": 0.8894916772842407
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1457,
          "text": "Proteins include the alpha2-macroglobulin receptor, IgA alpha chain, farnesoid X activated receptor, interferon regulatory factor 3, lacritin precursor, lactotransferrin, lipocalin 1, lysozyme C precursor, potential phospholipid transporting ATPase IK, seven transmembrane helix receptor (also termed somatostatin receptor type 4), testes development related NYD-SP21 (also termed high affinity IgE receptor beta subunit), and TrkC tyrosine kinase.",
          "score": 0.8720951676368713
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1458,
          "offsetInEndSection": 1556,
          "text": "These findings indicate that the meibomian gland secretes a number of proteins into the tear film.",
          "score": 0.8901387453079224
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1557,
          "offsetInEndSection": 1669,
          "text": "It is quite possible that these proteins contribute to the dynamics of the tear film in both health and disease.",
          "score": 0.8532549738883972
        }
      ]
    },
    {
      "id": "67d7208218b1e36f2e00002e",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20426708",
        "http://www.ncbi.nlm.nih.gov/pubmed/21061765",
        "http://www.ncbi.nlm.nih.gov/pubmed/24170634",
        "http://www.ncbi.nlm.nih.gov/pubmed/19689518",
        "http://www.ncbi.nlm.nih.gov/pubmed/21317611",
        "http://www.ncbi.nlm.nih.gov/pubmed/24800325",
        "http://www.ncbi.nlm.nih.gov/pubmed/17989730",
        "http://www.ncbi.nlm.nih.gov/pubmed/29377341",
        "http://www.ncbi.nlm.nih.gov/pubmed/21715249",
        "http://www.ncbi.nlm.nih.gov/pubmed/1958563"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "The immune response of males and females is not identical but instead has been shown to be dimorphic in its nature, with females generally demonstrating a greater overall response than males.",
          "score": 0.876181423664093
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 192,
          "offsetInEndSection": 383,
          "text": "This dimorphism extends to both the humoral and cell mediated systems and appears to be mechanistically based on the differences in type and concentration of sex steroids in males vs females.",
          "score": 0.8908284902572632
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 384,
          "offsetInEndSection": 537,
          "text": "Furthermore, growth hormone and prolactin secretions which are different in males and females may also be partly responsible for the observed dimorphism.",
          "score": 0.9001386165618896
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 538,
          "offsetInEndSection": 720,
          "text": "Because autoimmune disease results from a pathological perturbation of normal immune function, it follows that expression of these diseases will also demonstrate a dimorphic pattern."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 721,
          "offsetInEndSection": 945,
          "text": "Examples of this autoimmune dimorphism include (but are not limited to) lupus, rheumatoid arthritis and multiple sclerosis with the two former more prevalent in females than males and the latter more severe during pregnancy.",
          "score": 0.9077094197273254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 946,
          "offsetInEndSection": 1160,
          "text": "To explain autoimmune dimorphism it therefore becomes necessary firstly to describe the cellular and hormonal interactions found in normal immune regulation and thereafter extrapolate these to autoimmune phenomena.",
          "score": 0.9087775349617004
        }
      ]
    },
    {
      "id": "67fc381f18b1e36f2e00012f",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
        "http://www.ncbi.nlm.nih.gov/pubmed/36040798",
        "http://www.ncbi.nlm.nih.gov/pubmed/35810190",
        "http://www.ncbi.nlm.nih.gov/pubmed/37788736",
        "http://www.ncbi.nlm.nih.gov/pubmed/25818589",
        "http://www.ncbi.nlm.nih.gov/pubmed/29181082",
        "http://www.ncbi.nlm.nih.gov/pubmed/17611626",
        "http://www.ncbi.nlm.nih.gov/pubmed/23415641",
        "http://www.ncbi.nlm.nih.gov/pubmed/37268606",
        "http://www.ncbi.nlm.nih.gov/pubmed/34529939"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "text": "Melanomas can have multiple coexisting cell states, including proliferative (PRO) versus invasive (INV) subpopulations that represent a \"go or grow\" trade-off; however, how these populations interact is poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 222,
          "offsetInEndSection": 456,
          "text": "Using a combination of zebrafish modeling and analysis of patient samples, we show that INV and PRO cells form spatially structured heterotypic clusters and cooperate in the seeding of metastasis, maintaining cell state heterogeneity.",
          "score": 0.8829357624053955
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 457,
          "offsetInEndSection": 538,
          "text": "INV cells adhere tightly to each other and form clusters with a rim of PRO cells.",
          "score": 0.8375328183174133
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 656,
          "text": "Intravital imaging demonstrated cooperation in which INV cells facilitate dissemination of less metastatic PRO cells.",
          "score": 0.8750827312469482
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 657,
          "offsetInEndSection": 770,
          "text": "We identified the TFAP2 neural crest transcription factor as a master regulator of clustering and PRO/INV states.",
          "score": 0.8599121570587158
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 771,
          "offsetInEndSection": 884,
          "text": "Isolation of clusters from patients with metastatic melanoma revealed a subset with heterotypic PRO-INV clusters.",
          "score": 0.8853507041931152
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 885,
          "offsetInEndSection": 1051,
          "text": "Our data suggest a framework for the co-existence of these two divergent cell populations, in which heterotypic clusters promote metastasis via cell-cell cooperation.",
          "score": 0.8717839121818542
        }
      ]
    },
    {
      "id": "67c9e46881b1027333000004",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34788790",
        "http://www.ncbi.nlm.nih.gov/pubmed/20981248",
        "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
        "http://www.ncbi.nlm.nih.gov/pubmed/24106273",
        "http://www.ncbi.nlm.nih.gov/pubmed/19344285",
        "http://www.ncbi.nlm.nih.gov/pubmed/34535671",
        "http://www.ncbi.nlm.nih.gov/pubmed/24497360",
        "http://www.ncbi.nlm.nih.gov/pubmed/23161490",
        "http://www.ncbi.nlm.nih.gov/pubmed/21315458",
        "http://www.ncbi.nlm.nih.gov/pubmed/37124497"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Neoepitopes have attracted much attention as targets for immunotherapy against cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 87,
          "offsetInEndSection": 205,
          "text": "Therefore, efficient neoepitope screening technology is an essential step in the development of personalized vaccines.",
          "score": 0.9133186936378479
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 206,
          "offsetInEndSection": 319,
          "text": "Circular RNAs (circRNAs) are generated by back-splicing and have a single-stranded continuous circular structure.",
          "score": 0.8723249435424805
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 320,
          "offsetInEndSection": 463,
          "text": "So far, various circRNAs have been poorly characterized, though new evidence suggests that a few translated circRNAs may play a role in cancer.",
          "score": 0.8748505711555481
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 464,
          "offsetInEndSection": 614,
          "text": "In the present study, circRNA was used as a source of neoepitope, a novel strategy as circRNA-derived neoepitopes have never been previously explored.",
          "score": 0.9007308483123779
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 615,
          "offsetInEndSection": 837,
          "text": "The present study reports CIRC_neo (circRNA-derived neoepitope prediction pipeline), which is a comprehensive and automated bioinformatic pipeline for the prediction of circRNA-derived neoepitopes from RNA sequencing data.",
          "score": 0.908401608467102
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 838,
          "offsetInEndSection": 1112,
          "text": "The computational prediction from sequencing data requires complex computational workflows to identify circRNAs, derive the resulting peptides, infer the types of human leukocyte antigens (HLA I and HLA II) in patients, and predict the neoepitopes binding to these antigens.",
          "score": 0.8922362327575684
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1113,
          "offsetInEndSection": 1170,
          "text": "The present study proposes a novel source of neoepitopes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1171,
          "offsetInEndSection": 1287,
          "text": "The study focused on cancer-specific circRNAs, which have greatly expanded the source pool for neoepitope discovery.",
          "score": 0.9075019359588623
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1288,
          "offsetInEndSection": 1439,
          "text": "The statistical analysis of different features of circRNA-derived neoepitopes revealed that circRNAs could produce long proteins or truncated proteins.",
          "score": 0.9014647603034973
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1440,
          "offsetInEndSection": 1537,
          "text": "Because the peptides were completely foreign to the human body, they could be highly immunogenic.",
          "score": 0.9074610471725464
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1538,
          "offsetInEndSection": 1621,
          "text": "Importantly, circRNA-derived neoepitopes capable of binding to HLA were discovered.",
          "score": 0.894225001335144
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1622,
          "offsetInEndSection": 1815,
          "text": "In the current study, circRNAs were systematically analyzed, revealing potential targets and novel research clues for cancer diagnosis, treatment, and prospective personalized vaccine research.",
          "score": 0.8766614198684692
        }
      ]
    },
    {
      "id": "67fbe2ab18b1e36f2e000116",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32506848",
        "http://www.ncbi.nlm.nih.gov/pubmed/23456483",
        "http://www.ncbi.nlm.nih.gov/pubmed/30396206",
        "http://www.ncbi.nlm.nih.gov/pubmed/33014527",
        "http://www.ncbi.nlm.nih.gov/pubmed/33010179",
        "http://www.ncbi.nlm.nih.gov/pubmed/31574849",
        "http://www.ncbi.nlm.nih.gov/pubmed/26962464",
        "http://www.ncbi.nlm.nih.gov/pubmed/28951745",
        "http://www.ncbi.nlm.nih.gov/pubmed/17333068",
        "http://www.ncbi.nlm.nih.gov/pubmed/33178308"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "We performed a comprehensive search on PubMed, the Cochrane Library, EMBASE, and four Chinese databases for articles published prior to June 2020.",
          "score": 0.8204434514045715
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 425,
          "text": "We included only randomized controlled trials (RCTs) that used acupotomy therapy as the major intervention in adults with knee OA, were published in either Chinese and English, included more than 20 subjects in each group, and included pain and function in the outcome measures.",
          "score": 0.9010120630264282
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 426,
          "offsetInEndSection": 544,
          "text": "Knee OA was defined by the American College of Rheumatology or Chinese Orthopedic Association criteria in all studies.",
          "score": 0.8780169486999512
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 545,
          "offsetInEndSection": 824,
          "text": "We extracted the visual analogue scale (VAS) pain score, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score, the total effectiveness rate, the modified Japanese Orthopedic Association (JOA) activities of daily living score, and Lysholm's score.",
          "score": 0.8756891489028931
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 825,
          "offsetInEndSection": 909,
          "text": "We calculated the mean difference (MD) or risk ratio (RR) for all relevant outcomes.",
          "score": 0.827400803565979
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 910,
          "offsetInEndSection": 984,
          "text": "Meta-analyses were conducted using random-effects models when appropriate.",
          "score": 0.8349369168281555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 985,
          "offsetInEndSection": 1133,
          "text": "We identified 1317 potentially relevant studies, thirty-two of which met the eligibility criteria and were conducted in China between 2007 and 2020.",
          "score": 0.8044745922088623
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1134,
          "offsetInEndSection": 1259,
          "text": "A total of 3021 knee OA patients (62.96% female, median age: 57 years, and median disease duration: 33 months) were included.",
          "score": 0.8668040037155151
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1260,
          "offsetInEndSection": 1331,
          "text": "The treatment duration ranged from 1 week to 5 weeks (median: 3 weeks).",
          "score": 0.8390232920646667
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1332,
          "offsetInEndSection": 1477,
          "text": "The typical acupotomy treatment involved releasing soft tissue adhesions and was performed once a week for 1-5 weeks until the pain was relieved.",
          "score": 0.8780232667922974
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1478,
          "offsetInEndSection": 1708,
          "text": "The control group treatments included acupuncture (8 studies), electroacupuncture (10 studies), sodium hyaluronate (8 studies), radiofrequency electrotherapy (1 study), and nonsteroidal anti-inflammatory drugs (NSAIDs, 5 studies).",
          "score": 0.9036715626716614
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1709,
          "offsetInEndSection": 1966,
          "text": "The results from the meta-analysis showed that acupotomy led to superior improvements in the VAS pain score (MD\u2009=\u2009-1.11; 95% confidence interval (CI), -1.51 to -0.71; \nChinese acupotomy therapy may relieve pain and improve function in patients with knee OA.",
          "score": 0.9018192291259766
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1967,
          "offsetInEndSection": 2039,
          "text": "Furthermore, rigorously designed and well-controlled RCTs are warranted.",
          "score": 0.8256255984306335
        }
      ]
    },
    {
      "id": "67eaf14c18b1e36f2e0000de",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
        "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
        "http://www.ncbi.nlm.nih.gov/pubmed/15228586",
        "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
        "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
        "http://www.ncbi.nlm.nih.gov/pubmed/30349051",
        "http://www.ncbi.nlm.nih.gov/pubmed/14730707",
        "http://www.ncbi.nlm.nih.gov/pubmed/18786246",
        "http://www.ncbi.nlm.nih.gov/pubmed/37349788",
        "http://www.ncbi.nlm.nih.gov/pubmed/34385359"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34385359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Sox10 is a well known factor to control oligodendrocyte (OL) differentiation, and its expression is regulated by Olig2.",
          "score": 0.919823408126831
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34385359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 220,
          "text": "As an important protein kinase, Akt has been implicated in diseases with white matter abnormalities.",
          "score": 0.88831627368927
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34385359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 221,
          "offsetInEndSection": 316,
          "text": "To study whether and how Akt may regulate OL development, we generated OL lineage cell-specific",
          "score": 0.889400839805603
        }
      ]
    },
    {
      "id": "67c9e7ee81b1027333000007",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21042593",
        "http://www.ncbi.nlm.nih.gov/pubmed/22313602",
        "http://www.ncbi.nlm.nih.gov/pubmed/15220823",
        "http://www.ncbi.nlm.nih.gov/pubmed/27642012",
        "http://www.ncbi.nlm.nih.gov/pubmed/29790124",
        "http://www.ncbi.nlm.nih.gov/pubmed/23445625",
        "http://www.ncbi.nlm.nih.gov/pubmed/19946260",
        "http://www.ncbi.nlm.nih.gov/pubmed/22313737",
        "http://www.ncbi.nlm.nih.gov/pubmed/30964753",
        "http://www.ncbi.nlm.nih.gov/pubmed/36672434"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "Obesity or excess body fat is a major global health challenge that has not only been associated with diabetes mellitus and cardiovascular disease but is also a major risk factor for the development of and mortality related to a subgroup of cancer.",
          "score": 0.885459303855896
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 248,
          "offsetInEndSection": 418,
          "text": "This review focuses on epidemiology, the relationship between obesity and the risk associated with the development and recurrence of cancer and the management of obesity.",
          "score": 0.8909395933151245
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 419,
          "offsetInEndSection": 534,
          "text": "A literature search using PubMed and Google Scholar was performed and the keywords 'obesity' and cancer' were used.",
          "score": 0.8822851181030273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 535,
          "offsetInEndSection": 780,
          "text": "The search was limited to research papers published in English prior to September 2022 and focused on studies that investigated epidemiology, the pathogenesis of cancer, cancer incidence and the risk of recurrence, and the management of obesity.",
          "score": 0.8766800761222839
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 781,
          "offsetInEndSection": 833,
          "text": "About 4-8% of all cancers are attributed to obesity.",
          "score": 0.87723308801651
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 834,
          "offsetInEndSection": 1007,
          "text": "Obesity is a risk factor for several major cancers, including post-menopausal breast, colorectal, endometrial, kidney, esophageal, pancreatic, liver, and gallbladder cancer.",
          "score": 0.8833063840866089
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1008,
          "offsetInEndSection": 1100,
          "text": "Excess body fat results in an approximately 17% increased risk of cancer-specific mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1101,
          "offsetInEndSection": 1415,
          "text": "The relationship between obesity and the risk associated with the development of cancer and its recurrence is not fully understood and involves altered fatty acid metabolism, extracellular matrix remodeling, the secretion of adipokines and anabolic and sex hormones, immune dysregulation, and chronic inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1416,
          "offsetInEndSection": 1553,
          "text": "Obesity may also increase treatment-related adverse effects and influence treatment decisions regarding specific types of cancer therapy.",
          "score": 0.8886051774024963
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1554,
          "offsetInEndSection": 1659,
          "text": "Structured exercise in combination with dietary support and behavior therapy are effective interventions.",
          "score": 0.8188601732254028
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1660,
          "offsetInEndSection": 1815,
          "text": "Treatment with glucagon-like peptide-1 analogues and bariatric surgery result in more rapid weight loss and can be considered in selected cancer survivors.",
          "score": 0.8696893453598022
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1816,
          "offsetInEndSection": 1860,
          "text": "Obesity increases cancer risk and mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1861,
          "offsetInEndSection": 1980,
          "text": "Weight-reducing strategies in obesity-associated cancers are important interventions as a key component of cancer care.",
          "score": 0.8618992567062378
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1981,
          "offsetInEndSection": 2146,
          "text": "Future studies are warranted to further elucidate the complex relationship between obesity and cancer with the identification of targets for effective interventions.",
          "score": 0.8926912546157837
        }
      ]
    },
    {
      "id": "67d71d8f18b1e36f2e00002b",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18430081",
        "http://www.ncbi.nlm.nih.gov/pubmed/31076745",
        "http://www.ncbi.nlm.nih.gov/pubmed/25700419",
        "http://www.ncbi.nlm.nih.gov/pubmed/33465423",
        "http://www.ncbi.nlm.nih.gov/pubmed/28707191",
        "http://www.ncbi.nlm.nih.gov/pubmed/28396132",
        "http://www.ncbi.nlm.nih.gov/pubmed/25486992",
        "http://www.ncbi.nlm.nih.gov/pubmed/27753689",
        "http://www.ncbi.nlm.nih.gov/pubmed/28274145",
        "http://www.ncbi.nlm.nih.gov/pubmed/19651859"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "In gram-positive bacteria, CodY is an important regulator of genes whose expression changes upon nutrient limitation and acts as a repressor of virulence gene expression in some pathogenic species.",
          "score": 0.896908164024353
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 285,
          "text": "Here, we report the role of CodY in Bacillus anthracis, the etiologic agent of anthrax.",
          "score": 0.9015849828720093
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 449,
          "text": "Disruption of codY completely abolished virulence in a toxinogenic, noncapsulated strain, indicating that the activity of CodY is required for full virulence of B.",
          "score": 0.8911309242248535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 450,
          "offsetInEndSection": 460,
          "text": "anthracis.",
          "score": 0.8558405041694641
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 563,
          "text": "Global transcriptome analysis of a codY mutant and the parental strain revealed extensive differences.",
          "score": 0.8749881386756897
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 564,
          "offsetInEndSection": 843,
          "text": "These differences could reflect direct control for some genes, as suggested by the presence of CodY binding sequences in their promoter regions, or indirect effects via the CodY-dependent control of other regulatory proteins or metabolic rearrangements in the codY mutant strain.",
          "score": 0.8823984861373901
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 844,
          "offsetInEndSection": 1001,
          "text": "The differences included reduced expression of the anthrax toxin genes in the mutant strain, which was confirmed by lacZ reporter fusions and immunoblotting.",
          "score": 0.874374270439148
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1002,
          "offsetInEndSection": 1108,
          "text": "The accumulation of the global virulence regulator AtxA protein was strongly reduced in the mutant strain.",
          "score": 0.8538869619369507
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1109,
          "offsetInEndSection": 1308,
          "text": "However, in agreement with the microarray data, expression of atxA, as measured using an atxA-lacZ transcriptional fusion and by assaying atxA mRNA, was not significantly affected in the codY mutant.",
          "score": 0.8687071204185486
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1309,
          "offsetInEndSection": 1363,
          "text": "An atxA-lacZ translational fusion was also unaffected.",
          "score": 0.8294206261634827
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1364,
          "offsetInEndSection": 1448,
          "text": "Overexpression of atxA restored toxin component synthesis in the codY mutant strain.",
          "score": 0.8694157004356384
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1449,
          "offsetInEndSection": 1564,
          "text": "These results suggest that CodY controls toxin gene expression by regulating AtxA accumulation posttranslationally.",
          "score": 0.8550909757614136
        }
      ]
    },
    {
      "id": "67cdb26a81b1027333000017",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23326927",
        "http://www.ncbi.nlm.nih.gov/pubmed/24025022",
        "http://www.ncbi.nlm.nih.gov/pubmed/25962253",
        "http://www.ncbi.nlm.nih.gov/pubmed/24622320",
        "http://www.ncbi.nlm.nih.gov/pubmed/22547464",
        "http://www.ncbi.nlm.nih.gov/pubmed/25941565",
        "http://www.ncbi.nlm.nih.gov/pubmed/28811850",
        "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
        "http://www.ncbi.nlm.nih.gov/pubmed/25255411",
        "http://www.ncbi.nlm.nih.gov/pubmed/22977310"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "The kidney plays an important role in glucose metabolism, and has been considered a target for therapeutic intervention.",
          "score": 0.9197543859481812
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 242,
          "text": "The sodium-glucose cotransporter type 2 (SGLT2) mediates most of the glucose reabsorption from the proximal renal tubule.",
          "score": 0.9376730918884277
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 366,
          "text": "Inhibition of SGLT2 leads to glucosuria and provides a unique mechanism to lower elevated blood glucose levels in diabetes.",
          "score": 0.9391952753067017
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 527,
          "text": "The purpose of this review is to explore the physiology of SGLT2 and discuss several SGLT2 inhibitors which have clinical data in patients with type 2 diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 528,
          "offsetInEndSection": 626,
          "text": "We performed a PubMed search using the terms \"SGLT2\" and \"SGLT2 inhibitor\" through April 10, 2012.",
          "score": 0.9086259007453918
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 627,
          "offsetInEndSection": 742,
          "text": "Published articles, press releases, and abstracts presented at national and international meetings were considered.",
          "score": 0.8277672529220581
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 743,
          "offsetInEndSection": 1073,
          "text": "SGLT2 inhibitors correct a novel pathophysiological defect, have an insulin-independent action, are efficacious with glycosylated hemoglobin reduction ranging from 0.5% to 1.5%, promote weight loss, have a low incidence of hypoglycemia, complement the action of other antidiabetic agents, and can be used at any stage of diabetes.",
          "score": 0.9395961761474609
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1074,
          "offsetInEndSection": 1108,
          "text": "They are generally well tolerated.",
          "score": 0.8529253602027893
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1109,
          "offsetInEndSection": 1352,
          "text": "However, due to side effects, such as repeated urinary tract and genital infections, increased hematocrit, and decreased blood pressure, appropriate patient selection for drug initiation and close monitoring after initiation will be important.",
          "score": 0.8961342573165894
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1353,
          "offsetInEndSection": 1523,
          "text": "Results of ongoing clinical studies of the effect of SGLT2 inhibitors on diabetic complications and cardiovascular safety are crucial to determine the risk-benefit ratio.",
          "score": 0.9314731359481812
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1524,
          "offsetInEndSection": 1881,
          "text": "A recent decision by the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of dapagliflozin for the treatment of type 2 diabetes as an adjunct to diet and exercise, in combination with other glucose-lowering medicinal products, including insulin, and as a monotherapy for metformin-intolerant patients.",
          "score": 0.9106125235557556
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1882,
          "offsetInEndSection": 2109,
          "text": "Clinical research also remains to be carried out on the long-term effects of glucosuria and other potential effects of SGLT2 inhibitors, especially in view of the observed increase in the incidence of bladder and breast cancer.",
          "score": 0.9251750707626343
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2110,
          "offsetInEndSection": 2248,
          "text": "SGLT2 inhibitors represent a promising approach for the treatment of diabetes, and could potentially be an addition to existing therapies.",
          "score": 0.938571572303772
        }
      ]
    },
    {
      "id": "67e2b0a018b1e36f2e00008b",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22836745",
        "http://www.ncbi.nlm.nih.gov/pubmed/30088449",
        "http://www.ncbi.nlm.nih.gov/pubmed/33088545",
        "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
        "http://www.ncbi.nlm.nih.gov/pubmed/24772739",
        "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
        "http://www.ncbi.nlm.nih.gov/pubmed/19636526",
        "http://www.ncbi.nlm.nih.gov/pubmed/20877608",
        "http://www.ncbi.nlm.nih.gov/pubmed/19947304",
        "http://www.ncbi.nlm.nih.gov/pubmed/8007629"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "The efficacy and safety of oral ofloxacin, 400 mg once daily, for the treatment of patients with lower respiratory tract infections were studied.",
          "score": 0.9004391431808472
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 293,
          "text": "The most common species recovered from the sputum specimens of these patients were Haemophilus influenzae, followed by Streptococcus pneumoniae (S.",
          "score": 0.9211804866790771
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 294,
          "offsetInEndSection": 332,
          "text": "pneumoniae), Staphylococcus aureus (S.",
          "score": 0.910912036895752
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 333,
          "offsetInEndSection": 402,
          "text": "aureus), Gram positive cocci unidentified, Pseudomonas aeruginosa (P.",
          "score": 0.8894025087356567
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 512,
          "text": "aeruginosa), Morexella catarrhalis, Streptococcus epidermidis, and another Haemophilus species in this order.",
          "score": 0.8930625915527344
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 611,
          "text": "All these bacteria were susceptible to ofloxacin except for one strain of methicillin resistant S.",
          "score": 0.8973035216331482
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 612,
          "offsetInEndSection": 619,
          "text": "aureus.",
          "score": 0.8843994140625
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 692,
          "text": "A satisfactory clinical outcome was achieved in 34 of 40 patients (85%).",
          "score": 0.8664515018463135
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 693,
          "offsetInEndSection": 801,
          "text": "It is concluded that ofloxacin, 400 mg once daily, is useful for patients with respiratory tract infections.",
          "score": 0.9045735597610474
        }
      ]
    },
    {
      "id": "67e090be18b1e36f2e00006c",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12846937",
        "http://www.ncbi.nlm.nih.gov/pubmed/20890386",
        "http://www.ncbi.nlm.nih.gov/pubmed/24069959",
        "http://www.ncbi.nlm.nih.gov/pubmed/25400981",
        "http://www.ncbi.nlm.nih.gov/pubmed/22529959",
        "http://www.ncbi.nlm.nih.gov/pubmed/29076071",
        "http://www.ncbi.nlm.nih.gov/pubmed/24621781",
        "http://www.ncbi.nlm.nih.gov/pubmed/15076628",
        "http://www.ncbi.nlm.nih.gov/pubmed/8264800",
        "http://www.ncbi.nlm.nih.gov/pubmed/1482192"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Nisin produced by Lactococcus lactis 6F3 is used as a food preservative and is the most important member of a group of peptide-antibiotics containing lanthionine bridges (lantibiotics) (N.",
          "score": 0.8838070631027222
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 203,
          "text": "Schnell, K.-D.",
          "score": 0.7887359857559204
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 204,
          "offsetInEndSection": 214,
          "text": "Entian, U.",
          "score": 0.8149544596672058
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 228,
          "text": "Schneider, F.",
          "score": 0.7859167456626892
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 229,
          "offsetInEndSection": 237,
          "text": "G\u00f6tz, H.",
          "score": 0.7709696292877197
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 238,
          "offsetInEndSection": 248,
          "text": "Z\u00e4hner, R.",
          "score": 0.7855533361434937
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 249,
          "offsetInEndSection": 264,
          "text": "Kellner, and G.",
          "score": 0.8161589503288269
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 265,
          "offsetInEndSection": 306,
          "text": "Jung, Nature [London] 333:276-278, 1988).",
          "score": 0.7818228602409363
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 307,
          "offsetInEndSection": 467,
          "text": "Nisin is ribosomally synthesized, and its structural gene, nisA, encodes a prepeptide that is posttranslationally modified, revealing the active lantibiotic (C.",
          "score": 0.8629168272018433
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 468,
          "offsetInEndSection": 485,
          "text": "Kaletta and K.-D.",
          "score": 0.7882243990898132
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 496,
          "text": "Entian, J.",
          "score": 0.8070299625396729
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 507,
          "text": "Bacteriol.",
          "score": 0.8686009645462036
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 508,
          "offsetInEndSection": 529,
          "text": "171:1597-1601, 1989).",
          "score": 0.8071550726890564
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 530,
          "offsetInEndSection": 606,
          "text": "Adjacent to nisA, the additional genes nisB, nisT, and nisC were identified.",
          "score": 0.8466587066650391
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 849,
          "text": "Over their entire sequences, these genes were homologous to genes recently identified as important for the biosynthesis of lantibiotics, that is, subtilin from Bacillus subtilis ATCC 6633 and epidermin from Staphylococcus epidermidis T\u00fc 3298.",
          "score": 0.8818536400794983
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 850,
          "offsetInEndSection": 968,
          "text": "Genes nisB, nisT, and nisC corresponded to open reading frames of 993, 600, and 418 amino acid residues, respectively.",
          "score": 0.842536211013794
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 969,
          "offsetInEndSection": 1087,
          "text": "The nisT open reading frame is homologous to proteins of the HlyB (hemolysin B protein of Escherichia coli) subfamily.",
          "score": 0.8612540364265442
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1088,
          "offsetInEndSection": 1301,
          "text": "Proteins of this subfamily are responsible for the secretion of a variety of compounds, including large polypeptides, polysaccharides, and anti-drug tumors, indicating that NisT may be involved in nisin transport.",
          "score": 0.8542406558990479
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1302,
          "offsetInEndSection": 1478,
          "text": "Northern (RNA) blot analysis revealed a 0.3-kb transcript for the nisA structural gene, and the transcriptional start point of the nisA gene was determined by primer extension.",
          "score": 0.8294626474380493
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1479,
          "offsetInEndSection": 1580,
          "text": "Additionally, a mRNA of at least 3 kb was identified by using a hybridization probe specific to nisB.",
          "score": 0.8345738649368286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1581,
          "offsetInEndSection": 1832,
          "text": "Antibodies were raised against the NisB protein, and Western blot (immunoblot) analysis revealed a molecular weight of about 115 kDa, which is in accordance with the theoretical protein size of 117.5 kDa as calculated from the nisB open reading frame.",
          "score": 0.8365341424942017
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1833,
          "offsetInEndSection": 1933,
          "text": "Several amphipathic transmembrane alpha-helices indicated that NisB is associated with the membrane.",
          "score": 0.851203203201294
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1934,
          "offsetInEndSection": 1968,
          "text": "This was confirmed by preparing L.",
          "score": 0.817832887172699
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1969,
          "offsetInEndSection": 1985,
          "text": "lactis vesicles.",
          "score": 0.8134071230888367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1986,
          "offsetInEndSection": 2110,
          "text": "The NisB protein was tightly associated with the vesicle fraction and was released by sodium dodecyl sulfate treatment only.",
          "score": 0.8367201685905457
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2111,
          "offsetInEndSection": 2222,
          "text": "These results suggest that NisB is membrane associated and that nisin biosynthesis occurs at the cell membrane.",
          "score": 0.8544957637786865
        }
      ]
    },
    {
      "id": "67d7fded18b1e36f2e000042",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29417387",
        "http://www.ncbi.nlm.nih.gov/pubmed/28057084",
        "http://www.ncbi.nlm.nih.gov/pubmed/15341718",
        "http://www.ncbi.nlm.nih.gov/pubmed/36759100",
        "http://www.ncbi.nlm.nih.gov/pubmed/6769152",
        "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
        "http://www.ncbi.nlm.nih.gov/pubmed/25145720",
        "http://www.ncbi.nlm.nih.gov/pubmed/18372219",
        "http://www.ncbi.nlm.nih.gov/pubmed/15894210",
        "http://www.ncbi.nlm.nih.gov/pubmed/36868166"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Human papillomaviruses (HPVs) infect epithelial cells of human beings, and their replication cycle is associated with epithelial differentiation.",
          "score": 0.9171294569969177
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 271,
          "text": "More than 200 genotypes of HPVs were identified, and each of these HPVs shows distinct specificity for tissues and infection.",
          "score": 0.9036868214607239
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 272,
          "offsetInEndSection": 366,
          "text": "HPV infection was involved in the development of lesions on the feet, genital warts and hands.",
          "score": 0.9159266948699951
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 546,
          "text": "The evidence of HPV infection revealed the role of HPVs in neck and head squamous cell carcinoma, esophageal cancer, cervical cancer, head and neck cancer, brain and lung tumours.",
          "score": 0.9059386849403381
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 547,
          "offsetInEndSection": 738,
          "text": "The independent traditional risk factors, various clinical outcomes, and increased prevalence among certain populations and geographical regions have led increasing interest in HPV infection.",
          "score": 0.9197403788566589
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 739,
          "offsetInEndSection": 785,
          "text": "The mode of HPVs transmission remains unclear.",
          "score": 0.8957020044326782
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 786,
          "offsetInEndSection": 856,
          "text": "Moreover, in recent years, vertical transmission of HPVs was reported.",
          "score": 0.8945568799972534
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 857,
          "offsetInEndSection": 1021,
          "text": "This review concludes present knowledge about HPV infection, virulence strains, clinical significance of HPVs, and mode of transmission, and vaccination strategies.",
          "score": 0.9147503972053528
        }
      ]
    }
  ]
}